| Masuda N, Mukai H, Inoue K, Rai Y, Ohno S, Mori Y, Hashigaki S, Muramatsu Y, Umeyama Y, Iwata H, Toi M |
Masuda N, Mukai H, Inoue K, Rai Y, Ohno S, Mori Y, Hashigaki S, Muramatsu Y, Umeyama Y, Iwata H, Toi M |
Masuda N, Mukai H, Inoue K, Rai Y, Ohno S, Mori Y, Hashigaki S, Muramatsu Y, Umeyama Y, Iwata H, Toi M |
Correction to: Neutropenia management with palbociclib in Japanese patients with advanced breast cancer. |
Correction to: Neutropenia management with palbociclib in Japanese patients with advanced breast cancer. |
Correction to: Neutropenia management with palbociclib in Japanese patients with advanced breast cancer. |
Breast Cancer (Tokyo, Japan) |
Breast Cancer (Tokyo, Japan) |
Breast Cancer (Tokyo, Japan) |
2019/06 |
有 |
|
|
公開 |
| Takada M, Toi M |
Takada M, Toi M |
Takada M, Toi M |
Cryosurgery for primary breast cancers, its biological impact, and clinical outcomes. |
Cryosurgery for primary breast cancers, its biological impact, and clinical outcomes. |
Cryosurgery for primary breast cancers, its biological impact, and clinical outcomes. |
International Journal of Clinical Oncology, 24, 6, 608-613 |
International Journal of Clinical Oncology, 24, 6, 608-613 |
International Journal of Clinical Oncology, 24, 6, 608-613 |
2019/06 |
有 |
|
|
公開 |
| Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA 3rd, Stanzel S, Patre M, Ellis PA |
Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA 3rd, Stanzel S, Patre M, Ellis PA |
Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA 3rd, Stanzel S, Patre M, Ellis PA |
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.  |
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. |
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. |
BMC cancer, 19, 1, 517 |
BMC cancer, 19, 1, 517 |
BMC cancer, 19, 1, 517 |
2019/05 |
有 |
|
|
公開 |
| Im SA, Mukai H, Park IH, Masuda N, Shimizu C, Kim SB, Im YH, Ohtani S, Huang Bartlett C, Lu DR, Iyer S, Mori Y, Mori A, Gauthier E, Finn RS, Toi M |
Im SA, Mukai H, Park IH, Masuda N, Shimizu C, Kim SB, Im YH, Ohtani S, Huang Bartlett C, Lu DR, Iyer S, Mori Y, Mori A, Gauthier E, Finn RS, Toi M |
Im SA, Mukai H, Park IH, Masuda N, Shimizu C, Kim SB, Im YH, Ohtani S, Huang Bartlett C, Lu DR, Iyer S, Mori Y, Mori A, Gauthier E, Finn RS, Toi M |
Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. |
Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. |
Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. |
Journal of Global Oncology, 5, 1-19 |
Journal of Global Oncology, 5, 1-19 |
Journal of Global Oncology, 5, 1-19 |
2019/05 |
有 |
|
|
公開 |
| Sakaguchi R, Kataoka M, Kanao S, Miyake KK, Nakamoto Y, Sugie T, Toi M, Mikami Y, Togashi K |
Sakaguchi R, Kataoka M, Kanao S, Miyake KK, Nakamoto Y, Sugie T, Toi M, Mikami Y, Togashi K |
Sakaguchi R, Kataoka M, Kanao S, Miyake KK, Nakamoto Y, Sugie T, Toi M, Mikami Y, Togashi K |
Distribution pattern of FDG uptake using ring-type dedicated breast PET in comparison to whole-body PET/CT scanning in invasive breast cancer. |
Distribution pattern of FDG uptake using ring-type dedicated breast PET in comparison to whole-body PET/CT scanning in invasive breast cancer. |
Distribution pattern of FDG uptake using ring-type dedicated breast PET in comparison to whole-body PET/CT scanning in invasive breast cancer. |
Annals of Nuclear Medicine |
Annals of Nuclear Medicine |
Annals of Nuclear Medicine |
2019/05 |
有 |
|
|
公開 |
| Poudel S, Hirano S, Kurashima Y, Stefanidis D, Akiyama H, Eguchi S, Fukui T, Hagiwara M, Hashimoto D, Hida K, Izaki T, Iwase H, Kawamoto S, Otomo Y, Nagai E, Saito M, Takami H, Takeda Y, Toi M, Yamaue H, Yoshida M, Yoshida S, Kodera Y |
Poudel S, Hirano S, Kurashima Y, Stefanidis D, Akiyama H, Eguchi S, Fukui T, Hagiwara M, Hashimoto D, Hida K, Izaki T, Iwase H, Kawamoto S, Otomo Y, Nagai E, Saito M, Takami H, Takeda Y, Toi M, Yamaue H, Yoshida M, Yoshida S, Kodera Y |
Poudel S, Hirano S, Kurashima Y, Stefanidis D, Akiyama H, Eguchi S, Fukui T, Hagiwara M, Hashimoto D, Hida K, Izaki T, Iwase H, Kawamoto S, Otomo Y, Nagai E, Saito M, Takami H, Takeda Y, Toi M, Yamaue H, Yoshida M, Yoshida S, Kodera Y |
A snapshot of surgical resident training in Japan: results of a national-level needs assessment survey. |
A snapshot of surgical resident training in Japan: results of a national-level needs assessment survey. |
A snapshot of surgical resident training in Japan: results of a national-level needs assessment survey. |
Surgery Today |
Surgery Today |
Surgery Today |
2019/05 |
有 |
|
|
公開 |
| Yap YS, Lu YS, Tamura K, Lee JE, Ko EY, Park YH, Cao AY, Lin CH, Toi M, Wu J, Lee SC |
Yap YS, Lu YS, Tamura K, Lee JE, Ko EY, Park YH, Cao AY, Lin CH, Toi M, Wu J, Lee SC |
Yap YS, Lu YS, Tamura K, Lee JE, Ko EY, Park YH, Cao AY, Lin CH, Toi M, Wu J, Lee SC |
Insights Into Breast Cancer in the East vs the West: A Review. |
Insights Into Breast Cancer in the East vs the West: A Review. |
Insights Into Breast Cancer in the East vs the West: A Review. |
JAMA oncology |
JAMA oncology |
JAMA oncology |
2019/05 |
有 |
|
|
公開 |
| Benson JR, Jatoi I, Toi M |
Benson JR, Jatoi I, Toi M |
Benson JR, Jatoi I, Toi M |
Surgical management of multiple ipsilateral breast cancers. |
Surgical management of multiple ipsilateral breast cancers. |
Surgical management of multiple ipsilateral breast cancers. |
Future oncology (London, England), 15, 11, 1185-1191 |
Future oncology (London, England), 15, 11, 1185-1191 |
Future oncology (London, England), 15, 11, 1185-1191 |
2019/04 |
有 |
|
|
公開 |
| Ueno T, Saji S, Masuda N, Iwata H, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Sasano H, Toi M |
Ueno T, Saji S, Masuda N, Iwata H, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Sasano H, Toi M |
Ueno T, Saji S, Masuda N, Iwata H, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Sasano H, Toi M |
Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication. |
Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication. |
Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication. |
ESMO open, 4, 1, e000476 |
ESMO open, 4, 1, e000476 |
ESMO open, 4, 1, e000476 |
2019 |
有 |
|
|
公開 |
| Kiso M, Tanaka S, Saji S, Toi M, Sato F. |
Kiso M, Tanaka S, Saji S, Toi M, Sato F. |
Kiso M, Tanaka S, Saji S, Toi M, Sato F. |
Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network. |
Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network. |
Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network. |
Int J Cancer, 1;143, 11, 2905-2918 |
Int J Cancer, 1;143, 11, 2905-2918 |
Int J Cancer, 1;143, 11, 2905-2918 |
2018/12 |
有 |
|
|
公開 |
| Takada M, Sugimoto M, Masuda N, Iwata H, Kuroi K, Yamashiro H, Ohno S, Ishiguro H, Inamoto T, Toi M. |
Takada M, Sugimoto M, Masuda N, Iwata H, Kuroi K, Yamashiro H, Ohno S, Ishiguro H, Inamoto T, Toi M. |
Takada M, Sugimoto M, Masuda N, Iwata H, Kuroi K, Yamashiro H, Ohno S, Ishiguro H, Inamoto T, Toi M. |
Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm. |
Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm. |
Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm. |
Breast Cancer Res Treat, 172, 3, 611-618 |
Breast Cancer Res Treat, 172, 3, 611-618 |
Breast Cancer Res Treat, 172, 3, 611-618 |
2018/12 |
有 |
|
|
公開 |
| Sagawa H, Kataoka M, Kanao S, Onishi N, Nickel MD, Toi M, Togashi K. |
Sagawa H, Kataoka M, Kanao S, Onishi N, Nickel MD, Toi M, Togashi K. |
Sagawa H, Kataoka M, Kanao S, Onishi N, Nickel MD, Toi M, Togashi K. |
Impact of the Number of Iterations in Compressed Sensing Reconstruction on Ultrafast Dynamic Contrast-enhanced Breast MR Imaging. |
Impact of the Number of Iterations in Compressed Sensing Reconstruction on Ultrafast Dynamic Contrast-enhanced Breast MR Imaging. |
Impact of the Number of Iterations in Compressed Sensing Reconstruction on Ultrafast Dynamic Contrast-enhanced Breast MR Imaging. |
Magn Reson Med Sci, 9, doi: 10.2463/mrms.mp.2018-0015 |
Magn Reson Med Sci, 9, doi: 10.2463/mrms.mp.2018-0015 |
Magn Reson Med Sci, 9, doi: 10.2463/mrms.mp.2018-0015 |
2018/11 |
有 |
|
|
公開 |
| Sagara Y, Takada M, Ohi Y, Ohtani S, Kurozumi S, Inoue K, Kosaka Y, Hattori M, Yamashita T, Takao S, Sato N, Iwata H, Kurosumi M, Toi M. |
Sagara Y, Takada M, Ohi Y, Ohtani S, Kurozumi S, Inoue K, Kosaka Y, Hattori M, Yamashita T, Takao S, Sato N, Iwata H, Kurosumi M, Toi M. |
Sagara Y, Takada M, Ohi Y, Ohtani S, Kurozumi S, Inoue K, Kosaka Y, Hattori M, Yamashita T, Takao S, Sato N, Iwata H, Kurosumi M, Toi M. |
Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03. |
Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03. |
Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03. |
Breast Cancer Res Treat, 171, 3, 675-683 |
Breast Cancer Res Treat, 171, 3, 675-683 |
Breast Cancer Res Treat, 171, 3, 675-683 |
2018/10 |
有 |
|
|
公開 |
| Sasanuma H, Tsuda M, Morimoto S, Saha LK, Rahman MM, Kiyooka Y, Fujiike H, Cherniack AD, Itou J, Callen Moreu E, Toi M, Nakada S, Tanaka H, Tsutsui K, Yamada S, Nussenzweig A, Takeda S. |
Sasanuma H, Tsuda M, Morimoto S, Saha LK, Rahman MM, Kiyooka Y, Fujiike H, Cherniack AD, Itou J, Callen Moreu E, Toi M, Nakada S, Tanaka H, Tsutsui K, Yamada S, Nussenzweig A, Takeda S. |
Sasanuma H, Tsuda M, Morimoto S, Saha LK, Rahman MM, Kiyooka Y, Fujiike H, Cherniack AD, Itou J, Callen Moreu E, Toi M, Nakada S, Tanaka H, Tsutsui K, Yamada S, Nussenzweig A, Takeda S. |
BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes. |
BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes. |
BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes. |
Proc Natl Acad Sci U S A, 6;115, 45, E10642-E10651 |
Proc Natl Acad Sci U S A, 6;115, 45, E10642-E10651 |
Proc Natl Acad Sci U S A, 6;115, 45, E10642-E10651 |
2018/10 |
有 |
|
|
公開 |
| Saito S, Bise R, Yoshikawa A, Sekiguchi H, Tsuge I, Toi M. |
Saito S, Bise R, Yoshikawa A, Sekiguchi H, Tsuge I, Toi M. |
Saito S, Bise R, Yoshikawa A, Sekiguchi H, Tsuge I, Toi M. |
Digital artery deformation on movement of the proximal interphalangeal joint |
Digital artery deformation on movement of the proximal interphalangeal joint |
Digital artery deformation on movement of the proximal interphalangeal joint |
J Hand Surg Eur, 18:1753193418807833, doi: 10.1177/1753193418807833. |
J Hand Surg Eur, 18:1753193418807833, doi: 10.1177/1753193418807833. |
J Hand Surg Eur, 18:1753193418807833, doi: 10.1177/1753193418807833. |
2018/10 |
有 |
|
|
公開 |
| Suzuki E, Sugimoto M, Kawaguchi K, Pu F, Uozumi R, Yamaguchi A, Nishie M, Tsuda M, Kotake T, Morita S, Toi M. |
Suzuki E, Sugimoto M, Kawaguchi K, Pu F, Uozumi R, Yamaguchi A, Nishie M, Tsuda M, Kotake T, Morita S, Toi M. |
Suzuki E, Sugimoto M, Kawaguchi K, Pu F, Uozumi R, Yamaguchi A, Nishie M, Tsuda M, Kotake T, Morita S, Toi M. |
Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients. |
Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients. |
Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients. |
Breast Cancer, 13, doi: 10.1007/s12282-018-0920-2 |
Breast Cancer, 13, doi: 10.1007/s12282-018-0920-2 |
Breast Cancer, 13, doi: 10.1007/s12282-018-0920-2 |
2018/10 |
有 |
|
|
公開 |
| Matsumoto Y, Asao Y, Sekiguchi H, Yoshikawa A, Ishii T, Nagae KI, Kobayashi S, Tsuge I, Saito S, Takada M, Ishida Y, Kataoka M, Sakurai T, Yagi T, Kabashima K, Suzuki S, Togashi K, Shiina T, Toi M. |
Matsumoto Y, Asao Y, Sekiguchi H, Yoshikawa A, Ishii T, Nagae KI, Kobayashi S, Tsuge I, Saito S, Takada M, Ishida Y, Kataoka M, Sakurai T, Yagi T, Kabashima K, Suzuki S, Togashi K, Shiina T, Toi M. |
Matsumoto Y, Asao Y, Sekiguchi H, Yoshikawa A, Ishii T, Nagae KI, Kobayashi S, Tsuge I, Saito S, Takada M, Ishida Y, Kataoka M, Sakurai T, Yagi T, Kabashima K, Suzuki S, Togashi K, Shiina T, Toi M. |
Visualising peripheral arterioles and venules through high-resolution and large-area photoacoustic imaging. |
Visualising peripheral arterioles and venules through high-resolution and large-area photoacoustic imaging. |
Visualising peripheral arterioles and venules through high-resolution and large-area photoacoustic imaging. |
Sci Rep, 8;8, 1, 14930-doi: 10.1038/s41598-018-33255- |
Sci Rep, 8;8, 1, 14930-doi: 10.1038/s41598-018-33255- |
Sci Rep, 8;8, 1, 14930-doi: 10.1038/s41598-018-33255- |
2018/10 |
有 |
|
|
公開 |
| Yamamoto Y, Iwata H, Ueno T, Taira N, Kashiwaba M, Takahashi M, Tada H, Tsugawa K, Toyama T, Niikura N, Hara F, Fujisawa T, Yoshinami T, Saji S, Takano T, Masuda N, Morita S, Toi M, Ohno S. |
Yamamoto Y, Iwata H, Ueno T, Taira N, Kashiwaba M, Takahashi M, Tada H, Tsugawa K, Toyama T, Niikura N, Hara F, Fujisawa T, Yoshinami T, Saji S, Takano T, Masuda N, Morita S, Toi M, Ohno S. |
Yamamoto Y, Iwata H, Ueno T, Taira N, Kashiwaba M, Takahashi M, Tada H, Tsugawa K, Toyama T, Niikura N, Hara F, Fujisawa T, Yoshinami T, Saji S, Takano T, Masuda N, Morita S, Toi M, Ohno S. |
A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS s |
A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS s |
A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS s |
Jpn J Clin Oncol, 1;48, 9, 855-859 |
Jpn J Clin Oncol, 1;48, 9, 855-859 |
Jpn J Clin Oncol, 1;48, 9, 855-859 |
2018/09 |
有 |
|
|
公開 |
| Fukui Y, Kawashima M, Kawaguchi K, Takeuchi M, Hirata M, Kataoka TR, Sakurai T, Kataoka M, Kanao S, Nakamoto Y, Hirata K, Yoshimura M, Yoshikawa K, Ishiguro H, Toi M |
Fukui Y, Kawashima M, Kawaguchi K, Takeuchi M, Hirata M, Kataoka TR, Sakurai T, Kataoka M, Kanao S, Nakamoto Y, Hirata K, Yoshimura M, Yoshikawa K, Ishiguro H, Toi M |
Fukui Y, Kawashima M, Kawaguchi K, Takeuchi M, Hirata M, Kataoka TR, Sakurai T, Kataoka M, Kanao S, Nakamoto Y, Hirata K, Yoshimura M, Yoshikawa K, Ishiguro H, Toi M |
Granulocyte-colony-stimulating factor-producing metaplastic carcinoma of the breast with significant elevation of serum interleukin-17 and vascular endothelial growth factor levels. |
Granulocyte-colony-stimulating factor-producing metaplastic carcinoma of the breast with significant elevation of serum interleukin-17 and vascular endothelial growth factor levels. |
Granulocyte-colony-stimulating factor-producing metaplastic carcinoma of the breast with significant elevation of serum interleukin-17 and vascular endothelial growth factor levels. |
International cancer conference journal, 7, 3, 107-113 |
International cancer conference journal, 7, 3, 107-113 |
International cancer conference journal, 7, 3, 107-113 |
2018/07 |
有 |
|
|
公開 |
| Yamashiro H, Sawaki M, Masuda N, Okumura Y, Takano T, Tokunaga E, Saito T, Sagara Y, Yamazaki K, Kawaguchi Y, Lee T, Ozaki S, Yamagami K, Yamamoto N, Kuroi K, Suwa H, Ohtani S, Ito T, Yasuno S, Morita S, Ohno S, Toi M. |
Yamashiro H, Sawaki M, Masuda N, Okumura Y, Takano T, Tokunaga E, Saito T, Sagara Y, Yamazaki K, Kawaguchi Y, Lee T, Ozaki S, Yamagami K, Yamamoto N, Kuroi K, Suwa H, Ohtani S, Ito T, Yasuno S, Morita S, Ohno S, Toi M. |
Yamashiro H, Sawaki M, Masuda N, Okumura Y, Takano T, Tokunaga E, Saito T, Sagara Y, Yamazaki K, Kawaguchi Y, Lee T, Ozaki S, Yamagami K, Yamamoto N, Kuroi K, Suwa H, Ohtani S, Ito T, Yasuno S, Morita S, Ohno S, Toi M. |
Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study |
Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study |
Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study |
Breast Cancer, 5;12, :1178223418786243. |
Breast Cancer, 5;12, :1178223418786243. |
Breast Cancer, 5;12, :1178223418786243. |
2018/07 |
有 |
|
|
公開 |
| Yamaga I, Kawaguchi-Sakita N, Asao Y, Matsumoto Y, Yoshikawa A, Fukui T, Takada M, Kataoka M, Kawashima M, Fakhrejahani E, Kanao S, Nakayama Y, Tokiwa M, Torii M, Yagi T, Sakurai T, Haga H, Togashi K, Shiina T, Toi M. |
Yamaga I, Kawaguchi-Sakita N, Asao Y, Matsumoto Y, Yoshikawa A, Fukui T, Takada M, Kataoka M, Kawashima M, Fakhrejahani E, Kanao S, Nakayama Y, Tokiwa M, Torii M, Yagi T, Sakurai T, Haga H, Togashi K, Shiina T, Toi M. |
Yamaga I, Kawaguchi-Sakita N, Asao Y, Matsumoto Y, Yoshikawa A, Fukui T, Takada M, Kataoka M, Kawashima M, Fakhrejahani E, Kanao S, Nakayama Y, Tokiwa M, Torii M, Yagi T, Sakurai T, Haga H, Togashi K, Shiina T, Toi M. |
Vascular branching point counts using photoacoustic imaging in the superficial layer of the breast: A potential biomarker for breast cancer. |
Vascular branching point counts using photoacoustic imaging in the superficial layer of the breast: A potential biomarker for breast cancer. |
Vascular branching point counts using photoacoustic imaging in the superficial layer of the breast: A potential biomarker for breast cancer. |
Photoacoustics, 20;11, 6-13 |
Photoacoustics, 20;11, 6-13 |
Photoacoustics, 20;11, 6-13 |
2018/06 |
有 |
|
|
公開 |
| Mackenzie LJ, Carey ML, Suzuki E, Sanson-Fisher RW, Asada H, Ogura M, D'Este C, Yoshimura M, Toi M. |
Mackenzie LJ, Carey ML, Suzuki E, Sanson-Fisher RW, Asada H, Ogura M, D'Este C, Yoshimura M, Toi M. |
Mackenzie LJ, Carey ML, Suzuki E, Sanson-Fisher RW, Asada H, Ogura M, D'Este C, Yoshimura M, Toi M. |
Agreement between patients' and radiation oncologists' cancer diagnosis and prognosis perceptions: A cross sectional study in Japan. |
Agreement between patients' and radiation oncologists' cancer diagnosis and prognosis perceptions: A cross sectional study in Japan. |
Agreement between patients' and radiation oncologists' cancer diagnosis and prognosis perceptions: A cross sectional study in Japan. |
PLoS One, 8;13, 6, :e0198437. doi: 10.1371/journa |
PLoS One, 8;13, 6, :e0198437. doi: 10.1371/journa |
PLoS One, 8;13, 6, :e0198437. doi: 10.1371/journa |
2018/06 |
有 |
|
|
公開 |
| Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. |
Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. |
Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. |
Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. |
Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. |
Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. |
Cancer Med, 14, 1002/cam4.1600. [Epub ahead of |
Cancer Med, 14, 1002/cam4.1600. [Epub ahead of |
Cancer Med, 14, 1002/cam4.1600. [Epub ahead of |
2018/06 |
有 |
|
|
公開 |
| Takada M, Takeuchi M, Suzuki E, Sato F, Matsumoto Y, Torii M, Kawaguchi-Sakita N, Nishino H, Seo S, Hatano E, Toi M. |
Takada M, Takeuchi M, Suzuki E, Sato F, Matsumoto Y, Torii M, Kawaguchi-Sakita N, Nishino H, Seo S, Hatano E, Toi M. |
Takada M, Takeuchi M, Suzuki E, Sato F, Matsumoto Y, Torii M, Kawaguchi-Sakita N, Nishino H, Seo S, Hatano E, Toi M. |
Real-time navigation system for sentinel lymph node biopsy in breast cancer patients using projection mapping with indocyanine green fluorescence. |
Real-time navigation system for sentinel lymph node biopsy in breast cancer patients using projection mapping with indocyanine green fluorescence. |
Real-time navigation system for sentinel lymph node biopsy in breast cancer patients using projection mapping with indocyanine green fluorescence. |
Breast Cancer, 9, doi: 10.1007/s12282-018-0868-2 |
Breast Cancer, 9, doi: 10.1007/s12282-018-0868-2 |
Breast Cancer, 9, doi: 10.1007/s12282-018-0868-2 |
2018/05 |
有 |
|
|
公開 |
| Ueno T, Masuda N, Kamigaki S, Morimoto T, Akiyama F, Kurosumi M, Tsuda H, Mikami Y, Tanaka S, Morita S, Toi M. |
Ueno T, Masuda N, Kamigaki S, Morimoto T, Akiyama F, Kurosumi M, Tsuda H, Mikami Y, Tanaka S, Morita S, Toi M. |
Ueno T, Masuda N, Kamigaki S, Morimoto T, Akiyama F, Kurosumi M, Tsuda H, Mikami Y, Tanaka S, Morita S, Toi M. |
A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells. |
A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells. |
A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells. |
Cancer Med, 7, . doi: 10.1002/cam4.1516. [Epu |
Cancer Med, 7, . doi: 10.1002/cam4.1516. [Epu |
Cancer Med, 7, . doi: 10.1002/cam4.1516. [Epu |
2018/05 |
有 |
|
|
公開 |
| Shiina T, Toi M, Yagi T. |
Shiina T, Toi M, Yagi T. |
Shiina T, Toi M, Yagi T. |
Development and clinical translation of photoacoustic mammography. |
Development and clinical translation of photoacoustic mammography. |
Development and clinical translation of photoacoustic mammography. |
Biomed Eng Lett., 7;8, 2, 157-165 |
Biomed Eng Lett., 7;8, 2, 157-165 |
Biomed Eng Lett., 7;8, 2, 157-165 |
2018/05 |
有 |
|
|
公開 |
| Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017 . |
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017 . |
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017 . |
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. |
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. |
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. |
Ann Oncol, 3, doi: 10.1093/annonc/mdx806. [E |
Ann Oncol, 3, doi: 10.1093/annonc/mdx806. [E |
Ann Oncol, 3, doi: 10.1093/annonc/mdx806. [E |
2018/05 |
有 |
|
|
公開 |
| Tsuge I, Saito S, Sekiguchi H, Yoshikawa A, Matsumoto Y, Toi M, Suzuki S. |
Tsuge I, Saito S, Sekiguchi H, Yoshikawa A, Matsumoto Y, Toi M, Suzuki S. |
Tsuge I, Saito S, Sekiguchi H, Yoshikawa A, Matsumoto Y, Toi M, Suzuki S. |
Photoacoustic Tomography Shows the Branching Pattern of Anterolateral Thigh Perforators In Vivo. |
Photoacoustic Tomography Shows the Branching Pattern of Anterolateral Thigh Perforators In Vivo. |
Photoacoustic Tomography Shows the Branching Pattern of Anterolateral Thigh Perforators In Vivo. |
Plast Reconstr Surg, 141, 5, 1288-1292 |
Plast Reconstr Surg, 141, 5, 1288-1292 |
Plast Reconstr Surg, 141, 5, 1288-1292 |
2018/05 |
有 |
|
|
公開 |
| Miyake O, Murata K, Tanaka S, Ishiguro H, Toi M, Tamura K, Kawakami K. |
Miyake O, Murata K, Tanaka S, Ishiguro H, Toi M, Tamura K, Kawakami K. |
Miyake O, Murata K, Tanaka S, Ishiguro H, Toi M, Tamura K, Kawakami K. |
Costs associated with febrile neutropenia in Japanese patients with primary breast cancer: post-hoc analysis of a randomized clinical trial. |
Costs associated with febrile neutropenia in Japanese patients with primary breast cancer: post-hoc analysis of a randomized clinical trial. |
Costs associated with febrile neutropenia in Japanese patients with primary breast cancer: post-hoc analysis of a randomized clinical trial. |
Jpn J Clin Oncol, 1;48, 5, 410-416 |
Jpn J Clin Oncol, 1;48, 5, 410-416 |
Jpn J Clin Oncol, 1;48, 5, 410-416 |
2018/05 |
有 |
|
|
公開 |
| Kotake T, Toi M. |
Kotake T, Toi M. |
Kotake T, Toi M. |
Abemaciclib for the treatment of breast cancer. |
Abemaciclib for the treatment of breast cancer. |
Abemaciclib for the treatment of breast cancer. |
Expert Opin Pharmacother., 19, 5, 517-524 |
Expert Opin Pharmacother., 19, 5, 517-524 |
Expert Opin Pharmacother., 19, 5, 517-524 |
2018/04 |
有 |
|
|
公開 |
| Itou J, Li W, Ito S, Tanaka S, Matsumoto Y, Sato F, Toi M. |
Itou J, Li W, Ito S, Tanaka S, Matsumoto Y, Sato F, Toi M. |
Itou J, Li W, Ito S, Tanaka S, Matsumoto Y, Sato F, Toi M. |
Sal-like 4 protein levels in breast cancer cells are post-translationally down-regulated by tripartite motif-containing 21. |
Sal-like 4 protein levels in breast cancer cells are post-translationally down-regulated by tripartite motif-containing 21. |
Sal-like 4 protein levels in breast cancer cells are post-translationally down-regulated by tripartite motif-containing 21. |
J Biological Chemostry, 27;293, 17, 6556-6564 |
J Biological Chemostry, 27;293, 17, 6556-6564 |
J Biological Chemostry, 27;293, 17, 6556-6564 |
2018/04 |
有 |
|
|
公開 |
| Mukai H, Shimizu C, Masuda N, Ohtani S, Ohno S, Takahashi M, Yamamoto Y, Nishimura R, Sato N, Ohsumi S, Iwata H, Mori Y, Hashigaki S, Muramatsu Y, Nagasawa T, Umeyama Y, Lu DR, Toi M. |
Mukai H, Shimizu C, Masuda N, Ohtani S, Ohno S, Takahashi M, Yamamoto Y, Nishimura R, Sato N, Ohsumi S, Iwata H, Mori Y, Hashigaki S, Muramatsu Y, Nagasawa T, Umeyama Y, Lu DR, Toi M. |
Mukai H, Shimizu C, Masuda N, Ohtani S, Ohno S, Takahashi M, Yamamoto Y, Nishimura R, Sato N, Ohsumi S, Iwata H, Mori Y, Hashigaki S, Muramatsu Y, Nagasawa T, Umeyama Y, Lu DR, Toi M. |
Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. |
Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. |
Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. |
Int J Clin Oncol, doi: 10.1007/s10147-018-1353-9 |
Int J Clin Oncol, doi: 10.1007/s10147-018-1353-9 |
Int J Clin Oncol, doi: 10.1007/s10147-018-1353-9 |
2018/04 |
有 |
|
|
公開 |
| Mackenzie L, Carey M, Suzuki E, Yoshimura M, Toi M, D'Este C, Sanson-Fisher R. |
Mackenzie L, Carey M, Suzuki E, Yoshimura M, Toi M, D'Este C, Sanson-Fisher R. |
Mackenzie L, Carey M, Suzuki E, Yoshimura M, Toi M, D'Este C, Sanson-Fisher R. |
A cross-sectional study of agreement between the Hospital Anxiety and Depression Scale and patient- and radiation oncologist-reported single-item assessment of depression and anxiety. |
A cross-sectional study of agreement between the Hospital Anxiety and Depression Scale and patient- and radiation oncologist-reported single-item assessment of depression and anxiety. |
A cross-sectional study of agreement between the Hospital Anxiety and Depression Scale and patient- and radiation oncologist-reported single-item assessment of depression and anxiety. |
Psychooncology, 16, doi: 10.1002/pon.4736. [Epub |
Psychooncology, 16, doi: 10.1002/pon.4736. [Epub |
Psychooncology, 16, doi: 10.1002/pon.4736. [Epub |
2018/04 |
有 |
|
|
公開 |
| Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K. |
Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K. |
Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K. |
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. |
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. |
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. |
J Natl Cancer Inst, 12, doi: 10.1093/jnci/djy018. [Ep |
J Natl Cancer Inst, 12, doi: 10.1093/jnci/djy018. [Ep |
J Natl Cancer Inst, 12, doi: 10.1093/jnci/djy018. [Ep |
2018/04 |
有 |
|
|
公開 |
| Kanao S, Kataoka M, Iima M, Ikeda DM, Toi M, Togashi K. |
Kanao S, Kataoka M, Iima M, Ikeda DM, Toi M, Togashi K. |
Kanao S, Kataoka M, Iima M, Ikeda DM, Toi M, Togashi K. |
Differentiating benign and malignant inflammatory breast lesions: Value of T2 weighted and diffusion weighted MR images. |
Differentiating benign and malignant inflammatory breast lesions: Value of T2 weighted and diffusion weighted MR images. |
Differentiating benign and malignant inflammatory breast lesions: Value of T2 weighted and diffusion weighted MR images. |
Magn Reson Imaging, 12;50, 38-44 doi: 10.1016/j.mri.2018.03. |
Magn Reson Imaging, 12;50, 38-44 doi: 10.1016/j.mri.2018.03. |
Magn Reson Imaging, 12;50, 38-44 doi: 10.1016/j.mri.2018.03. |
2018/03 |
有 |
|
|
公開 |
| Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart MJ, Dowsett M; TransHERA investigators. |
Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart MJ, Dowsett M; TransHERA investigators. |
Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart MJ, Dowsett M; TransHERA investigators. |
Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. |
Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. |
Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. |
Clin Cancer Res, 12, doi: 10.1158/1078-0432.CCR-17- |
Clin Cancer Res, 12, doi: 10.1158/1078-0432.CCR-17- |
Clin Cancer Res, 12, doi: 10.1158/1078-0432.CCR-17- |
2018/03 |
有 |
|
|
公開 |
| 戸井 雅和 |
戸井 雅和 |
Masuda N, Nishimura R, Takahashi M, Inoue K, Ohno S, Iwata H, Mori Y, Hashigaki S, Muramatsu Y, Nagasawa T, Umeyama Y, Toi M. |
Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study. |
Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study. |
Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study. |
Cancer Sci, 109(3), 803-813 |
Cancer Sci, 109(3), 803-813 |
Cancer Sci, 109(3), 803-813 |
2018/02 |
有 |
|
|
公開 |
| Ueno T, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Yamanaka T, Sasano H, Toi M. |
Ueno T, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Yamanaka T, Sasano H, Toi M. |
Ueno T, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Yamanaka T, Sasano H, Toi M. |
Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. |
Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. |
Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. |
ESMO Open, 14;3, 2, e000314. doi: 10.1136/esmoopen |
ESMO Open, 14;3, 2, e000314. doi: 10.1136/esmoopen |
ESMO Open, 14;3, 2, e000314. doi: 10.1136/esmoopen |
2018/02 |
有 |
|
|
公開 |
| Förnvik D, Kataoka M, Iima M, Ohashi A, Kanao S, Toi M, Togashi K. |
Förnvik D, Kataoka M, Iima M, Ohashi A, Kanao S, Toi M, Togashi K. |
Förnvik D, Kataoka M, Iima M, Ohashi A, Kanao S, Toi M, Togashi K. |
The role of breast tomosynthesis in a predominantly dense breast population at a tertiary breast centre: breast density assessment and diagnostic performance in comparison with MRI. |
The role of breast tomosynthesis in a predominantly dense breast population at a tertiary breast centre: breast density assessment and diagnostic performance in comparison with MRI. |
The role of breast tomosynthesis in a predominantly dense breast population at a tertiary breast centre: breast density assessment and diagnostic performance in comparison with MRI. |
Eur Radiol, 19, doi: 10.1007/s00330-017-52-1846 |
Eur Radiol, 19, doi: 10.1007/s00330-017-52-1846 |
Eur Radiol, 19, doi: 10.1007/s00330-017-52-1846 |
2018/02 |
有 |
|
|
公開 |
| Hanai A, Ishiguro H, Sozu T, Tsuda M, Yano I, Nakagawa T, Imai S, Hamabe Y, Toi M, Arai H, Tsuboyama T. |
Hanai A, Ishiguro H, Sozu T, Tsuda M, Yano I, Nakagawa T, Imai S, Hamabe Y, Toi M, Arai H, Tsuboyama T. |
Hanai A, Ishiguro H, Sozu T, Tsuda M, Yano I, Nakagawa T, Imai S, Hamabe Y, Toi M, Arai H, Tsuboyama T. |
Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial. |
Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial. |
Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial. |
J Natl Cancer Inst, 1;110, 2, 141-148 |
J Natl Cancer Inst, 1;110, 2, 141-148 |
J Natl Cancer Inst, 1;110, 2, 141-148 |
2018/02 |
有 |
|
|
公開 |
| Toi M, Masuda N, Lee SJ. |
Toi M, Masuda N, Lee SJ. |
Toi M, Masuda N, Lee SJ. |
Capecitabine for primary breast cancer. |
Capecitabine for primary breast cancer. |
Capecitabine for primary breast cancer. |
Oncotarget, 6;8, 67, 110739-110740 |
Oncotarget, 6;8, 67, 110739-110740 |
Oncotarget, 6;8, 67, 110739-110740 |
2017/12 |
有 |
|
|
公開 |
| Kawaguchi K, Suzuki E, Nishie M, Kii I, Kataoka TR, Hirata M, Inoue M, Pu F, Iwaisako K, Tsuda M, Yamaguchi A, Haga H, Hagiwara M, Toi M. |
Kawaguchi K, Suzuki E, Nishie M, Kii I, Kataoka TR, Hirata M, Inoue M, Pu F, Iwaisako K, Tsuda M, Yamaguchi A, Haga H, Hagiwara M, Toi M. |
Kawaguchi K, Suzuki E, Nishie M, Kii I, Kataoka TR, Hirata M, Inoue M, Pu F, Iwaisako K, Tsuda M, Yamaguchi A, Haga H, Hagiwara M, Toi M. |
Downregulation of neuropilin-1 on macrophages modulates antibody-mediated tumoricidal activity. |
Downregulation of neuropilin-1 on macrophages modulates antibody-mediated tumoricidal activity. |
Downregulation of neuropilin-1 on macrophages modulates antibody-mediated tumoricidal activity. |
Cancer Immunol Immunother, 66, 9, 1131-1142 |
Cancer Immunol Immunother, 66, 9, 1131-1142 |
Cancer Immunol Immunother, 66, 9, 1131-1142 |
2017/09 |
有 |
英語 |
|
公開 |
| Bell R, Brown J, Parmar M, Toi M, Suter T, Steger GG, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Xu N, Morales L, Provencher L, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F, Cameron D. |
Bell R, Brown J, Parmar M, Toi M, Suter T, Steger GG, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Xu N, Morales L, Provencher L, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F, Cameron D. |
Bell R, Brown J, Parmar M, Toi M, Suter T, Steger GG, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Xu N, Morales L, Provencher L, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F, Cameron D. |
Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. |
Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. |
Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. |
Ann Oncol, 1;28, 4, 754-760 |
Ann Oncol, 1;28, 4, 754-760 |
Ann Oncol, 1;28, 4, 754-760 |
2017/04 |
有 |
|
|
公開 |
| Ikeda T, Sugie T, Shimizu A, Toi M |
Ikeda T, Sugie T, Shimizu A, Toi M |
Ikeda T, Sugie T, Shimizu A, Toi M |
Patterns of clinical practice for sentinel lymph node biopsy in women with node-negative breast cancer: the results of a national survey in Japan. |
Patterns of clinical practice for sentinel lymph node biopsy in women with node-negative breast cancer: the results of a national survey in Japan. |
Patterns of clinical practice for sentinel lymph node biopsy in women with node-negative breast cancer: the results of a national survey in Japan. |
Breast Cancer, 24, 2, 341-344 |
Breast Cancer, 24, 2, 341-344 |
Breast Cancer, 24, 2, 341-344 |
2017/03 |
有 |
英語 |
|
公開 |
| Masakazu Toi, Yasufumi Asao, Yoshiaki Matsumoto, Hiroyuki Sekiguchi, Aya Yoshikawa, Masahiro Takada, Masako Kataoka, Takaaki Endo, Nobuko Kawaguchi, Masahiro Kawashima, Elham Fakhrejahani, Shotaro Kanao, Iku Yamaga, Yoshie Nakayama, Mariko Tokiwa, Masae Torii, Takayuki Yagi, Takaki Sakurai, Kaori Togashi, Tsuyoshi Shiina. |
Masakazu Toi, Yasufumi Asao, Yoshiaki Matsumoto, Hiroyuki Sekiguchi, Aya Yoshikawa, Masahiro Takada, Masako Kataoka, Takaaki Endo, Nobuko Kawaguchi, Masahiro Kawashima, Elham Fakhrejahani, Shotaro Kanao, Iku Yamaga, Yoshie Nakayama, Mariko Tokiwa, Masae Torii, Takayuki Yagi, Takaki Sakurai, Kaori Togashi, Tsuyoshi Shiina. |
Masakazu Toi, Yasufumi Asao, Yoshiaki Matsumoto, Hiroyuki Sekiguchi, Aya Yoshikawa, Masahiro Takada, Masako Kataoka, Takaaki Endo, Nobuko Kawaguchi, Masahiro Kawashima, Elham Fakhrejahani, Shotaro Kanao, Iku Yamaga, Yoshie Nakayama, Mariko Tokiwa, Masae Torii, Takayuki Yagi, Takaki Sakurai, Kaori Togashi, Tsuyoshi Shiina. |
Visualization of tumor-related blood vessels in human breast by photoacoustic imaging system with a hemispherical detector array |
Visualization of tumor-related blood vessels in human breast by photoacoustic imaging system with a hemispherical detector array |
Visualization of tumor-related blood vessels in human breast by photoacoustic imaging system with a hemispherical detector array |
Sci Rep., 7;7:41970. doi: 10.1038/srep41 |
, 7;7:41970. doi: 10.1038/srep41 |
Sci Rep., 7;7:41970. doi: 10.1038/srep41 |
2017/02 |
有 |
|
|
公開 |
| Sugie T, Ikeda T, Kawaguchi A, Shimizu A, Toi M. |
Sugie T, Ikeda T, Kawaguchi A, Shimizu A, Toi M. |
Sugie T, Ikeda T, Kawaguchi A, Shimizu A, Toi M. |
Sentinel lymph node biopsy using indocyanine green fluorescence in early-stage breast cancer: a meta-analysis. |
Sentinel lymph node biopsy using indocyanine green fluorescence in early-stage breast cancer: a meta-analysis. |
Sentinel lymph node biopsy using indocyanine green fluorescence in early-stage breast cancer: a meta-analysis. |
Int J Clin Oncol., 22, 1, 11-17 |
Int J Clin Oncol., 22, 1, 11-17 |
Int J Clin Oncol., 22, 1, 11-17 |
2017/02 |
有 |
|
|
公開 |
| Itou J, Tanaka S, Li W, Iida A, Sehara-Fujisawa A, Sato F, Toi M. |
Itou J, Tanaka S, Li W, Iida A, Sehara-Fujisawa A, Sato F, Toi M. |
Itou J, Tanaka S, Li W, Iida A, Sehara-Fujisawa A, Sato F, Toi M. |
The Sal-like 4 - integrin α6β1 network promotes cell migration for metastasis via activation of focal adhesion dynamics in basal-like breast cancer cells. |
The Sal-like 4 - integrin α6β1 network promotes cell migration for metastasis via activation of focal adhesion dynamics in basal-like breast cancer cells. |
The Sal-like 4 - integrin α6β1 network promotes cell migration for metastasis via activation of focal adhesion dynamics in basal-like breast cancer cells. |
Biochim Biophys Acta., 1864, 1, 76-88 |
Biochim Biophys Acta., 1864, 1, 76-88 |
Biochim Biophys Acta., 1864, 1, 76-88 |
2017/01 |
有 |
|
|
公開 |
| Hirata K, Yoshimura M, Inoue M, Yamauchi C, Ogura M, Toi M, Suzuki E, Takeuchi M, Takada M, Hiraoka M. |
Hirata K, Yoshimura M, Inoue M, Yamauchi C, Ogura M, Toi M, Suzuki E, Takeuchi M, Takada M, Hiraoka M. |
Hirata K, Yoshimura M, Inoue M, Yamauchi C, Ogura M, Toi M, Suzuki E, Takeuchi M, Takada M, Hiraoka M. |
Regional recurrence in breast cancer patients with one to three positive axillary lymph nodes treated with breast-conserving surgery and whole breast irradiation. |
Regional recurrence in breast cancer patients with one to three positive axillary lymph nodes treated with breast-conserving surgery and whole breast irradiation. |
Regional recurrence in breast cancer patients with one to three positive axillary lymph nodes treated with breast-conserving surgery and whole breast irradiation. |
J Radiat Res, 58, 1, 79-85 |
J Radiat Res, 58, 1, 79-85 |
J Radiat Res, 58, 1, 79-85 |
2017/01 |
有 |
|
|
公開 |
| Kawaguchi K, Suzuki E, Yamaguchi A, Yamamoto M, Morita S, Toi M. |
Kawaguchi K, Suzuki E, Yamaguchi A, Yamamoto M, Morita S, Toi M. |
Kawaguchi K, Suzuki E, Yamaguchi A, Yamamoto M, Morita S, Toi M. |
Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. |
Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. |
Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. |
Breast Cancer, 24, 1, 111-120 |
Breast Cancer, 24, 1, 111-120 |
Breast Cancer, 24, 1, 111-120 |
2017/01 |
有 |
|
|
公開 |
| Onishi N, Kataoka M, Kanao S, Kawai M, Iima M, Ohashi A, Toi M, Togashi K. |
Onishi N, Kataoka M, Kanao S, Kawai M, Iima M, Ohashi A, Toi M, Togashi K. |
Onishi N, Kataoka M, Kanao S, Kawai M, Iima M, Ohashi A, Toi M, Togashi K. |
A pilot study to determine the diagnostic criteria of spiculated masses for BI-RADS MRI category 5: when to perform re-biopsy after discordant pathologic result? |
A pilot study to determine the diagnostic criteria of spiculated masses for BI-RADS MRI category 5: when to perform re-biopsy after discordant pathologic result? |
A pilot study to determine the diagnostic criteria of spiculated masses for BI-RADS MRI category 5: when to perform re-biopsy after discordant pathologic result? |
Breast Cancer, 24, 1, 69-78 |
Breast Cancer, 24, 1, 69-78 |
Breast Cancer, 24, 1, 69-78 |
2017/01 |
有 |
|
|
公開 |
| Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H 3rd, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P. |
Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H 3rd, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P. |
Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H 3rd, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P. |
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. |
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. |
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. |
J Clin Oncol, 10;35, 2, 141-148 |
J Clin Oncol, 10;35, 2, 141-148 |
J Clin Oncol, 10;35, 2, 141-148 |
2017/01 |
有 |
|
|
公開 |
| N. Masuda, S.-J. Lee, S. Ohtani, Y.-H. Im, E.-S. Lee, I. Yokota, K. Kuroi, S.-A. Im, B.-W. Park, S.-B. Kim, Y. Yanagita, S. Ohno, S. Takao, K. Aogi, H. Iwata, J. Jeong, A. Kim, K.-H. Park, H. Sasano, Y. Ohashi, and M. Toi |
N. Masuda, S.-J. Lee, S. Ohtani, Y.-H. Im, E.-S. Lee, I. Yokota, K. Kuroi, S.-A. Im, B.-W. Park, S.-B. Kim, Y. Yanagita, S. Ohno, S. Takao, K. Aogi, H. Iwata, J. Jeong, A. Kim, K.-H. Park, H. Sasano, Y. Ohashi, and M. Toi |
N. Masuda, S.-J. Lee, S. Ohtani, Y.-H. Im, E.-S. Lee, I. Yokota, K. Kuroi, S.-A. Im, B.-W. Park, S.-B. Kim, Y. Yanagita, S. Ohno, S. Takao, K. Aogi, H. Iwata, J. Jeong, A. Kim, K.-H. Park, H. Sasano, Y. Ohashi, and M. Toi |
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy |
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy |
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy |
N Engl J Med, 1;376, 22, 2147-2159 |
N Engl J Med, 1;376, 22, 2147-2159 |
N Engl J Med, 1;376, 22, 2147-2159 |
2017/01 |
有 |
|
|
公開 |
| Shi G, Yoshida Y, Yuki K, Nishimura T, Kawata Y, Kawashima M, Iwaisako K, Yoshikawa K, Kurebayashi J, Toi M, Noda M. |
Shi G, Yoshida Y, Yuki K, Nishimura T, Kawata Y, Kawashima M, Iwaisako K, Yoshikawa K, Kurebayashi J, Toi M, Noda M. |
Shi G, Yoshida Y, Yuki K, Nishimura T, Kawata Y, Kawashima M, Iwaisako K, Yoshikawa K, Kurebayashi J, Toi M, Noda M. |
Pattern of RECK CpG methylation as a potential marker for predicting breast cancer prognosis and drug-sensitivity. |
Pattern of RECK CpG methylation as a potential marker for predicting breast cancer prognosis and drug-sensitivity. |
Pattern of RECK CpG methylation as a potential marker for predicting breast cancer prognosis and drug-sensitivity. |
Oncotarget, 13;7, 50, 82158-82169 |
Oncotarget, 13;7, 50, 82158-82169 |
Oncotarget, 13;7, 50, 82158-82169 |
2016/12 |
有 |
|
|
公開 |
| Uehiro N, Sato F, Pu F, Tanaka S, Kawashima M, Kawaguchi K, Sugimoto M, Saji S, Toi M. |
Uehiro N, Sato F, Pu F, Tanaka S, Kawashima M, Kawaguchi K, Sugimoto M, Saji S, Toi M. |
Uehiro N, Sato F, Pu F, Tanaka S, Kawashima M, Kawaguchi K, Sugimoto M, Saji S, Toi M. |
Circulating cell-free DNA-based epigenetic assay can detect early breast cancer. |
Circulating cell-free DNA-based epigenetic assay can detect early breast cancer. |
Circulating cell-free DNA-based epigenetic assay can detect early breast cancer. |
Breast Cancer Res., 19;18, 1, 129 |
Breast Cancer Res., 19;18, 1, 129 |
Breast Cancer Res., 19;18, 1, 129 |
2016/12 |
有 |
|
|
公開 |
| Benson JR, Jatoi I, Toi M. |
Benson JR, Jatoi I, Toi M. |
Benson JR, Jatoi I, Toi M. |
Treatment of low-risk ductal carcinoma in situ: is nothing better than something? |
Treatment of low-risk ductal carcinoma in situ: is nothing better than something? |
Treatment of low-risk ductal carcinoma in situ: is nothing better than something? |
Lancet Oncol., 17, 10, e442-e451. |
Lancet Oncol., 17, 10, e442-e451. |
Lancet Oncol., 17, 10, e442-e451. |
2016/10 |
有 |
|
|
公開 |
| Jatoi I, Benson JR, Toi M. |
Jatoi I, Benson JR, Toi M. |
Jatoi I, Benson JR, Toi M. |
De-escalation of axillary surgery in early breast cancer. |
De-escalation of axillary surgery in early breast cancer. |
De-escalation of axillary surgery in early breast cancer. |
Lancet Oncol., 17, 10, e430-e441 |
Lancet Oncol., 17, 10, e430-e441 |
Lancet Oncol., 17, 10, e430-e441 |
2016/10 |
有 |
|
|
公開 |
| Suzuki E, Mackenzie L, Sanson-Fisher R, Carey M, D'Este C, Asada H, Toi M. |
Suzuki E, Mackenzie L, Sanson-Fisher R, Carey M, D'Este C, Asada H, Toi M. |
Suzuki E, Mackenzie L, Sanson-Fisher R, Carey M, D'Este C, Asada H, Toi M. |
Acceptability of a Touch Screen Tablet Psychosocial Survey Administered to Radiation Therapy Patients in Japa |
Acceptability of a Touch Screen Tablet Psychosocial Survey Administered to Radiation Therapy Patients in Japa |
Acceptability of a Touch Screen Tablet Psychosocial Survey Administered to Radiation Therapy Patients in Japa |
Int J Behav Med, 23, 4, 485-491 |
Int J Behav Med, 23, 4, 485-491 |
Int J Behav Med, 23, 4, 485-491 |
2016/08 |
有 |
英語 |
|
公開 |
| Lee ES, Han W, Shin HC, Takada M, Ryu HS, Cho N, Kim MK, Kim J, Yoo TK, Moon HG, Toi M, Moon WK, Park IA, Noh DY. |
Lee ES, Han W, Shin HC, Takada M, Ryu HS, Cho N, Kim MK, Kim J, Yoo TK, Moon HG, Toi M, Moon WK, Park IA, Noh DY. |
Lee ES, Han W, Shin HC, Takada M, Ryu HS, Cho N, Kim MK, Kim J, Yoo TK, Moon HG, Toi M, Moon WK, Park IA, Noh DY. |
Clinical benefit of nomogram for predicting positive resection margins in breast conserving surgery. |
Clinical benefit of nomogram for predicting positive resection margins in breast conserving surgery. |
Clinical benefit of nomogram for predicting positive resection margins in breast conserving surgery. |
Eur J Surg Oncol, 42, 8, 1169-1175 |
Eur J Surg Oncol, 42, 8, 1169-1175 |
Eur J Surg Oncol, 42, 8, 1169-1175 |
2016/08 |
有 |
|
|
公開 |
| Ueno T, Utsumi J, Toi M, Shimizu K. |
Ueno T, Utsumi J, Toi M, Shimizu K. |
Ueno T, Utsumi J, Toi M, Shimizu K. |
Characteristic gene expression profiles of human fibroblasts and breast cancer cells in a newly developed bilateral coculture system. |
Characteristic gene expression profiles of human fibroblasts and breast cancer cells in a newly developed bilateral coculture system. |
Characteristic gene expression profiles of human fibroblasts and breast cancer cells in a newly developed bilateral coculture system. |
Biomed Res Int, 11 |
Biomed Res Int, 11 |
Biomed Res Int, 11 |
2016/06 |
有 |
|
|
公開 |
| Li W, Itou J,Tanaka S, Nishimura T, Sato F, Toi M. |
Li W, Itou J,Tanaka S, Nishimura T, Sato F, Toi M. |
Li W, Itou J, Tanaka S, Nishimura T, Sato F, Toi M. |
A homeobox protein, NKX6.1, up-regulates interleukin-6 expression for cell growth in basal-like breast cancer cells. |
A homeobox protein, NKX6.1, up-regulates interleukin-6 expression for cell growth in basal-like breast cancer cells. |
A homeobox protein, NKX6.1, up-regulates interleukin-6 expression for cell growth in basal-like breast cancer cells. |
Exp Cell Res, 1;343, 2, 177-189 |
Exp Cell Res, 1;343, 2, 177-189 |
Exp Cell Res, 1;343, 2, 177-189 |
2016/05 |
有 |
|
|
公開 |
| Buyse M, Hurvitz SA, Andre F, Jiang Z, Burris HA, Toi M, Eiermann W, Lindsay MA, Slamon D. |
Buyse M, Hurvitz SA, Andre F, Jiang Z, Burris HA, Toi M, Eiermann W, Lindsay MA, Slamon D. |
Buyse M, Hurvitz SA, Andre F, Jiang Z, Burris HA, Toi M, Eiermann W, Lindsay MA, Slamon D. |
Statistical controversies in clinical research: statistical significance-too much of a good thing …. |
Statistical controversies in clinical research: statistical significance-too much of a good thing …. |
Statistical controversies in clinical research: statistical significance-too much of a good thing …. |
Ann Oncol, 27, 5, 760-762 |
Ann Oncol, 27, 5, 760-762 |
Ann Oncol, 27, 5, 760-762 |
2016/05 |
有 |
|
|
公開 |
| Toi M, Ohno S, Saeki T, Nakamura S, Thürlimann B. |
Toi M, Ohno S, Saeki T, Nakamura S, Thürlimann B. |
Toi M, Ohno S, Saeki T, Nakamura S, Thürlimann B. |
For choosing axillary treatment, and adjuvant hormonal treatment. |
For choosing axillary treatment, and adjuvant hormonal treatment. |
For choosing axillary treatment, and adjuvant hormonal treatment. |
Breast Cancer, 23, 2, 167-169 |
Breast Cancer, 23, 2, 167-169 |
Breast Cancer, 23, 2, 167-169 |
2016/03 |
有 |
英語 |
|
公開 |
| Hayakawa Y, Kawada M, Nishikawa H, Ochiya T, Saya H, Seimiya H, Yao R, Hayashi M, Kai C, Matsuda A, Naoe T, Ohtsu A, Okazaki T, Saji H, Sata M, Sugimura H, Sugiyama Y, Toi M, Irimura T. |
Hayakawa Y, Kawada M, Nishikawa H, Ochiya T, Saya H, Seimiya H, Yao R, Hayashi M, Kai C, Matsuda A, Naoe T, Ohtsu A, Okazaki T, Saji H, Sata M, Sugimura H, Sugiyama Y, Toi M, Irimura T. |
Hayakawa Y, Kawada M, Nishikawa H, Ochiya T, Saya H, Seimiya H, Yao R, Hayashi M, Kai C, Matsuda A, Naoe T, Ohtsu A, Okazaki T, Saji H, Sata M, Sugimura H, Sugiyama Y, Toi M, Irimura T. |
Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs. |
Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs. |
Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs. |
Cancer Sci, 107, 2, 189-202 |
Cancer Sci, 107, 2, 189-202 |
Cancer Sci, 107, 2, 189-202 |
2016/02 |
有 |
|
|
公開 |
| Sato F, Saji S, Toi M. |
Sato F, Saji S, Toi M. |
Sato F, Saji S, Toi M. |
Genomic tumor evolution of breast cancer. |
Genomic tumor evolution of breast cancer. |
Genomic tumor evolution of breast cancer. |
Breast Cancer, 23, 1, 4-11 |
Breast Cancer, 23, 1, 4-11 |
Breast Cancer, 23, 1, 4-11 |
2016/01 |
有 |
英語 |
|
公開 |
| Sugie T, Kinoshita T, Masuda N, Sawada T, Yamauchi A, Kuroi K, Taguchi T, Bando H, Yamashiro H, Lee T, Shinkura N, Kato H, Ikeda T, Yoshimura K, Ueyama H, Toi M. |
|
Sugie T, Kinoshita T, Masuda N, Sawada T, Yamauchi A, Kuroi K, Taguchi T, Bando H, Yamashiro H, Lee T, Shinkura N, Kato H, Ikeda T, Yoshimura K, Ueyama H, Toi M. |
Evaluation of the Clinical utility of the ICG fluorescence method compared with the radioisotope method for sentinel lymph node biopsy in breast cancer. |
Evaluation of the Clinical utility of the ICG fluorescence method compared with the radioisotope method for sentinel lymph node biopsy in breast cancer. |
Evaluation of the Clinical utility of the ICG fluorescence method compared with the radioisotope method for sentinel lymph node biopsy in breast cancer. |
Ann Surg Oncol, 23, 1, 44-50 |
Ann Surg Oncol, 23, 1, 44-50 |
Ann Surg Oncol, 23, 1, 44-50 |
2016/01 |
有 |
|
|
公開 |
| Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans V, Pan H, Peto R, Bradley R, Gray R. |
|
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans V, Pan H, Peto R, Bradley R, Gray R. |
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. |
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. |
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. |
Lancet, 3;386, 10001, 1353-1361 |
Lancet, 3;386, 10001, 1353-1361 |
Lancet, 3;386, 10001, 1353-1361 |
2016/01 |
有 |
|
|
公開 |
| Kawaguchi-Sakita N, Kaneshiro-Nakagawa K, Kawashima M, Sugimoto M, Tokiwa M, Suzuki E, Kajihara S, Fujita Y, Iwamoto S, Tanaka K, Toi M |
|
Kawaguchi-Sakita N, Kaneshiro-Nakagawa K, Kawashima M, Sugimoto M, Tokiwa M, Suzuki E, Kajihara S, Fujita Y, Iwamoto S, Tanaka K, Toi M |
Serum immunoglobulin G Fc region N-glycosylation profiling by matrix-assisted laser desorption/ionization mass spectrometry can distinguish breast cancer patients from cancer-free controls. |
Serum immunoglobulin G Fc region N-glycosylation profiling by matrix-assisted laser desorption/ionization mass spectrometry can distinguish breast cancer patients from cancer-free controls. |
Serum immunoglobulin G Fc region N-glycosylation profiling by matrix-assisted laser desorption/ionization mass spectrometry can distinguish breast cancer patients from cancer-free controls. |
Biochem Biophys Res Commun, 22;469, 4, 1140-1145 |
Biochem Biophys Res Commun, 22;469, 4, 1140-1145 |
Biochem Biophys Res Commun, 22;469, 4, 1140-1145 |
2015/12 |
有 |
|
|
公開 |
| Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS; 2014 Kyoto Breast Cancer Consensus Conference. |
Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS; 2014 Kyoto Breast Cancer Consensus Conference. |
Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS; 2014 Kyoto Breast Cancer Consensus Conference. |
Personalization of loco-regional care for primary breast cancer patients (part 2). |
Personalization of loco-regional care for primary breast cancer patients (part 2). |
Personalization of loco-regional care for primary breast cancer patients (part 2). |
Future Oncol, 11, 9, 1301-1305 |
Future Oncol, 11, 9, 1301-1305 |
Future Oncol, 11, 9, 1301-1305 |
2015/11 |
有 |
|
|
公開 |
| Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS; 2014 Kyoto Breast Cancer Consensus Conference. |
Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS; 2014 Kyoto Breast Cancer Consensus Conference. |
Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS; 2014 Kyoto Breast Cancer Consensus Conference. |
Personalization of loco-regional care for primary breast cancer patients (part 1). |
Personalization of loco-regional care for primary breast cancer patients (part 1). |
Personalization of loco-regional care for primary breast cancer patients (part 1). |
Future Oncol, 11, 9, 1297-1300 |
Future Oncol, 11, 9, 1297-1300 |
Future Oncol, 11, 9, 1297-1300 |
2015/11 |
有 |
|
|
公開 |
| Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F. |
|
Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F. |
Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG. |
Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG. |
Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG. |
Breast Cancer., 22, 6, 586-596 |
Breast Cancer., 22, 6, 586-596 |
Breast Cancer., 22, 6, 586-596 |
2015/11 |
有 |
|
|
公開 |
| Fakhrejahani E, Torii M, Kitai T, Kanao S, Asao Y, Hashizume Y, Mikami Y, Yamaga I, Kataoka M, Sugie T, Takada M, Haga H, Togashi K, Shiina T, Toi M. |
|
Fakhrejahani E, Torii M, Kitai T, Kanao S, Asao Y, Hashizume Y, Mikami Y, Yamaga I, Kataoka M, Sugie T, Takada M, Haga H, Togashi K, Shiina T, Toi M. |
Clinical report on the first prototype of a photoacoustic tomography system with dual illumination for breast cancer imaging. |
Clinical report on the first prototype of a photoacoustic tomography system with dual illumination for breast cancer imaging. |
Clinical report on the first prototype of a photoacoustic tomography system with dual illumination for breast cancer imaging. |
PLoS One, Oct 27;10, 10, e0139113 |
PLoS One, Oct 27;10, 10, e0139113 |
PLoS One, Oct 27;10, 10, e0139113 |
2015/10 |
有 |
|
|
公開 |
| Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann B, van de Velde C, Pan H, Peto R, Davies C, Gray R. |
|
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann B, van de Velde C, Pan H, Peto R, Davies C, Gray R. |
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. |
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. |
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. |
Lancet, 3;386, 10001, 1341-1352 |
Lancet, 3;386, 10001, 1341-1352 |
Lancet, 3;386, 10001, 1341-1352 |
2015/10 |
有 |
|
|
公開 |
| Mukai H, Masuda N, Ishiguro H, Mitsuma A, Shibata T, Yamamura J, Toi M, Watabe A, Sarashina A, Uttenreuther-Fischer M, Ando Y. |
|
Mukai H, Masuda N, Ishiguro H, Mitsuma A, Shibata T, Yamamura J, Toi M, Watabe A, Sarashina A, Uttenreuther-Fischer M, Ando Y. |
Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer. |
Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer. |
Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer. |
Cancer Chemother Pharmacol., 76, 4, 739-750 |
Cancer Chemother Pharmacol., 76, 4, 739-750 |
Cancer Chemother Pharmacol., 76, 4, 739-750 |
2015/10 |
有 |
|
|
公開 |
| Suzuki E, Mackenzie L, Sanson-Fisher R, Carey M, D'Este C, Asada H, Toi M |
|
Suzuki E, Mackenzie L, Sanson-Fisher R, Carey M, D'Este C, Asada H, Toi M |
Acceptability of a Touch Screen Tablet Psychosocial Survey Administered to Radiation Therapy Patients in Japan. |
Acceptability of a Touch Screen Tablet Psychosocial Survey Administered to Radiation Therapy Patients in Japan. |
Acceptability of a Touch Screen Tablet Psychosocial Survey Administered to Radiation Therapy Patients in Japan. |
Int J Behav Med |
Int J Behav Med |
Int J Behav Med |
2015/08 |
有 |
|
|
公開 |
| Sato F, Saji S, Toi M |
|
Sato F, Saji S, Toi M |
Genomic tumor evolution of breast cancer. Breast Cancer |
Genomic tumor evolution of breast cancer. Breast Cancer |
Genomic tumor evolution of breast cancer. Breast Cancer |
Breast Cancer, 22 |
Breast Cancer, 22 |
Breast Cancer, 22 |
2015/05 |
有 |
|
|
公開 |
| Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel Members. |
|
Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel Members. |
-Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. |
-Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. |
-Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. |
Ann Oncol, 26, 8, 1533-1546 |
Ann Oncol, 26, 8, 1533-1546 |
Ann Oncol, 26, 8, 1533-1546 |
2015/05 |
有 |
|
|
公開 |
| Toi M, Masuda N, Ishiguro H, Saji S, Ohno S, Chow LW |
Toi M, Masuda N, Ishiguro H, Saji S, Ohno S, Chow LW |
Toi M, Masuda N, Ishiguro H, Saji S, Ohno S, Chow LW |
Development of breast cancer therapy: biomarker-driven and response-guided approaches in a neoadjuvant setting. |
Development of breast cancer therapy: biomarker-driven and response-guided approaches in a neoadjuvant setting. |
Development of breast cancer therapy: biomarker-driven and response-guided approaches in a neoadjuvant setting. |
Int J Biol Markers, Feb 7;30, 2 |
Int J Biol Markers, Feb 7;30, 2 |
Int J Biol Markers, Feb 7;30, 2 |
2015/02 |
有 |
|
|
公開 |
| Suzuki E, Kataoka TR, Hirata M, Kawaguchi K, Nishie M, Haga H, Toi M. |
|
Suzuki E, Kataoka TR, Hirata M, Kawaguchi K, Nishie M, Haga H, Toi M. |
Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients. |
Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients. |
Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients. |
BMC Cancer, 6;15, 1, 39 |
BMC Cancer, 6;15, 1, 39 |
BMC Cancer, 6;15, 1, 39 |
2015/02 |
有 |
|
|
公開 |
| Yamshiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Ohno S, Kuroi K, Takano T, Takada M, Yasuno S, Morita S, Toi M. |
|
Yamshiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Ohno S, Kuroi K, Takano T, Takada M, Yasuno S, Morita S, Toi M. |
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients. |
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients. |
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients. |
Int J Clin Oncol, 20, 4, 723-724 |
Int J Clin Oncol, 20, 4, 723-724 |
Int J Clin Oncol, 20, 4, 723-724 |
2015/02 |
有 |
|
|
公開 |
| Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay MA, Rao S, Pacaud LB, Taran T, Slamon D. |
|
Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay MA, Rao S, Pacaud LB, Taran T, Slamon D. |
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. |
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. |
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. |
Lancet Oncol, 16, 7, 816-829 |
Lancet Oncol, 16, 7, 816-829 |
Lancet Oncol, 16, 7, 816-829 |
2015/01 |
有 |
|
|
公開 |
| Goto Y, Zeng L, Yeom CJ, Zhu Y, Morinibu A, Shinomiya K, Kobayashi M, Hirota K, Itasaka S, Yoshimura M, Tanimoto K, Torii M, Sowa T, Menju T, Sonobe M, Kakeya H, Toi M, Date H, Hammond EM, Hiraoka M, Harada H. |
|
Goto Y, Zeng L, Yeom CJ, Zhu Y, Morinibu A, Shinomiya K, Kobayashi M, Hirota K, Itasaka S, Yoshimura M, Tanimoto K, Torii M, Sowa T, Menju T, Sonobe M, Kakeya H, Toi M, Date H, Hammond EM, Hiraoka M, Harada H. |
UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1α. Nat Commun. |
UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1α. Nat Commun. |
UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1α. Nat Commun. |
Nature Communications, 23, 6, 6153 |
Nature Communications, 23, 6, 6153 |
Nature Communications, 23, 6, 6153 |
2015/01 |
有 |
|
|
公開 |
| Sugimoto M, Takada M, Toi M. |
|
Sugimoto M, Takada M, Toi M. |
Development of Web tools to predict axillary lymph node metastasis and pathological response to neoadjuvant chemotherapy in breast cancer patients. |
Development of Web tools to predict axillary lymph node metastasis and pathological response to neoadjuvant chemotherapy in breast cancer patients. |
Development of Web tools to predict axillary lymph node metastasis and pathological response to neoadjuvant chemotherapy in breast cancer patients. |
Int J Biol Markers, 29, 4, e372-379 |
Int J Biol Markers, 29, 4, e372-379 |
Int J Biol Markers, 29, 4, e372-379 |
2014/12 |
有 |
英語 |
|
公開 |
| Sumi E, Sugie T, Yoshimura K, Tada H, Ikeda T, Suzuki E, Tanaka Y, Teramukai S, Shimizu A, Toi M, Minato N. |
|
Sumi E, Sugie T, Yoshimura K, Tada H, Ikeda T, Suzuki E, Tanaka Y, Teramukai S, Shimizu A, Toi M, Minato N. |
Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol. |
Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol. |
Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol. |
J Transl Med, 25, 12 |
J Transl Med, 25, 12 |
J Transl Med, 25, 12 |
2014/11 |
有 |
|
|
公開 |
| Itou J, Tanaka S, Sato F, Akiyama R, Kawakami Y, Toi M |
Itou J, Tanaka S, Sato F, Akiyama R, Kawakami Y, Toi M |
Itou J, Tanaka S, Sato F, Akiyama R, Kawakami Y, Toi M |
An optical labeling-based proliferation assay system reveals the paracrine effect of interleukin-6 in breast cancer |
An optical labeling-based proliferation assay system reveals the paracrine effect of interleukin-6 in breast cancer |
An optical labeling-based proliferation assay system reveals the paracrine effect of interleukin-6 in breast cancer |
Biochim Biophys Acta., 1853, 1, 27-40 |
Biochim Biophys Acta., 1853, 1, 27-40 |
Biochim Biophys Acta., 1853, 1, 27-40 |
2014/10 |
有 |
|
|
公開 |
| Fakhrejahani E, Asao Y, Toi M |
Fakhrejahani E, Asao Y, Toi M |
Fakhrejahani E, Asao Y, Toi M |
Tumor microvasculature characteristics studied by image analysis: Histologically-driven angiogenic profile. |
Tumor microvasculature characteristics studied by image analysis: Histologically-driven angiogenic profile. |
Tumor microvasculature characteristics studied by image analysis: Histologically-driven angiogenic profile. |
Int J Biol Markers, 29, 3, 204-207 |
Int J Biol Markers, 29, 3, 204-207 |
Int J Biol Markers, 29, 3, 204-207 |
2014/09 |
有 |
|
|
公開 |
| Masuda N, Higaki K, Takano T, Matsunami N, Morimoto T, Ohtani S, Mizutani M, Miyamoto T, Kuroi K, Ohno S, Morita S, Toi M |
Masuda N, Higaki K, Takano T, Matsunami N, Morimoto T, Ohtani S, Mizutani M, Miyamoto T, Kuroi K, Ohno S, Morita S, Toi M |
Masuda N, Higaki K, Takano T, Matsunami N, Morimoto T, Ohtani S, Mizutani M, Miyamoto T, Kuroi K, Ohno S, Morita S, Toi M |
A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer |
A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer |
A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer |
Cancer Chemother Pharmacol, 74, 2, 229-238 |
Cancer Chemother Pharmacol, 74, 2, 229-238 |
Cancer Chemother Pharmacol, 74, 2, 229-238 |
2014/08 |
有 |
|
|
公開 |
| Miyake KK, Nakamoto Y, Kanao S, Tanaka S, Sugie T, Mikami Y, Toi M, Togashi K |
Miyake KK, Nakamoto Y, Kanao S, Tanaka S, Sugie T, Mikami Y, Toi M, Togashi K |
Miyake KK, Nakamoto Y, Kanao S, Tanaka S, Sugie T, Mikami Y, Toi M, Togashi K |
Journal Club: Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer |
Journal Club: Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer |
Journal Club: Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer |
AJR Am J Roentgenol, 203, 2, 272-279 |
AJR Am J Roentgenol, 203, 2, 272-279 |
AJR Am J Roentgenol, 203, 2, 272-279 |
2014/08 |
有 |
|
|
公開 |
| Sugimoto M, Takada M, Toi M |
Sugimoto M, Takada M, Toi M |
Sugimoto M, Takada M, Toi M |
Development of Web tools to predict axillary lymph node metastasis and pathological response to neoadjuvant chemotherapy in breast cancer patients |
Development of Web tools to predict axillary lymph node metastasis and pathological response to neoadjuvant chemotherapy in breast cancer patients |
Development of Web tools to predict axillary lymph node metastasis and pathological response to neoadjuvant chemotherapy in breast cancer patients |
Int J Biol Markers |
Int J Biol Markers |
Int J Biol Markers |
2014/07 |
有 |
|
|
公開 |
| Mukai H, Noguchi S, Akiyama F, Inaji H, Iwase H, Horiguchi J, Kurebayashi J, Hirata K, Toi M, Kurosumi M, Kohno N, Nishimura R, Nakamura S, Imoto S, Iwase T, Endo T, Saeki T, Ogawa Y, Ito Y, Tokuda Y, Ikeda T |
Mukai H, Noguchi S, Akiyama F, Inaji H, Iwase H, Horiguchi J, Kurebayashi J, Hirata K, Toi M, Kurosumi M, Kohno N, Nishimura R, Nakamura S, Imoto S, Iwase T, Endo T, Saeki T, Ogawa Y, Ito Y, Tokuda Y, Ikeda T |
Mukai H, Noguchi S, Akiyama F, Inaji H, Iwase H, Horiguchi J, Kurebayashi J, Hirata K, Toi M, Kurosumi M, Kohno N, Nishimura R, Nakamura S, Imoto S, Iwase T, Endo T, Saeki T, Ogawa Y, Ito Y, Tokuda Y, Ikeda T |
2013 clinical practice guidelines (The Japanese Breast Cancer Society) |
2013 clinical practice guidelines (The Japanese Breast Cancer Society) |
2013 clinical practice guidelines (The Japanese Breast Cancer Society) |
history, policy and mission. Breast Cancer |
history, policy and mission. Breast Cancer |
history, policy and mission. Breast Cancer |
2014/07 |
有 |
|
|
公開 |
| M. Takada; H. Ishiguro; S. Nagai; S. Ohtani; H. Kawabata; Y. Yanagita; Y. Hozumi; C. Shimizu; S. Takao; N. Sato; Y. Kosaka; Y. Sagara; H. Iwata; S. Ohno; K. Kuroi; N. Masuda; H. Yamashiro; M. Sugimoto; M. Kondo; Y. Naito; H. Sasano; T. Inamoto; S. Morita; M. Toi |
M. Takada; H. Ishiguro; S. Nagai; S. Ohtani; H. Kawabata; Y. Yanagita; Y. Hozumi; C. Shimizu; S. Takao; N. Sato; Y. Kosaka; Y. Sagara; H. Iwata; S. Ohno; K. Kuroi; N. Masuda; H. Yamashiro; M. Sugimoto; M. Kondo; Y. Naito; H. Sasano; T. Inamoto; S. Morita; M. Toi |
M. Takada; H. Ishiguro; S. Nagai; S. Ohtani; H. Kawabata; Y. Yanagita; Y. Hozumi; C. Shimizu; S. Takao; N. Sato; Y. Kosaka; Y. Sagara; H. Iwata; S. Ohno; K. Kuroi; N. Masuda; H. Yamashiro; M. Sugimoto; M. Kondo; Y. Naito; H. Sasano; T. Inamoto; S. Morita; M. Toi |
Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study) |
Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study) |
Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study) |
Breast Cancer Research and Treatment, 145, 1, 143-153 |
Breast Cancer Research and Treatment, 145, 1, 143-153 |
Breast Cancer Research and Treatment, 145, 1, 143-153 |
2014/05 |
有 |
英語 |
|
公開 |
| F. André; R. O'Regan; M. Ozguroglu; M. Toi; B. Xu; G. Jerusalem; N. Masuda; S. Wilks; F. Arena; C. Isaacs; Y.-S. Yap; Z. Papai; I. Lang; A. Armstrong; G. Lerzo; M. White; K. Shen; J. Litton; D. Chen; Y. Zhang; S. Ali; T. Taran; L. Gianni |
F. André; R. O'Regan; M. Ozguroglu; M. Toi; B. Xu; G. Jerusalem; N. Masuda; S. Wilks; F. Arena; C. Isaacs; Y.-S. Yap; Z. Papai; I. Lang; A. Armstrong; G. Lerzo; M. White; K. Shen; J. Litton; D. Chen; Y. Zhang; S. Ali; T. Taran; L. Gianni |
F. André; R. O'Regan; M. Ozguroglu; M. Toi; B. Xu; G. Jerusalem; N. Masuda; S. Wilks; F. Arena; C. Isaacs; Y.-S. Yap; Z. Papai; I. Lang; A. Armstrong; G. Lerzo; M. White; K. Shen; J. Litton; D. Chen; Y. Zhang; S. Ali; T. Taran; L. Gianni |
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial |
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial |
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial |
The Lancet Oncology, 15, 6, 580-591 |
The Lancet Oncology, 15, 6, 580-591 |
The Lancet Oncology, 15, 6, 580-591 |
2014/04 |
有 |
英語 |
|
公開 |
| N. Onishi; S. Kanao; M. Kataoka; M. Iima; R. Sakaguchi; M. Kawai; T.R. Kataoka; Y. Mikami; M. Toi; K. Togashi |
N. Onishi; S. Kanao; M. Kataoka; M. Iima; R. Sakaguchi; M. Kawai; T.R. Kataoka; Y. Mikami; M. Toi; K. Togashi |
N. Onishi; S. Kanao; M. Kataoka; M. Iima; R. Sakaguchi; M. Kawai; T.R. Kataoka; Y. Mikami; M. Toi; K. Togashi |
Apparent diffusion coefficient as a potential surrogate marker for Ki-67 index in mucinous breast carcinoma |
Apparent diffusion coefficient as a potential surrogate marker for Ki-67 index in mucinous breast carcinoma |
Apparent diffusion coefficient as a potential surrogate marker for Ki-67 index in mucinous breast carcinoma |
Journal of Magnetic Resonance Imaging |
Journal of Magnetic Resonance Imaging |
Journal of Magnetic Resonance Imaging |
2014/03 |
有 |
英語 |
|
公開 |
| Fakhrejahani E, Toi M |
Fakhrejahani E, Toi M |
Fakhrejahani E, Toi M |
Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials |
Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials |
Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials |
Jpn J Clin Oncol, 44, 3, 197-207 |
Jpn J Clin Oncol, 44, 3, 197-207 |
Jpn J Clin Oncol, 44, 3, 197-207 |
2014/03 |
有 |
|
|
公開 |
| K. Kuroi; M. Toi; S. Ohno; S. Nakamura; H. Iwata; N. Masuda; N. Sato; H. Tsuda; M. Kurosumi; F. Akiyama |
K. Kuroi; M. Toi; S. Ohno; S. Nakamura; H. Iwata; N. Masuda; N. Sato; H. Tsuda; M. Kurosumi; F. Akiyama |
K. Kuroi; M. Toi; S. Ohno; S. Nakamura; H. Iwata; N. Masuda; N. Sato; H. Tsuda; M. Kurosumi; F. Akiyama |
Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG |
Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG |
Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG |
Breast Cancer, 1-10 |
Breast Cancer, 1-10 |
Breast Cancer, 1-10 |
2014/02 |
有 |
英語 |
|
公開 |
| W. Tsuji; S. Teramukai; M. Ueno; M. Toi; T. Inamoto |
W. Tsuji; S. Teramukai; M. Ueno; M. Toi; T. Inamoto |
W. Tsuji; S. Teramukai; M. Ueno; M. Toi; T. Inamoto |
Prognostic factors for survival after first recurrence in breast cancer: A retrospective analysis of 252 recurrent cases at a single institution |
Prognostic factors for survival after first recurrence in breast cancer: A retrospective analysis of 252 recurrent cases at a single institution |
Prognostic factors for survival after first recurrence in breast cancer: A retrospective analysis of 252 recurrent cases at a single institution |
Breast Cancer, 21, 1, 86-95 |
Breast Cancer, 21, 1, 86-95 |
Breast Cancer, 21, 1, 86-95 |
2014/01 |
有 |
英語 |
|
公開 |
| M. Toi; T. Saeki; H. Iwata; K. Inoue; Y. Tokuda; Y. Sato; Y. Ito; K. Aogi; Y. Takatsuka; H. Arioka |
M. Toi; T. Saeki; H. Iwata; K. Inoue; Y. Tokuda; Y. Sato; Y. Ito; K. Aogi; Y. Takatsuka; H. Arioka |
M. Toi; T. Saeki; H. Iwata; K. Inoue; Y. Tokuda; Y. Sato; Y. Ito; K. Aogi; Y. Takatsuka; H. Arioka |
A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance |
A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance |
A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance |
Breast Cancer, 21, 1, 20-27 |
Breast Cancer, 21, 1, 20-27 |
Breast Cancer, 21, 1, 20-27 |
2014 |
有 |
英語 |
|
公開 |
| T. Kitai; M. Torii; T. Sugie; S. Kanao; Y. Mikami; T. Shiina; M. Toi |
T. Kitai; M. Torii; T. Sugie; S. Kanao; Y. Mikami; T. Shiina; M. Toi |
T. Kitai; M. Torii; T. Sugie; S. Kanao; Y. Mikami; T. Shiina; M. Toi |
Photoacoustic mammography: Initial clinical results |
Photoacoustic mammography: Initial clinical results |
Photoacoustic mammography: Initial clinical results |
Breast Cancer, 21, 2, 146-153 |
Breast Cancer, 21, 2, 146-153 |
Breast Cancer, 21, 2, 146-153 |
2014 |
有 |
英語 |
|
公開 |
| A.-A. Lertkhachonsuk; C.H. Yip; T. Khuhaprema; D.-S. Chen; M. Plummer; S.H. Jee; M. Toi; S. Wilailak |
A.-A. Lertkhachonsuk; C.H. Yip; T. Khuhaprema; D.-S. Chen; M. Plummer; S.H. Jee; M. Toi; S. Wilailak |
A.-A. Lertkhachonsuk; C.H. Yip; T. Khuhaprema; D.-S. Chen; M. Plummer; S.H. Jee; M. Toi; S. Wilailak |
Cancer prevention in asia: Resource-stratified guidelines from the asian oncology summit 2013 |
Cancer prevention in asia: Resource-stratified guidelines from the asian oncology summit 2013 |
Cancer prevention in asia: Resource-stratified guidelines from the asian oncology summit 2013 |
The Lancet Oncology, 14, 12, E497-E507 |
The Lancet Oncology, 14, 12, E497-E507 |
The Lancet Oncology, 14, 12, E497-E507 |
2013/11 |
有 |
英語 |
|
公開 |
| M. Kawashima; N. Iwamoto; N. Kawaguchi-Sakita; M. Sugimoto; T. Ueno; Y. Mikami; K. Terasawa; T.-A. Sato; K. Tanaka; K. Shimizu; M. Toi |
M. Kawashima; N. Iwamoto; N. Kawaguchi-Sakita; M. Sugimoto; T. Ueno; Y. Mikami; K. Terasawa; T.-A. Sato; K. Tanaka; K. Shimizu; M. Toi |
M. Kawashima; N. Iwamoto; N. Kawaguchi-Sakita; M. Sugimoto; T. Ueno; Y. Mikami; K. Terasawa; T.-A. Sato; K. Tanaka; K. Shimizu; M. Toi |
High-resolution imaging mass spectrometry reveals detailed spatial distribution of phosphatidylinositols in human breast cancer |
High-resolution imaging mass spectrometry reveals detailed spatial distribution of phosphatidylinositols in human breast cancer |
High-resolution imaging mass spectrometry reveals detailed spatial distribution of phosphatidylinositols in human breast cancer |
Cancer Science, 104, 10, 1372-1379 |
Cancer Science, 104, 10, 1372-1379 |
Cancer Science, 104, 10, 1372-1379 |
2013/10 |
有 |
英語 |
|
公開 |
| J. Itou; Y. Matsumoto; K. Yoshikawa; M. Toi |
J. Itou; Y. Matsumoto; K. Yoshikawa; M. Toi |
J. Itou; Y. Matsumoto; K. Yoshikawa; M. Toi |
Sal-like 4 (SALL4) suppresses CDH1 expression and maintains cell dispersion in basal-like breast cancer |
Sal-like 4 (SALL4) suppresses CDH1 expression and maintains cell dispersion in basal-like breast cancer |
Sal-like 4 (SALL4) suppresses CDH1 expression and maintains cell dispersion in basal-like breast cancer |
FEBS Letters, 587, 18, 3115-3121 |
FEBS Letters, 587, 18, 3115-3121 |
FEBS Letters, 587, 18, 3115-3121 |
2013/09/17 |
有 |
英語 |
|
公開 |
| A. Goldhirsch; E.P. Winer; A.S. Coates; R.D. Gelber; M. Piccart-Gebhart; B. Thürlimann; H.-J. Senn; K.S. Albain; F. André; J. Bergh; H. Bonnefoi; D. Bretel-Morales; H. Burstein; F. Cardoso; M. Castiglione-Gertsch; A.S. Coates; M. Colleoni; A. Costa; G. Curigliano; N.E. Davidson; A.D. Leo; B. Ejlertsen; J.F. Forbes; R.D. Gelber; M. Gnant; A. Goldhirsch; P. Goodwin; P.E. Goss; J.R. Harris; D.F. Hayes; C.A. Hudis; J.N. Ingle; J. Jassem; Z. Jiang; P. Karlsson; S. Loibl; M. Morrow; M. Namer; C.K. Osborne; A.H. Partridge; F. Penault-Llorca; C.M. Perou; M.J. Piccart-Gebhart; K.I. Pritchard; E.J.T. Rutgers; F. Sedlmayer; V. Semiglazov; Z.-M. Shao; I. Smith; B. Thürlimann; M. Toi; A. Tutt; M. Untch; G. Viale; T. Watanabe; N. Wilcken; E.P. Winer; W.C. Wood |
A. Goldhirsch; E.P. Winer; A.S. Coates; R.D. Gelber; M. Piccart-Gebhart; B. Thürlimann; H.-J. Senn; K.S. Albain; F. André; J. Bergh; H. Bonnefoi; D. Bretel-Morales; H. Burstein; F. Cardoso; M. Castiglione-Gertsch; A.S. Coates; M. Colleoni; A. Costa; G. Curigliano; N.E. Davidson; A.D. Leo; B. Ejlertsen; J.F. Forbes; R.D. Gelber; M. Gnant; A. Goldhirsch; P. Goodwin; P.E. Goss; J.R. Harris; D.F. Hayes; C.A. Hudis; J.N. Ingle; J. Jassem; Z. Jiang; P. Karlsson; S. Loibl; M. Morrow; M. Namer; C.K. Osborne; A.H. Partridge; F. Penault-Llorca; C.M. Perou; M.J. Piccart-Gebhart; K.I. Pritchard; E.J.T. Rutgers; F. Sedlmayer; V. Semiglazov; Z.-M. Shao; I. Smith; B. Thürlimann; M. Toi; A. Tutt; M. Untch; G. Viale; T. Watanabe; N. Wilcken; E.P. Winer; W.C. Wood |
A. Goldhirsch; E.P. Winer; A.S. Coates; R.D. Gelber; M. Piccart-Gebhart; B. Thürlimann; H.-J. Senn; K.S. Albain; F. André; J. Bergh; H. Bonnefoi; D. Bretel-Morales; H. Burstein; F. Cardoso; M. Castiglione-Gertsch; A.S. Coates; M. Colleoni; A. Costa; G. Curigliano; N.E. Davidson; A.D. Leo; B. Ejlertsen; J.F. Forbes; R.D. Gelber; M. Gnant; A. Goldhirsch; P. Goodwin; P.E. Goss; J.R. Harris; D.F. Hayes; C.A. Hudis; J.N. Ingle; J. Jassem; Z. Jiang; P. Karlsson; S. Loibl; M. Morrow; M. Namer; C.K. Osborne; A.H. Partridge; F. Penault-Llorca; C.M. Perou; M.J. Piccart-Gebhart; K.I. Pritchard; E.J.T. Rutgers; F. Sedlmayer; V. Semiglazov; Z.-M. Shao; I. Smith; B. Thürlimann; M. Toi; A. Tutt; M. Untch; G. Viale; T. Watanabe; N. Wilcken; E.P. Winer; W.C. Wood |
Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013 |
Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013 |
Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013 |
Annals of Oncology, 24, 9, 2206-2223 |
Annals of Oncology, 24, 9, 2206-2223 |
Annals of Oncology, 24, 9, 2206-2223 |
2013/09 |
有 |
英語 |
|
公開 |
| H. Ishiguro; M. Toi |
H. Ishiguro; M. Toi |
H. Ishiguro; M. Toi |
Colony-stimulating factors for febrile neutropenia [5] |
Colony-stimulating factors for febrile neutropenia [5] |
Colony-stimulating factors for febrile neutropenia [5] |
New England Journal of Medicine, 369, 3, 284-284 |
New England Journal of Medicine, 369, 3, 284-284 |
New England Journal of Medicine, 369, 3, 284-284 |
2013/07/18 |
|
英語 |
|
公開 |
| T. Sugie; T. Sawada; N. Tagaya; T. Kinoshita; K. Yamagami; H. Suwa; T. Ikeda; K. Yoshimura; M. Niimi; A. Shimizu; M. Toi |
T. Sugie; T. Sawada; N. Tagaya; T. Kinoshita; K. Yamagami; H. Suwa; T. Ikeda; K. Yoshimura; M. Niimi; A. Shimizu; M. Toi |
T. Sugie; T. Sawada; N. Tagaya; T. Kinoshita; K. Yamagami; H. Suwa; T. Ikeda; K. Yoshimura; M. Niimi; A. Shimizu; M. Toi |
Comparison of the indocyanine green fluorescence and blue dye methods in detection of sentinel lymph nodes in early-stage breast cancer |
Comparison of the indocyanine green fluorescence and blue dye methods in detection of sentinel lymph nodes in early-stage breast cancer |
Comparison of the indocyanine green fluorescence and blue dye methods in detection of sentinel lymph nodes in early-stage breast cancer |
Annals of Surgical Oncology, 20, 7, 2213-2218 |
Annals of Surgical Oncology, 20, 7, 2213-2218 |
Annals of Surgical Oncology, 20, 7, 2213-2218 |
2013/07 |
有 |
英語 |
|
公開 |
| M. Komuro; K. Suzuki; M. Kanebako; T. Kawahara; T. Otoi; K. Kitazato; T. Inagi; K. Makino; M. Toi; H. Terada |
M. Komuro; K. Suzuki; M. Kanebako; T. Kawahara; T. Otoi; K. Kitazato; T. Inagi; K. Makino; M. Toi; H. Terada |
M. Komuro; K. Suzuki; M. Kanebako; T. Kawahara; T. Otoi; K. Kitazato; T. Inagi; K. Makino; M. Toi; H. Terada |
Novel iontophoretic administration method for local therapy of breast cancer |
Novel iontophoretic administration method for local therapy of breast cancer |
Novel iontophoretic administration method for local therapy of breast cancer |
Journal of Controlled Release, 168, 3, 298-306 |
Journal of Controlled Release, 168, 3, 298-306 |
Journal of Controlled Release, 168, 3, 298-306 |
2013/06/28 |
有 |
英語 |
|
公開 |
| A.S.M. Idrees; T. Sugie; C. Inoue; K. Murata-Hirai; H. Okamura; C.T. Morita; N. Minato; M. Toi; Y. Tanaka |
A.S.M. Idrees; T. Sugie; C. Inoue; K. Murata-Hirai; H. Okamura; C.T. Morita; N. Minato; M. Toi; Y. Tanaka |
A.S.M. Idrees; T. Sugie; C. Inoue; K. Murata-Hirai; H. Okamura; C.T. Morita; N. Minato; M. Toi; Y. Tanaka |
Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid |
Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid |
Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid |
Cancer Science, 104, 5, 536-542 |
Cancer Science, 104, 5, 536-542 |
Cancer Science, 104, 5, 536-542 |
2013/05 |
有 |
日本語 |
|
公開 |
| H. Ishiguro; K. Kawaguchi; T. Nishimura; M. Toi |
H. Ishiguro; K. Kawaguchi; T. Nishimura; M. Toi |
H. Ishiguro; K. Kawaguchi; T. Nishimura; M. Toi |
Antipsychotics-containing regimen as an alternative to standard antiemetics for delayed nausea induced by highly emetogenic chemotherapy |
Antipsychotics-containing regimen as an alternative to standard antiemetics for delayed nausea induced by highly emetogenic chemotherapy |
Antipsychotics-containing regimen as an alternative to standard antiemetics for delayed nausea induced by highly emetogenic chemotherapy |
Journal of Clinical Oncology, 31, 10, 1377-1378 |
Journal of Clinical Oncology, 31, 10, 1377-1378 |
Journal of Clinical Oncology, 31, 10, 1377-1378 |
2013/04/01 |
|
英語 |
|
公開 |
| W. Li; S. Saji; F. Sato; M. Noda; M. Toi |
W. Li; S. Saji; F. Sato; M. Noda; M. Toi |
W. Li; S. Saji; F. Sato; M. Noda; M. Toi |
Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects |
Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects |
Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects |
International Journal of Biological Markers, 28, 2, 117-130 |
International Journal of Biological Markers, 28, 2, 117-130 |
International Journal of Biological Markers, 28, 2, 117-130 |
2013/04 |
有 |
日本語 |
|
公開 |
| L.W. Chow; S.Y. Tung; T.-Y. Ng; S.-A. Im; M.-H. Lee; A.Y. Yip; M. Toi; S. Glück |
L.W. Chow; S.Y. Tung; T.-Y. Ng; S.-A. Im; M.-H. Lee; A.Y. Yip; M. Toi; S. Glück |
L.W. Chow; S.Y. Tung; T.-Y. Ng; S.-A. Im; M.-H. Lee; A.Y. Yip; M. Toi; S. Glück |
Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II-III invasive breast cancer: The OOTR-N001 study |
Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II-III invasive breast cancer: The OOTR-N001 study |
Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II-III invasive breast cancer: The OOTR-N001 study |
Expert Opinion on Investigational Drugs, 22, 3, 299-307 |
Expert Opinion on Investigational Drugs, 22, 3, 299-307 |
Expert Opinion on Investigational Drugs, 22, 3, 299-307 |
2013/03 |
有 |
英語 |
|
公開 |
| W. Tsuji; T. Inamoto; R. Ito; N. Morimoto; Y. Tabata; M. Toi |
W. Tsuji; T. Inamoto; R. Ito; N. Morimoto; Y. Tabata; M. Toi |
W. Tsuji; T. Inamoto; R. Ito; N. Morimoto; Y. Tabata; M. Toi |
Simple and longstanding adipose tissue engineering in rabbits |
Simple and longstanding adipose tissue engineering in rabbits |
Simple and longstanding adipose tissue engineering in rabbits |
Journal of Artificial Organs, 16, 1, 110-114 |
Journal of Artificial Organs, 16, 1, 110-114 |
Journal of Artificial Organs, 16, 1, 110-114 |
2013/03 |
有 |
英語 |
|
公開 |
| T. Sugie; K. Murata-Hirai; M. Iwasaki; C.T. Morita; W. Li; H. Okamura; N. Minato; M. Toi; Y. Tanaka |
T. Sugie; K. Murata-Hirai; M. Iwasaki; C.T. Morita; W. Li; H. Okamura; N. Minato; M. Toi; Y. Tanaka |
T. Sugie; K. Murata-Hirai; M. Iwasaki; C.T. Morita; W. Li; H. Okamura; N. Minato; M. Toi; Y. Tanaka |
Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: Effect of IL-18 on helper NK cells |
Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: Effect of IL-18 on helper NK cells |
Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: Effect of IL-18 on helper NK cells |
Cancer Immunology, Immunotherapy, 62, 4, 677-687 |
Cancer Immunology, Immunotherapy, 62, 4, 677-687 |
Cancer Immunology, Immunotherapy, 62, 4, 677-687 |
2013 |
有 |
日本語 |
|
公開 |
| Mikami, Yoshiki;Ueno, Takayuki;Yoshimura, Kenichi;Tsuda, Hitoshi;Kurosumi, Masafumi;Masuda, Shinobu;Horii, Rie;Toi, Masakazu;Sasano, Hironobu |
Mikami, Yoshiki;Ueno, Takayuki;Yoshimura, Kenichi;Tsuda, Hitoshi;Kurosumi, Masafumi;Masuda, Shinobu;Horii, Rie;Toi, Masakazu;Sasano, Hironobu |
Mikami, Yoshiki;Ueno, Takayuki;Yoshimura, Kenichi;Tsuda, Hitoshi;Kurosumi, Masafumi;Masuda, Shinobu;Horii, Rie;Toi, Masakazu;Sasano, Hironobu |
Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study. |
Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study. |
Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study. |
Cancer science |
Cancer science |
Cancer science |
2013 |
有 |
英語 |
|
公開 |
| Tsuji, Wakako;Ishiguro, Hiroshi;Tanaka, Sunao;Takeuchi, Megumi;Ueno, Takayuki;Toi, Masakazu |
Tsuji, Wakako;Ishiguro, Hiroshi;Tanaka, Sunao;Takeuchi, Megumi;Ueno, Takayuki;Toi, Masakazu |
Tsuji, Wakako;Ishiguro, Hiroshi;Tanaka, Sunao;Takeuchi, Megumi;Ueno, Takayuki;Toi, Masakazu |
Orally administered S-1 suppresses circulating endothelial cell counts in metastatic breast cancer patients. |
Orally administered S-1 suppresses circulating endothelial cell counts in metastatic breast cancer patients. |
Orally administered S-1 suppresses circulating endothelial cell counts in metastatic breast cancer patients. |
International journal of clinical oncology |
International journal of clinical oncology |
International journal of clinical oncology |
2013 |
有 |
英語 |
|
公開 |
| Ueno, Takayuki;Masuda, Norikazu;Yamanaka, Takeharu;Saji, Shigehira;Kuroi, Katsumasa;Sato, Nobuaki;Takei, Hiroyuki;Yamamoto, Yutaka;Ohno, Shinji;Yamashita, Hiroko;Hisamatsu, Kazufumi;Aogi, Kenjiro;Iwata, Hiroji;Sasano, Hironobu;Toi, Masakazu |
Ueno, Takayuki;Masuda, Norikazu;Yamanaka, Takeharu;Saji, Shigehira;Kuroi, Katsumasa;Sato, Nobuaki;Takei, Hiroyuki;Yamamoto, Yutaka;Ohno, Shinji;Yamashita, Hiroko;Hisamatsu, Kazufumi;Aogi, Kenjiro;Iwata, Hiroji;Sasano, Hironobu;Toi, Masakazu |
Ueno, Takayuki;Masuda, Norikazu;Yamanaka, Takeharu;Saji, Shigehira;Kuroi, Katsumasa;Sato, Nobuaki;Takei, Hiroyuki;Yamamoto, Yutaka;Ohno, Shinji;Yamashita, Hiroko;Hisamatsu, Kazufumi;Aogi, Kenjiro;Iwata, Hiroji;Sasano, Hironobu;Toi, Masakazu |
Evaluating the 21-gene assay Recurrence Score(®) as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer. |
Evaluating the 21-gene assay Recurrence Score(®) as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer. |
Evaluating the 21-gene assay Recurrence Score(®) as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer. |
International journal of clinical oncology |
International journal of clinical oncology |
International journal of clinical oncology |
2013 |
有 |
日本語 |
|
公開 |
| M. Chan; L. Wang; N. Chanplakorn; K. Tamaki; T. Ueno; M. Toi; W. Loo; L.W.C. Chow; T. Suzuki; H. Sasano |
M. Chan; L. Wang; N. Chanplakorn; K. Tamaki; T. Ueno; M. Toi; W. Loo; L.W.C. Chow; T. Suzuki; H. Sasano |
M. Chan; L. Wang; N. Chanplakorn; K. Tamaki; T. Ueno; M. Toi; W. Loo; L.W.C. Chow; T. Suzuki; H. Sasano |
Author\\'s response |
Author\\'s response |
Author\\'s response |
Expert Opinion on Therapeutic Targets, 17, 1, 106- |
Expert Opinion on Therapeutic Targets, 17, 1, 106- |
Expert Opinion on Therapeutic Targets, 17, 1, 106- |
2013 |
有 |
英語 |
|
公開 |
| B. Zheng; R. Ishikawa; J. Takamatsu; K. Ikeuchi; T. Endo; K. Sato; T. Ueno; T. Sugie; M. Toi; S. Kanao; K. Togashi |
B. Zheng; R. Ishikawa; J. Takamatsu; K. Ikeuchi; T. Endo; K. Sato; T. Ueno; T. Sugie; M. Toi; S. Kanao; K. Togashi |
B. Zheng; R. Ishikawa; J. Takamatsu; K. Ikeuchi; T. Endo; K. Sato; T. Ueno; T. Sugie; M. Toi; S. Kanao; K. Togashi |
Breast MR Image fusion by deformable implicit polynomial (DIP) |
Breast MR Image fusion by deformable implicit polynomial (DIP) |
Breast MR Image fusion by deformable implicit polynomial (DIP) |
IPSJ Transactions on Computer Vision and Applications, 5, 99-103 |
IPSJ Transactions on Computer Vision and Applications, 5, 99-103 |
IPSJ Transactions on Computer Vision and Applications, 5, 99-103 |
2013 |
有 |
英語 |
|
公開 |
| Y. Suzuki; T. Saeki; K. Aogi; M. Toi; H. Fujii; K. Inoue; T. Watanabe; Y. Fujiwara; Y. Ito; Y. Takatsuka; H. Iwata; H. Arioka; Y. Tokuda |
Y. Suzuki; T. Saeki; K. Aogi; M. Toi; H. Fujii; K. Inoue; T. Watanabe; Y. Fujiwara; Y. Ito; Y. Takatsuka; H. Iwata; H. Arioka; Y. Tokuda |
Y. Suzuki; T. Saeki; K. Aogi; M. Toi; H. Fujii; K. Inoue; T. Watanabe; Y. Fujiwara; Y. Ito; Y. Takatsuka; H. Iwata; H. Arioka; Y. Tokuda |
A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane |
A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane |
A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane |
International Journal of Clinical Oncology, 18, 4, 590-597 |
International Journal of Clinical Oncology, 18, 4, 590-597 |
International Journal of Clinical Oncology, 18, 4, 590-597 |
2013 |
有 |
英語 |
|
公開 |
| D. Cameron; J. Brown; R. Dent; C. Jackisch; J. Mackey; X. Pivot; G.G. Steger; T.M. Suter; M. Toi; M. Parmar; R. Laeufle; Y.-H. Im; G. Romieu; V. Harvey; O. Lipatov; T. Pienkowski; P. Cottu; A. Chan; S.-A. Im; P.S. Hall; L. Bubuteishvili-Pacaud; V. Henschel; R.J. Deurloo; C. Pallaud; R. Bell |
D. Cameron; J. Brown; R. Dent; C. Jackisch; J. Mackey; X. Pivot; G.G. Steger; T.M. Suter; M. Toi; M. Parmar; R. Laeufle; Y.-H. Im; G. Romieu; V. Harvey; O. Lipatov; T. Pienkowski; P. Cottu; A. Chan; S.-A. Im; P.S. Hall; L. Bubuteishvili-Pacaud; V. Henschel; R.J. Deurloo; C. Pallaud; R. Bell |
D. Cameron; J. Brown; R. Dent; C. Jackisch; J. Mackey; X. Pivot; G.G. Steger; T.M. Suter; M. Toi; M. Parmar; R. Laeufle; Y.-H. Im; G. Romieu; V. Harvey; O. Lipatov; T. Pienkowski; P. Cottu; A. Chan; S.-A. Im; P.S. Hall; L. Bubuteishvili-Pacaud; V. Henschel; R.J. Deurloo; C. Pallaud; R. Bell |
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): Primary results of a randomised, phase 3 trial |
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): Primary results of a randomised, phase 3 trial |
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): Primary results of a randomised, phase 3 trial |
The Lancet Oncology, 14, 10, 933-942 |
The Lancet Oncology, 14, 10, 933-942 |
The Lancet Oncology, 14, 10, 933-942 |
2013 |
有 |
英語 |
|
公開 |
| R. Kumar; A. Horvath; R. Mazumder; M. Toi; F. Sato; M.R. Pillai; L. Costa; M. Carmo-Fonseca; S. Knapp; A. Dutt; S. Gupta; R. Badwe |
R. Kumar; A. Horvath; R. Mazumder; M. Toi; F. Sato; M.R. Pillai; L. Costa; M. Carmo-Fonseca; S. Knapp; A. Dutt; S. Gupta; R. Badwe |
R. Kumar; A. Horvath; R. Mazumder; M. Toi; F. Sato; M.R. Pillai; L. Costa; M. Carmo-Fonseca; S. Knapp; A. Dutt; S. Gupta; R. Badwe |
The Global Cancer Genomics Consortium\\'s Second Annual Symposium: Genomics Medicine in Cancer Research |
The Global Cancer Genomics Consortium\\'s Second Annual Symposium: Genomics Medicine in Cancer Research |
The Global Cancer Genomics Consortium\\'s Second Annual Symposium: Genomics Medicine in Cancer Research |
Genes and Cancer, 4, 5-6, 196-200 |
Genes and Cancer, 4, 5-6, 196-200 |
Genes and Cancer, 4, 5-6, 196-200 |
2013 |
有 |
英語 |
|
公開 |
| C. Kaga; A. Takagi; M. Kano; S. Kado; I. Kato; M. Sakai; K. Miyazaki; M. Nanno; F. Ishikawa; Y. Ohashi; M. Toi |
C. Kaga; A. Takagi; M. Kano; S. Kado; I. Kato; M. Sakai; K. Miyazaki; M. Nanno; F. Ishikawa; Y. Ohashi; M. Toi |
C. Kaga; A. Takagi; M. Kano; S. Kado; I. Kato; M. Sakai; K. Miyazaki; M. Nanno; F. Ishikawa; Y. Ohashi; M. Toi |
Lactobacillus casei Shirota enhances the preventive efficacy of soymilk in chemically induced breast cancer |
Lactobacillus casei Shirota enhances the preventive efficacy of soymilk in chemically induced breast cancer |
Lactobacillus casei Shirota enhances the preventive efficacy of soymilk in chemically induced breast cancer |
Cancer Science, 104, 11, 1508-1514 |
Cancer Science, 104, 11, 1508-1514 |
Cancer Science, 104, 11, 1508-1514 |
2013 |
有 |
英語 |
|
公開 |
| M. Toi; S. Hirota; A. Tomotaki; N. Sato; Y. Hozumi; K. Anan; T. Nagashima; Y. Tokuda; N. Masuda; S. Ohsumi; S. Ohno; M. Takahashi; H. Hayashi; S. Yamamoto; Y. Ohashi |
M. Toi; S. Hirota; A. Tomotaki; N. Sato; Y. Hozumi; K. Anan; T. Nagashima; Y. Tokuda; N. Masuda; S. Ohsumi; S. Ohno; M. Takahashi; H. Hayashi; S. Yamamoto; Y. Ohashi |
M. Toi; S. Hirota; A. Tomotaki; N. Sato; Y. Hozumi; K. Anan; T. Nagashima; Y. Tokuda; N. Masuda; S. Ohsumi; S. Ohno; M. Takahashi; H. Hayashi; S. Yamamoto; Y. Ohashi |
Probiotic beverage with soy isoflavone consumption for breast cancer prevention: A case-control study |
Probiotic beverage with soy isoflavone consumption for breast cancer prevention: A case-control study |
Probiotic beverage with soy isoflavone consumption for breast cancer prevention: A case-control study |
Current Nutrition and Food Science, 9, 3, 194-200 |
Current Nutrition and Food Science, 9, 3, 194-200 |
Current Nutrition and Food Science, 9, 3, 194-200 |
2013 |
有 |
英語 |
|
公開 |
| H. Yamashiro; M. Takada; E. Nakatani; S. Imai; A. Yamauchi; S. Tsuyuki; Y. Matsutani; S. Sakata; Y. Wada; R. Okamura; T. Harada; F. Tanaka; Y. Moriguchi; H. Kato; S. Higashide; N. Kan; H. Yoshibayashi; H. Suwa; T. Okino; I. Nakayama; Y. Ichinose; K. Yamagami; T. Hashimoto; T. Inamoto; M. Toi |
H. Yamashiro; M. Takada; E. Nakatani; S. Imai; A. Yamauchi; S. Tsuyuki; Y. Matsutani; S. Sakata; Y. Wada; R. Okamura; T. Harada; F. Tanaka; Y. Moriguchi; H. Kato; S. Higashide; N. Kan; H. Yoshibayashi; H. Suwa; T. Okino; I. Nakayama; Y. Ichinose; K. Yamagami; T. Hashimoto; T. Inamoto; M. Toi |
H. Yamashiro; M. Takada; E. Nakatani; S. Imai; A. Yamauchi; S. Tsuyuki; Y. Matsutani; S. Sakata; Y. Wada; R. Okamura; T. Harada; F. Tanaka; Y. Moriguchi; H. Kato; S. Higashide; N. Kan; H. Yoshibayashi; H. Suwa; T. Okino; I. Nakayama; Y. Ichinose; K. Yamagami; T. Hashimoto; T. Inamoto; M. Toi |
Prevalence and risk factors of bone metastasis and skeletal related events in patients with primary breast cancer in Japan |
Prevalence and risk factors of bone metastasis and skeletal related events in patients with primary breast cancer in Japan |
Prevalence and risk factors of bone metastasis and skeletal related events in patients with primary breast cancer in Japan |
International Journal of Clinical Oncology, 1-11 |
International Journal of Clinical Oncology, 1-11 |
International Journal of Clinical Oncology, 1-11 |
2013 |
有 |
英語 |
|
公開 |
| S. Ohno; L.W.C. Chow; N. Sato; N. Masuda; H. Sasano; F. Takahashi; H. Bando; H. Iwata; T. Morimoto; S. Kamigaki; T. Nakayama; S. Nakamura; K. Kuroi; K. Aogi; M. Kashiwaba; H. Yamashita; K. Hisamatsu; Y. Ito; Y. Yamamoto; T. Ueno; E. Fakhrejahani; N. Yoshida; M. Toi |
S. Ohno; L.W.C. Chow; N. Sato; N. Masuda; H. Sasano; F. Takahashi; H. Bando; H. Iwata; T. Morimoto; S. Kamigaki; T. Nakayama; S. Nakamura; K. Kuroi; K. Aogi; M. Kashiwaba; H. Yamashita; K. Hisamatsu; Y. Ito; Y. Yamamoto; T. Ueno; E. Fakhrejahani; N. Yoshida; M. Toi |
S. Ohno; L.W.C. Chow; N. Sato; N. Masuda; H. Sasano; F. Takahashi; H. Bando; H. Iwata; T. Morimoto; S. Kamigaki; T. Nakayama; S. Nakamura; K. Kuroi; K. Aogi; M. Kashiwaba; H. Yamashita; K. Hisamatsu; Y. Ito; Y. Yamamoto; T. Ueno; E. Fakhrejahani; N. Yoshida; M. Toi |
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: Exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuva |
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: Exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuva |
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: Exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuva |
Breast Cancer Research and Treatment, 142, 1, 69-80 |
Breast Cancer Research and Treatment, 142, 1, 69-80 |
Breast Cancer Research and Treatment, 142, 1, 69-80 |
2013 |
有 |
英語 |
|
公開 |
| K. Kuroi; M. Toi; S. Ohno; S. Nakamura; H. Iwata; N. Masuda; N. Sato; H. Tsuda; M. Kurosumi; F. Akiyama |
K. Kuroi; M. Toi; S. Ohno; S. Nakamura; H. Iwata; N. Masuda; N. Sato; H. Tsuda; M. Kurosumi; F. Akiyama |
K. Kuroi; M. Toi; S. Ohno; S. Nakamura; H. Iwata; N. Masuda; N. Sato; H. Tsuda; M. Kurosumi; F. Akiyama |
Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG |
Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG |
Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG |
Breast Cancer, 1-10 |
Breast Cancer, 1-10 |
Breast Cancer, 1-10 |
2013 |
有 |
英語 |
|
公開 |
| S. Ohno; K. Kuroi; M. Toi |
S. Ohno; K. Kuroi; M. Toi |
S. Ohno; K. Kuroi; M. Toi |
An overview of the Japan Breast Cancer Research Group (JBCRG) activities |
An overview of the Japan Breast Cancer Research Group (JBCRG) activities |
An overview of the Japan Breast Cancer Research Group (JBCRG) activities |
Breast Cancer, 20, 4, 291-295 |
Breast Cancer, 20, 4, 291-295 |
Breast Cancer, 20, 4, 291-295 |
2013 |
有 |
英語 |
|
公開 |
| S. Hamada; S. Hinotsu; H. Ishiguro; M. Toi; K. Kawakami |
S. Hamada; S. Hinotsu; H. Ishiguro; M. Toi; K. Kawakami |
S. Hamada; S. Hinotsu; H. Ishiguro; M. Toi; K. Kawakami |
Cross-national comparison of medical costs shared by payers and patients: A study of postmenopausal women with early-stage breast cancer based on assumption case scenarios and reimbursement fees |
Cross-national comparison of medical costs shared by payers and patients: A study of postmenopausal women with early-stage breast cancer based on assumption case scenarios and reimbursement fees |
Cross-national comparison of medical costs shared by payers and patients: A study of postmenopausal women with early-stage breast cancer based on assumption case scenarios and reimbursement fees |
Breast Care, 8, 4, 282-288 |
Breast Care, 8, 4, 282-288 |
Breast Care, 8, 4, 282-288 |
2013 |
有 |
英語 |
|
公開 |
| M. Toi; J.R. Benson; E.P. Winer; J.F. Forbes; G. Von Minckwitz; M. Golshan; J.F.R. Robertson; H. Sasano; B.F. Cole; L.W.C. Chow; M.D. Pegram; W. Han; C.-S. Huang; T. Ikeda; S. Kanao; E.-S. Lee; S. Noguchi; S. Ohno; A.H. Partridge; R. Rouzier; M. Tozaki; T. Sugie; A. Yamauchi; T. Inamoto |
M. Toi; J.R. Benson; E.P. Winer; J.F. Forbes; G. Von Minckwitz; M. Golshan; J.F.R. Robertson; H. Sasano; B.F. Cole; L.W.C. Chow; M.D. Pegram; W. Han; C.-S. Huang; T. Ikeda; S. Kanao; E.-S. Lee; S. Noguchi; S. Ohno; A.H. Partridge; R. Rouzier; M. Tozaki; T. Sugie; A. Yamauchi; T. Inamoto |
M. Toi; J.R. Benson; E.P. Winer; J.F. Forbes; G. Von Minckwitz; M. Golshan; J.F.R. Robertson; H. Sasano; B.F. Cole; L.W.C. Chow; M.D. Pegram; W. Han; C.-S. Huang; T. Ikeda; S. Kanao; E.-S. Lee; S. Noguchi; S. Ohno; A.H. Partridge; R. Rouzier; M. Tozaki; T. Sugie; A. Yamauchi; T. Inamoto |
Preoperative systemic therapy in locoregional management of early breast cancer: Highlights from the Kyoto Breast Cancer Consensus Conference |
Preoperative systemic therapy in locoregional management of early breast cancer: Highlights from the Kyoto Breast Cancer Consensus Conference |
Preoperative systemic therapy in locoregional management of early breast cancer: Highlights from the Kyoto Breast Cancer Consensus Conference |
Breast Cancer Research and Treatment, 136, 3, 919-926 |
Breast Cancer Research and Treatment, 136, 3, 919-926 |
Breast Cancer Research and Treatment, 136, 3, 919-926 |
2012/12 |
有 |
英語 |
|
公開 |
| S. Tanaka; T. Ueno; F. Sato; Y. Chigusa; N. Kawaguchi-Sakita; M. Kawashima; N. Fujisawa; K. Yoshimura; S. Teramukai; H. Fujiwara; M. Fujita; M. Toi |
S. Tanaka; T. Ueno; F. Sato; Y. Chigusa; N. Kawaguchi-Sakita; M. Kawashima; N. Fujisawa; K. Yoshimura; S. Teramukai; H. Fujiwara; M. Fujita; M. Toi |
S. Tanaka; T. Ueno; F. Sato; Y. Chigusa; N. Kawaguchi-Sakita; M. Kawashima; N. Fujisawa; K. Yoshimura; S. Teramukai; H. Fujiwara; M. Fujita; M. Toi |
Alterations of circulating endothelial cell and endothelial progenitor cell counts around the ovulation |
Alterations of circulating endothelial cell and endothelial progenitor cell counts around the ovulation |
Alterations of circulating endothelial cell and endothelial progenitor cell counts around the ovulation |
Journal of Clinical Endocrinology and Metabolism, 97, 11, 4182-4192 |
Journal of Clinical Endocrinology and Metabolism, 97, 11, 4182-4192 |
Journal of Clinical Endocrinology and Metabolism, 97, 11, 4182-4192 |
2012/11 |
有 |
英語 |
|
公開 |
| K. Takeda; S. Kanao; T. Okada; M. Kataoka; T. Ueno; M. Toi; H. Ishiguro; Y. Mikami; K. Togashi |
K. Takeda; S. Kanao; T. Okada; M. Kataoka; T. Ueno; M. Toi; H. Ishiguro; Y. Mikami; K. Togashi |
K. Takeda; S. Kanao; T. Okada; M. Kataoka; T. Ueno; M. Toi; H. Ishiguro; Y. Mikami; K. Togashi |
Assessment of CAD-generated tumor volumes measured using MRI in breast cancers before and after neoadjuvant chemotherapy |
Assessment of CAD-generated tumor volumes measured using MRI in breast cancers before and after neoadjuvant chemotherapy |
Assessment of CAD-generated tumor volumes measured using MRI in breast cancers before and after neoadjuvant chemotherapy |
European Journal of Radiology, 81, 10, 2627-2631 |
European Journal of Radiology, 81, 10, 2627-2631 |
European Journal of Radiology, 81, 10, 2627-2631 |
2012/10 |
有 |
英語 |
|
公開 |
| M. Iima; Y. Nakamoto; S. Kanao; T. Sugie; T. Ueno; M. Kawada; Y. Mikami; M. Toi; K. Togashi |
M. Iima; Y. Nakamoto; S. Kanao; T. Sugie; T. Ueno; M. Kawada; Y. Mikami; M. Toi; K. Togashi |
M. Iima; Y. Nakamoto; S. Kanao; T. Sugie; T. Ueno; M. Kawada; Y. Mikami; M. Toi; K. Togashi |
Clinical performance of 2 dedicated PET scanners for breast imaging: initial evaluation |
Clinical performance of 2 dedicated PET scanners for breast imaging: initial evaluation |
Clinical performance of 2 dedicated PET scanners for breast imaging: initial evaluation |
Journal of Nuclear Medicine, 53, 10, 1534-1542 |
Journal of Nuclear Medicine, 53, 10, 1534-1542 |
Journal of Nuclear Medicine, 53, 10, 1534-1542 |
2012/10 |
有 |
英語 |
|
公開 |
| M.S.M. Chan; L. Wang; S.J.A. Felizola; T. Ueno; M. Toi; W. Loo; L.W.C. Chow; T. Suzuki; H. Sasano |
M.S.M. Chan; L. Wang; S.J.A. Felizola; T. Ueno; M. Toi; W. Loo; L.W.C. Chow; T. Suzuki; H. Sasano |
M.S.M. Chan; L. Wang; S.J.A. Felizola; T. Ueno; M. Toi; W. Loo; L.W.C. Chow; T. Suzuki; H. Sasano |
Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients - an immunohistochemical study of cd8+ and foxp3+ using double immunostaining with correlation to the pat |
Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients - an immunohistochemical study of cd8+ and foxp3+ using double immunostaining with correlation to the pat |
Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients - an immunohistochemical study of cd8+ and foxp3+ using double immunostaining with correlation to the pat |
International Journal of Biological Markers, 27, 4, E295-E304 |
International Journal of Biological Markers, 27, 4, E295-E304 |
International Journal of Biological Markers, 27, 4, E295-E304 |
2012/10 |
有 |
英語 |
|
公開 |
| K. Takeda; S. Kanao; T. Okada; T. Ueno; M. Toi; H. Ishiguro; Y. Mikami; S. Tanaka; K. Togashi |
K. Takeda; S. Kanao; T. Okada; T. Ueno; M. Toi; H. Ishiguro; Y. Mikami; S. Tanaka; K. Togashi |
K. Takeda; S. Kanao; T. Okada; T. Ueno; M. Toi; H. Ishiguro; Y. Mikami; S. Tanaka; K. Togashi |
MRI evaluation of residual tumor size after neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy |
MRI evaluation of residual tumor size after neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy |
MRI evaluation of residual tumor size after neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy |
European Journal of Radiology, 81, 9, 2148-2153 |
European Journal of Radiology, 81, 9, 2148-2153 |
European Journal of Radiology, 81, 9, 2148-2153 |
2012/09 |
有 |
英語 |
|
公開 |
| M. Takada; M. Sugimoto; S. Ohno; K. Kuroi; N. Sato; H. Bando; N. Masuda; H. Iwata; M. Kondo; H. Sasano; L.W.C. Chow; T. Inamoto; Y. Naito; M. Tomita; M. Toi |
M. Takada; M. Sugimoto; S. Ohno; K. Kuroi; N. Sato; H. Bando; N. Masuda; H. Iwata; M. Kondo; H. Sasano; L.W.C. Chow; T. Inamoto; Y. Naito; M. Tomita; M. Toi |
M. Takada; M. Sugimoto; S. Ohno; K. Kuroi; N. Sato; H. Bando; N. Masuda; H. Iwata; M. Kondo; H. Sasano; L.W.C. Chow; T. Inamoto; Y. Naito; M. Tomita; M. Toi |
Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique |
Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique |
Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique |
Breast Cancer Research and Treatment, 134, 2, 661-670 |
Breast Cancer Research and Treatment, 134, 2, 661-670 |
Breast Cancer Research and Treatment, 134, 2, 661-670 |
2012/07 |
有 |
英語 |
|
公開 |
| M. Takada; M. Sugimoto; Y. Naito; H.-G. Moon; W. Han; D.-Y. Noh; M. Kondo; K. Kuroi; H. Sasano; T. Inamoto; M. Tomita; M. Toi |
M. Takada; M. Sugimoto; Y. Naito; H.-G. Moon; W. Han; D.-Y. Noh; M. Kondo; K. Kuroi; H. Sasano; T. Inamoto; M. Tomita; M. Toi |
M. Takada; M. Sugimoto; Y. Naito; H.-G. Moon; W. Han; D.-Y. Noh; M. Kondo; K. Kuroi; H. Sasano; T. Inamoto; M. Tomita; M. Toi |
Prediction of axillary lymph node metastasis in primary breast cancer patients using a decision tree-based model |
Prediction of axillary lymph node metastasis in primary breast cancer patients using a decision tree-based model |
Prediction of axillary lymph node metastasis in primary breast cancer patients using a decision tree-based model |
BMC Medical Informatics and Decision Making, 12 |
BMC Medical Informatics and Decision Making, 12 |
BMC Medical Informatics and Decision Making, 12 |
2012/06/13 |
有 |
英語 |
|
公開 |
| M. Kondo; S.-L. Hoshi; H. Ishiguro; M. Toi |
M. Kondo; S.-L. Hoshi; H. Ishiguro; M. Toi |
M. Kondo; S.-L. Hoshi; H. Ishiguro; M. Toi |
Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan |
Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan |
Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan |
Breast Cancer Research and Treatment, 133, 2, 759-768 |
Breast Cancer Research and Treatment, 133, 2, 759-768 |
Breast Cancer Research and Treatment, 133, 2, 759-768 |
2012/06 |
有 |
日本語 |
|
公開 |
| C. Barrios; J.F. Forbes; W. Jonat; P. Conte; W. Gradishar; A. Buzdar; K. Gelmon; M. Gnant; J. Bonneterre; M. Toi; C. Hudis; J.F.R. Robertson |
C. Barrios; J.F. Forbes; W. Jonat; P. Conte; W. Gradishar; A. Buzdar; K. Gelmon; M. Gnant; J. Bonneterre; M. Toi; C. Hudis; J.F.R. Robertson |
C. Barrios; J.F. Forbes; W. Jonat; P. Conte; W. Gradishar; A. Buzdar; K. Gelmon; M. Gnant; J. Bonneterre; M. Toi; C. Hudis; J.F.R. Robertson |
The sequential use of endocrine treatment for advanced breast cancer: Where are we? |
The sequential use of endocrine treatment for advanced breast cancer: Where are we? |
The sequential use of endocrine treatment for advanced breast cancer: Where are we? |
Annals of Oncology, 23, 6, 1378-1386 |
Annals of Oncology, 23, 6, 1378-1386 |
Annals of Oncology, 23, 6, 1378-1386 |
2012/06 |
有 |
英語 |
|
公開 |
| G. Gasparini; F. Torino; T. Ueno; S. Cascinu; T. Troiani; A. Ballestrero; R. Berardi; J. Shishido; A. Yoshizawa; Y. Mori; S. Nagayama; P. Morosini; M. Toi |
G. Gasparini; F. Torino; T. Ueno; S. Cascinu; T. Troiani; A. Ballestrero; R. Berardi; J. Shishido; A. Yoshizawa; Y. Mori; S. Nagayama; P. Morosini; M. Toi |
G. Gasparini; F. Torino; T. Ueno; S. Cascinu; T. Troiani; A. Ballestrero; R. Berardi; J. Shishido; A. Yoshizawa; Y. Mori; S. Nagayama; P. Morosini; M. Toi |
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer |
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer |
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer |
Angiogenesis, 15, 1, 141-150 |
Angiogenesis, 15, 1, 141-150 |
Angiogenesis, 15, 1, 141-150 |
2012/03 |
有 |
英語 |
|
公開 |
| T. Ichikawa; F. Sato; K. Terasawa; S. Tsuchiya; M. Toi; G. Tsujimoto; K. Shimizu |
T. Ichikawa; F. Sato; K. Terasawa; S. Tsuchiya; M. Toi; G. Tsujimoto; K. Shimizu |
T. Ichikawa; F. Sato; K. Terasawa; S. Tsuchiya; M. Toi; G. Tsujimoto; K. Shimizu |
Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells |
Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells |
Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells |
PLoS ONE, 7, 2 |
PLoS ONE, 7, 2 |
PLoS ONE, 7, 2 |
2012/02/27 |
有 |
英語 |
|
公開 |
| M. Takada; S. Saji; N. Masuda; K. Kuroi; N. Sato; H. Takei; Y. Yamamoto; S. Ohno; H. Yamashita; K. Hisamatsu; K. Aogi; H. Iwata; T. Ueno; H. Sasano; M. Toi |
M. Takada; S. Saji; N. Masuda; K. Kuroi; N. Sato; H. Takei; Y. Yamamoto; S. Ohno; H. Yamashita; K. Hisamatsu; K. Aogi; H. Iwata; T. Ueno; H. Sasano; M. Toi |
M. Takada; S. Saji; N. Masuda; K. Kuroi; N. Sato; H. Takei; Y. Yamamoto; S. Ohno; H. Yamashita; K. Hisamatsu; K. Aogi; H. Iwata; T. Ueno; H. Sasano; M. Toi |
Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer |
Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer |
Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer |
Breast, 21, 1, 40-45 |
Breast, 21, 1, 40-45 |
Breast, 21, 1, 40-45 |
2012 |
有 |
英語 |
|
公開 |
| E. Fakhrejahani; M. Toi |
E. Fakhrejahani; M. Toi |
E. Fakhrejahani; M. Toi |
Tumor angiogenesis: Pericytes and maturation are not to be ignored |
Tumor angiogenesis: Pericytes and maturation are not to be ignored |
Tumor angiogenesis: Pericytes and maturation are not to be ignored |
Journal of Oncology |
Journal of Oncology |
Journal of Oncology |
2012 |
有 |
英語 |
|
公開 |
| R. Ito; N. Morimoto; P.H. Liem; Y. Nakamura; K. Kawai; T. Taira; W. Tsuji; M. Toi; S. Suzuki |
R. Ito; N. Morimoto; P.H. Liem; Y. Nakamura; K. Kawai; T. Taira; W. Tsuji; M. Toi; S. Suzuki |
R. Ito; N. Morimoto; P.H. Liem; Y. Nakamura; K. Kawai; T. Taira; W. Tsuji; M. Toi; S. Suzuki |
Adipogenesis using human adipose tissue-derived stromal cells combined with a collagen/gelatin sponge sustaining release of basic fibroblast growth factor |
Adipogenesis using human adipose tissue-derived stromal cells combined with a collagen/gelatin sponge sustaining release of basic fibroblast growth factor |
Adipogenesis using human adipose tissue-derived stromal cells combined with a collagen/gelatin sponge sustaining release of basic fibroblast growth factor |
Journal of Tissue Engineering and Regenerative Medicine |
Journal of Tissue Engineering and Regenerative Medicine |
Journal of Tissue Engineering and Regenerative Medicine |
2012 |
有 |
英語 |
|
公開 |
| Y.-S. Ren; N.-S. Qian; Y. Tang; Y.-H. Liao; Y.-L. Yang; K.-F. Dou; M. Toi |
Y.-S. Ren; N.-S. Qian; Y. Tang; Y.-H. Liao; Y.-L. Yang; K.-F. Dou; M. Toi |
Y.-S. Ren; N.-S. Qian; Y. Tang; Y.-H. Liao; Y.-L. Yang; K.-F. Dou; M. Toi |
Sodium channel Nav1.6 is up-regulated in the dorsal root ganglia in a mouse model of type 2 diabetes |
Sodium channel Nav1.6 is up-regulated in the dorsal root ganglia in a mouse model of type 2 diabetes |
Sodium channel Nav1.6 is up-regulated in the dorsal root ganglia in a mouse model of type 2 diabetes |
Brain Research Bulletin, 87, 2-3, 244-249 |
Brain Research Bulletin, 87, 2-3, 244-249 |
Brain Research Bulletin, 87, 2-3, 244-249 |
2012 |
有 |
英語 |
|
公開 |
| T. Ueno; M. Emi; H. Sato; N. Ito; M. Muta; K. Kuroi; M. Toi |
T. Ueno; M. Emi; H. Sato; N. Ito; M. Muta; K. Kuroi; M. Toi |
T. Ueno; M. Emi; H. Sato; N. Ito; M. Muta; K. Kuroi; M. Toi |
Genome-wide copy number analysis in primary breast cancer |
Genome-wide copy number analysis in primary breast cancer |
Genome-wide copy number analysis in primary breast cancer |
Expert Opinion on Therapeutic Targets, 16, SUPPL. 1, S31-S35 |
Expert Opinion on Therapeutic Targets, 16, SUPPL. 1, S31-S35 |
Expert Opinion on Therapeutic Targets, 16, SUPPL. 1, S31-S35 |
2012 |
有 |
英語 |
|
公開 |
| M.S. Chan; L. Wang; N. Chanplakorn; K. Tamaki; T. Ueno; M. Toi; W.T. Loo; L.W. Chow; T. Suzuki; H. Sasano |
M.S. Chan; L. Wang; N. Chanplakorn; K. Tamaki; T. Ueno; M. Toi; W.T. Loo; L.W. Chow; T. Suzuki; H. Sasano |
M.S. Chan; L. Wang; N. Chanplakorn; K. Tamaki; T. Ueno; M. Toi; W.T. Loo; L.W. Chow; T. Suzuki; H. Sasano |
Effects of estrogen depletion on angiogenesis in estrogen-receptor-positive breast carcinoma an immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy |
Effects of estrogen depletion on angiogenesis in estrogen-receptor-positive breast carcinoma an immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy |
Effects of estrogen depletion on angiogenesis in estrogen-receptor-positive breast carcinoma an immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy |
Expert Opinion on Therapeutic Targets, 16, SUPPL. 1, S69-S78 |
Expert Opinion on Therapeutic Targets, 16, SUPPL. 1, S69-S78 |
Expert Opinion on Therapeutic Targets, 16, SUPPL. 1, S69-S78 |
2012 |
有 |
英語 |
|
公開 |
| J. Eswaran; S. Gupta; A. Dutt; M. Toi; M.R. Pillai; L. Costa; S. Knapp; R. Badwe; R. Kumar |
J. Eswaran; S. Gupta; A. Dutt; M. Toi; M.R. Pillai; L. Costa; S. Knapp; R. Badwe; R. Kumar |
J. Eswaran; S. Gupta; A. Dutt; M. Toi; M.R. Pillai; L. Costa; S. Knapp; R. Badwe; R. Kumar |
The Global Cancer Genomics Consortium: Interfacing genomics and cancer medicine |
The Global Cancer Genomics Consortium: Interfacing genomics and cancer medicine |
The Global Cancer Genomics Consortium: Interfacing genomics and cancer medicine |
Cancer Research, 72, 15, 3720-3724 |
Cancer Research, 72, 15, 3720-3724 |
Cancer Research, 72, 15, 3720-3724 |
2012 |
有 |
英語 |
|
公開 |
| H. Ishiguro; S. Takashima; K. Yoshimura; I. Yano; T. Yamamoto; M. Niimi; H. Yamashiro; T. Ueno; M. Takeuchi; T. Sugie; K. Yanagihara; M. Toi; M. Fukushima |
H. Ishiguro; S. Takashima; K. Yoshimura; I. Yano; T. Yamamoto; M. Niimi; H. Yamashiro; T. Ueno; M. Takeuchi; T. Sugie; K. Yanagihara; M. Toi; M. Fukushima |
H. Ishiguro; S. Takashima; K. Yoshimura; I. Yano; T. Yamamoto; M. Niimi; H. Yamashiro; T. Ueno; M. Takeuchi; T. Sugie; K. Yanagihara; M. Toi; M. Fukushima |
Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patients |
Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patients |
Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patients |
Supportive Care in Cancer, 20, 9, 2017-2024 |
Supportive Care in Cancer, 20, 9, 2017-2024 |
Supportive Care in Cancer, 20, 9, 2017-2024 |
2012 |
有 |
英語 |
|
公開 |
| Y. Tang; X. Zeng; F. He; Y. Liao; N. Qian; M. Toi |
Y. Tang; X. Zeng; F. He; Y. Liao; N. Qian; M. Toi |
Y. Tang; X. Zeng; F. He; Y. Liao; N. Qian; M. Toi |
Caveolin-1 is related to invasion, survival, and poor prognosis in hepatocellular cancer |
Caveolin-1 is related to invasion, survival, and poor prognosis in hepatocellular cancer |
Caveolin-1 is related to invasion, survival, and poor prognosis in hepatocellular cancer |
Medical Oncology, 29, 2, 977-984 |
Medical Oncology, 29, 2, 977-984 |
Medical Oncology, 29, 2, 977-984 |
2012 |
有 |
英語 |
|
公開 |
| M. Takeuchi; T. Sugie; K. Abdelazeem; H. Kato; N. Shinkura; M. Takada; H. Yamashiro; T. Ueno; M. Toi |
M. Takeuchi; T. Sugie; K. Abdelazeem; H. Kato; N. Shinkura; M. Takada; H. Yamashiro; T. Ueno; M. Toi |
M. Takeuchi; T. Sugie; K. Abdelazeem; H. Kato; N. Shinkura; M. Takada; H. Yamashiro; T. Ueno; M. Toi |
Lymphatic mapping with fluorescence navigation using indocyanine green and axillary surgery in patients with primary breast cancer |
Lymphatic mapping with fluorescence navigation using indocyanine green and axillary surgery in patients with primary breast cancer |
Lymphatic mapping with fluorescence navigation using indocyanine green and axillary surgery in patients with primary breast cancer |
Breast Journal, 18, 6, 535-541 |
Breast Journal, 18, 6, 535-541 |
Breast Journal, 18, 6, 535-541 |
2012 |
有 |
英語 |
|
公開 |
| K. Imami; N. Sugiyama; H. Imamura; M. Wakabayashi; M. Tomita; M. Taniguchi; T. Ueno; M. Toi; Y. Ishihama |
K. Imami; N. Sugiyama; H. Imamura; M. Wakabayashi; M. Tomita; M. Taniguchi; T. Ueno; M. Toi; Y. Ishihama |
K. Imami; N. Sugiyama; H. Imamura; M. Wakabayashi; M. Tomita; M. Taniguchi; T. Ueno; M. Toi; Y. Ishihama |
Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways |
Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways |
Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways |
Molecular and Cellular Proteomics, 11, 12, 1741-1757 |
Molecular and Cellular Proteomics, 11, 12, 1741-1757 |
Molecular and Cellular Proteomics, 11, 12, 1741-1757 |
2012 |
有 |
英語 |
|
公開 |
| L.W. Chow; M. Toi |
L.W. Chow; M. Toi |
L.W. Chow; M. Toi |
The clinical trials of the organisation for oncology and translational research (ootr) |
The clinical trials of the organisation for oncology and translational research (ootr) |
The clinical trials of the organisation for oncology and translational research (ootr) |
International Journal of Biological Markers, 27, 4, e353-e356 |
International Journal of Biological Markers, 27, 4, e353-e356 |
International Journal of Biological Markers, 27, 4, e353-e356 |
2012 |
有 |
英語 |
|
公開 |
| N. Masuda; M. Toi; K. Kuroi |
N. Masuda; M. Toi; K. Kuroi |
N. Masuda; M. Toi; K. Kuroi |
[Current activities and perspective of JBCRG (Japan Breast Cancer Research Group)]. |
[Current activities and perspective of JBCRG (Japan Breast Cancer Research Group)]. |
[Current activities and perspective of JBCRG (Japan Breast Cancer Research Group)]. |
Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 7, 763-772 |
Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 7, 763-772 |
Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 7, 763-772 |
2012 |
有 |
英語 |
|
公開 |
| T. Kitai; M. Toi |
T. Kitai; M. Toi |
T. Kitai; M. Toi |
[Photoacoustic mammography for the diagnosis of breast cancer]. |
[Photoacoustic mammography for the diagnosis of breast cancer]. |
[Photoacoustic mammography for the diagnosis of breast cancer]. |
Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 7, 326-330 |
Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 7, 326-330 |
Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 7, 326-330 |
2012 |
有 |
英語 |
|
公開 |
| Y. Mitsudo; M. Takada; M. Toi |
Y. Mitsudo; M. Takada; M. Toi |
Y. Mitsudo; M. Takada; M. Toi |
[Multidisciplinary treatment of chemotherapy and surgical therapy]. |
[Multidisciplinary treatment of chemotherapy and surgical therapy]. |
[Multidisciplinary treatment of chemotherapy and surgical therapy]. |
Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 7, 571-575 |
Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 7, 571-575 |
Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 7, 571-575 |
2012 |
有 |
英語 |
|
公開 |
| E. Suzuki; M. Toi |
E. Suzuki; M. Toi |
E. Suzuki; M. Toi |
[Targeting therapy perspectives]. |
[Targeting therapy perspectives]. |
[Targeting therapy perspectives]. |
Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 7, 620-626 |
Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 7, 620-626 |
Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 7, 620-626 |
2012 |
有 |
英語 |
|
公開 |
| H. Ishiguro; M. Toi |
H. Ishiguro; M. Toi |
H. Ishiguro; M. Toi |
Pharmacokinetics and pharmacogenomics of selective estrogen receptor modulators in breast cancer patients |
Pharmacokinetics and pharmacogenomics of selective estrogen receptor modulators in breast cancer patients |
Pharmacokinetics and pharmacogenomics of selective estrogen receptor modulators in breast cancer patients |
Current Topics in Pharmacology, 16, 1, 53-58 |
Current Topics in Pharmacology, 16, 1, 53-58 |
Current Topics in Pharmacology, 16, 1, 53-58 |
2012 |
有 |
英語 |
|
公開 |
| H. Ishiguro; M. Toi |
H. Ishiguro; M. Toi |
H. Ishiguro; M. Toi |
How to dose cytotoxic chemotherapeutic drugs |
How to dose cytotoxic chemotherapeutic drugs |
How to dose cytotoxic chemotherapeutic drugs |
Current Topics in Pharmacology, 16, 1, 67-81 |
Current Topics in Pharmacology, 16, 1, 67-81 |
Current Topics in Pharmacology, 16, 1, 67-81 |
2012 |
有 |
英語 |
|
公開 |
| H. Ishiguro; S. Saji; M. Toi |
H. Ishiguro; S. Saji; M. Toi |
H. Ishiguro; S. Saji; M. Toi |
[Clinical pharmacology of targeted drug for breast cancer]. |
[Clinical pharmacology of targeted drug for breast cancer]. |
[Clinical pharmacology of targeted drug for breast cancer]. |
Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 8, 443-446 |
Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 8, 443-446 |
Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 8, 443-446 |
2012 |
有 |
英語 |
|
公開 |
| M. Kanai; H. Ishiguro; Y. Mori; T. Kitano; T. Nishimura; S. Matsumoto; K. Yanagihara; T. Chiba; M. Toi |
M. Kanai; H. Ishiguro; Y. Mori; T. Kitano; T. Nishimura; S. Matsumoto; K. Yanagihara; T. Chiba; M. Toi |
M. Kanai; H. Ishiguro; Y. Mori; T. Kitano; T. Nishimura; S. Matsumoto; K. Yanagihara; T. Chiba; M. Toi |
Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced colorectal cancer |
Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced colorectal cancer |
Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced colorectal cancer |
British Journal of Cancer, 105, 11, 1693-1696 |
British Journal of Cancer, 105, 11, 1693-1696 |
British Journal of Cancer, 105, 11, 1693-1696 |
2011/11/22 |
有 |
英語 |
|
公開 |
| K. Kawaguchi; H. Ishiguro; S. Morita; S. Nakamura; S. Ohno; N. Masuda; H. Iwata; K. Aogi; K. Kuroi; M. Toi |
K. Kawaguchi; H. Ishiguro; S. Morita; S. Nakamura; S. Ohno; N. Masuda; H. Iwata; K. Aogi; K. Kuroi; M. Toi |
K. Kawaguchi; H. Ishiguro; S. Morita; S. Nakamura; S. Ohno; N. Masuda; H. Iwata; K. Aogi; K. Kuroi; M. Toi |
Correlation between docetaxel-induced skin toxicity and the use of steroids and H <sub>2</sub> blockers: A multi-institution survey |
Correlation between docetaxel-induced skin toxicity and the use of steroids and H <sub>2</sub> blockers: A multi-institution survey |
Correlation between docetaxel-induced skin toxicity and the use of steroids and H <sub>2</sub> blockers: A multi-institution survey |
Breast Cancer Research and Treatment, 130, 2, 627-634 |
Breast Cancer Research and Treatment, 130, 2, 627-634 |
Breast Cancer Research and Treatment, 130, 2, 627-634 |
2011/11 |
有 |
英語 |
|
公開 |
| H.S. Han; I.M. Reis; W. Zhao; K. Kuroi; M. Toi; E. Suzuki; R. Syme; L. Chow; A.Y.S. Yip; S. Glück |
H.S. Han; I.M. Reis; W. Zhao; K. Kuroi; M. Toi; E. Suzuki; R. Syme; L. Chow; A.Y.S. Yip; S. Glück |
H.S. Han; I.M. Reis; W. Zhao; K. Kuroi; M. Toi; E. Suzuki; R. Syme; L. Chow; A.Y.S. Yip; S. Glück |
Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer |
Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer |
Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer |
European Journal of Cancer, 47, 17, 2537-2545 |
European Journal of Cancer, 47, 17, 2537-2545 |
European Journal of Cancer, 47, 17, 2537-2545 |
2011/11 |
有 |
英語 |
|
公開 |
| A.M. Ali; T. Ueno; S. Tanaka; M. Takada; H. Ishiguro; A.Z. Abdellah; M. Toi |
A.M. Ali; T. Ueno; S. Tanaka; M. Takada; H. Ishiguro; A.Z. Abdellah; M. Toi |
A.M. Ali; T. Ueno; S. Tanaka; M. Takada; H. Ishiguro; A.Z. Abdellah; M. Toi |
Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients |
Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients |
Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients |
European Journal of Cancer, 47, 15, 2265-2272 |
European Journal of Cancer, 47, 15, 2265-2272 |
European Journal of Cancer, 47, 15, 2265-2272 |
2011/10 |
有 |
英語 |
|
公開 |
| N. Qian; T. Ueno; N. Kawaguchi-Sakita; M. Kawashima; N. Yoshida; Y. Mikami; T. Wakasa; M. Shintaku; S. Tsuyuki; T. Inamoto; M. Toi |
N. Qian; T. Ueno; N. Kawaguchi-Sakita; M. Kawashima; N. Yoshida; Y. Mikami; T. Wakasa; M. Shintaku; S. Tsuyuki; T. Inamoto; M. Toi |
N. Qian; T. Ueno; N. Kawaguchi-Sakita; M. Kawashima; N. Yoshida; Y. Mikami; T. Wakasa; M. Shintaku; S. Tsuyuki; T. Inamoto; M. Toi |
Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients |
Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients |
Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients |
Cancer Science, 102, 8, 1590-1596 |
Cancer Science, 102, 8, 1590-1596 |
Cancer Science, 102, 8, 1590-1596 |
2011/08 |
有 |
英語 |
|
公開 |
| M. Kondo; S.-L. Hoshi; T. Yamanaka; H. Ishiguro; M. Toi |
M. Kondo; S.-L. Hoshi; T. Yamanaka; H. Ishiguro; M. Toi |
M. Kondo; S.-L. Hoshi; T. Yamanaka; H. Ishiguro; M. Toi |
Economic evaluation of the 21-gene signature (Oncotype DX <sup>®</sup>) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03) |
Economic evaluation of the 21-gene signature (Oncotype DX <sup>®</sup>) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03) |
Economic evaluation of the 21-gene signature (Oncotype DX <sup>®</sup>) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03) |
Breast Cancer Research and Treatment, 127, 3, 739-749 |
Breast Cancer Research and Treatment, 127, 3, 739-749 |
Breast Cancer Research and Treatment, 127, 3, 739-749 |
2011/06 |
有 |
日本語 |
|
公開 |
| K. Aogi; M. Yoshida; Y. Sagara; S. Kamigaki; M. Okazaki; J. Funai; T. Fujimoto; M. Toi; T. Saeki; S. Takashima |
K. Aogi; M. Yoshida; Y. Sagara; S. Kamigaki; M. Okazaki; J. Funai; T. Fujimoto; M. Toi; T. Saeki; S. Takashima |
K. Aogi; M. Yoshida; Y. Sagara; S. Kamigaki; M. Okazaki; J. Funai; T. Fujimoto; M. Toi; T. Saeki; S. Takashima |
The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype |
The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype |
The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype |
Cancer Chemotherapy and Pharmacology, 67, 5, 1007-1015 |
Cancer Chemotherapy and Pharmacology, 67, 5, 1007-1015 |
Cancer Chemotherapy and Pharmacology, 67, 5, 1007-1015 |
2011/05 |
有 |
英語 |
|
公開 |
| L.W.C. Chow; A.Y.S. Yip; W.P. Chu; W.T.Y. Loo; M. Toi |
L.W.C. Chow; A.Y.S. Yip; W.P. Chu; W.T.Y. Loo; M. Toi |
L.W.C. Chow; A.Y.S. Yip; W.P. Chu; W.T.Y. Loo; M. Toi |
Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: Sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial |
Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: Sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial |
Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: Sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial |
Journal of Steroid Biochemistry and Molecular Biology, 125, 1-2, 112-119 |
Journal of Steroid Biochemistry and Molecular Biology, 125, 1-2, 112-119 |
Journal of Steroid Biochemistry and Molecular Biology, 125, 1-2, 112-119 |
2011/05 |
有 |
英語 |
|
公開 |
| M. Toi; S. Saji; N. Masuda; K. Kuroi; N. Sato; H. Takei; Y. Yamamoto; S. Ohno; H. Yamashita; K. Hisamatsu; K. Aogi; H. Iwata; M. Takada; T. Ueno; S. Saji; N. Chanplakorn; T. Suzuki; H. Sasano |
M. Toi; S. Saji; N. Masuda; K. Kuroi; N. Sato; H. Takei; Y. Yamamoto; S. Ohno; H. Yamashita; K. Hisamatsu; K. Aogi; H. Iwata; M. Takada; T. Ueno; S. Saji; N. Chanplakorn; T. Suzuki; H. Sasano |
M. Toi; S. Saji; N. Masuda; K. Kuroi; N. Sato; H. Takei; Y. Yamamoto; S. Ohno; H. Yamashita; K. Hisamatsu; K. Aogi; H. Iwata; M. Takada; T. Ueno; S. Saji; N. Chanplakorn; T. Suzuki; H. Sasano |
Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24weeks of aromatase inhibition |
Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24weeks of aromatase inhibition |
Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24weeks of aromatase inhibition |
Cancer Science, 102, 4, 858-865 |
Cancer Science, 102, 4, 858-865 |
Cancer Science, 102, 4, 858-865 |
2011/04 |
有 |
英語 |
|
公開 |
| M. Honda; S. Saji; S.-I. Horiguchi; E. Suzuki; T. Aruga; K. Horiguchi; D. Kitagawa; S. Sekine; N. Funata; M. Toi; K. Kuroi |
M. Honda; S. Saji; S.-I. Horiguchi; E. Suzuki; T. Aruga; K. Horiguchi; D. Kitagawa; S. Sekine; N. Funata; M. Toi; K. Kuroi |
M. Honda; S. Saji; S.-I. Horiguchi; E. Suzuki; T. Aruga; K. Horiguchi; D. Kitagawa; S. Sekine; N. Funata; M. Toi; K. Kuroi |
Clinicopathological analysis of ten patients with metaplastic squamous cell carcinoma of the breast |
Clinicopathological analysis of ten patients with metaplastic squamous cell carcinoma of the breast |
Clinicopathological analysis of ten patients with metaplastic squamous cell carcinoma of the breast |
Surgery Today, 41, 3, 328-332 |
Surgery Today, 41, 3, 328-332 |
Surgery Today, 41, 3, 328-332 |
2011/03 |
有 |
英語 |
|
公開 |
| M. Takada; H. Terunuma; X. Deng; M.Z. Dewan; S. Saji; K. Kuroi; N. Yamamoto; M. Toi |
M. Takada; H. Terunuma; X. Deng; M.Z. Dewan; S. Saji; K. Kuroi; N. Yamamoto; M. Toi |
M. Takada; H. Terunuma; X. Deng; M.Z. Dewan; S. Saji; K. Kuroi; N. Yamamoto; M. Toi |
Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach |
Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach |
Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach |
Breast Cancer, 18, 1, 64-67 |
Breast Cancer, 18, 1, 64-67 |
Breast Cancer, 18, 1, 64-67 |
2011/01 |
有 |
英語 |
|
公開 |
| Toi M, Winer EP, Inamoto T, Benson JR, Forbes JF, Mitsumori M, Robertson JF, Sasano H, von Minckwitz G, Yamauchi A, Klimberg VS. |
Toi M, Winer EP, Inamoto T, Benson JR, Forbes JF, Mitsumori M, Robertson JF, Sasano H, von Minckwitz G, Yamauchi A, Klimberg VS. |
Toi M, Winer EP, Inamoto T, Benson JR, Forbes JF, Mitsumori M, Robertson JF, Sasano H, von Minckwitz G, Yamauchi A, Klimberg VS. |
Identifying gaps in the locoregional management of early breast cancer: Highlights from the Kyoto Consensus Conference. |
Identifying gaps in the locoregional management of early breast cancer: Highlights from the Kyoto Consensus Conference. |
Identifying gaps in the locoregional management of early breast cancer: Highlights from the Kyoto Consensus Conference. |
Ann Surg Oncol 2011 Mar 23. [Epub] |
Ann Surg Oncol 2011 Mar 23. [Epub] |
Ann Surg Oncol 2011 Mar 23. [Epub] |
2011 |
有 |
英語 |
|
公開 |
| M. Iwasaki; Y. Tanaka; H. Kobayashi; K. Murata-Hirai; H. Miyabe; T. Sugie; M. Toi; N. Minato |
M. Iwasaki; Y. Tanaka; H. Kobayashi; K. Murata-Hirai; H. Miyabe; T. Sugie; M. Toi; N. Minato |
M. Iwasaki; Y. Tanaka; H. Kobayashi; K. Murata-Hirai; H. Miyabe; T. Sugie; M. Toi; N. Minato |
Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens |
Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens |
Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens |
European Journal of Immunology, 41, 2, 345-355 |
European Journal of Immunology, 41, 2, 345-355 |
European Journal of Immunology, 41, 2, 345-355 |
2011 |
有 |
日本語 |
|
公開 |
| H. Takuwa; T. Ueno; H. Ishiguro; Y. Mikami; S. Kanao; M. Takada; T. Sugie; M. Toi |
H. Takuwa; T. Ueno; H. Ishiguro; Y. Mikami; S. Kanao; M. Takada; T. Sugie; M. Toi |
H. Takuwa; T. Ueno; H. Ishiguro; Y. Mikami; S. Kanao; M. Takada; T. Sugie; M. Toi |
A case of metaplastic breast cancer that showed a good response to platinum-based preoperative chemotherapy |
A case of metaplastic breast cancer that showed a good response to platinum-based preoperative chemotherapy |
A case of metaplastic breast cancer that showed a good response to platinum-based preoperative chemotherapy |
Breast Cancer, 1-4 |
Breast Cancer, 1-4 |
Breast Cancer, 1-4 |
2011 |
有 |
英語 |
|
公開 |
| Y. Tang; F. Xu; K. Tao; N. Qian; M. Toi |
Y. Tang; F. Xu; K. Tao; N. Qian; M. Toi |
Y. Tang; F. Xu; K. Tao; N. Qian; M. Toi |
Clinical applications of sentinel lymph node biopsy in Ductal carcinoma in situ of the breast: A dilemma |
Clinical applications of sentinel lymph node biopsy in Ductal carcinoma in situ of the breast: A dilemma |
Clinical applications of sentinel lymph node biopsy in Ductal carcinoma in situ of the breast: A dilemma |
Tohoku Journal of Experimental Medicine, 224, 1, 1-5 |
Tohoku Journal of Experimental Medicine, 224, 1, 1-5 |
Tohoku Journal of Experimental Medicine, 224, 1, 1-5 |
2011 |
有 |
英語 |
|
公開 |
| M. Toi; W. Yasui; H. Ito; E. Tahara |
M. Toi; W. Yasui; H. Ito; E. Tahara |
M. Toi; W. Yasui; H. Ito; E. Tahara |
Recent progress in carcinogenesis, progression and therapy of breast cancer: The 20th Hiroshima Cancer seminar-the 4th three universities\\' Consortium International Symposium, october 2010 |
Recent progress in carcinogenesis, progression and therapy of breast cancer: The 20th Hiroshima Cancer seminar-the 4th three universities\\' Consortium International Symposium, october 2010 |
Recent progress in carcinogenesis, progression and therapy of breast cancer: The 20th Hiroshima Cancer seminar-the 4th three universities\\' Consortium International Symposium, october 2010 |
Japanese Journal of Clinical Oncology, 41, 7, 924-930 |
Japanese Journal of Clinical Oncology, 41, 7, 924-930 |
Japanese Journal of Clinical Oncology, 41, 7, 924-930 |
2011 |
有 |
英語 |
|
公開 |
| H. Iwata; N. Sato; N. Masuda; S. Nakamura; N. Yamamoto; K. Kuroi; M. Kurosumi; H. Tsuda; F. Akiyama; Y. Ohashi; M. Toi |
H. Iwata; N. Sato; N. Masuda; S. Nakamura; N. Yamamoto; K. Kuroi; M. Kurosumi; H. Tsuda; F. Akiyama; Y. Ohashi; M. Toi |
H. Iwata; N. Sato; N. Masuda; S. Nakamura; N. Yamamoto; K. Kuroi; M. Kurosumi; H. Tsuda; F. Akiyama; Y. Ohashi; M. Toi |
Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer |
Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer |
Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer |
Japanese Journal of Clinical Oncology, 41, 7, 867-875 |
Japanese Journal of Clinical Oncology, 41, 7, 867-875 |
Japanese Journal of Clinical Oncology, 41, 7, 867-875 |
2011 |
有 |
英語 |
|
公開 |
| Y. Tang; Y. Liao; N. Kawaguchi-Sakita; V. Raut; E. Fakhrejahani; N. Qian; M. Toi |
Y. Tang; Y. Liao; N. Kawaguchi-Sakita; V. Raut; E. Fakhrejahani; N. Qian; M. Toi |
Y. Tang; Y. Liao; N. Kawaguchi-Sakita; V. Raut; E. Fakhrejahani; N. Qian; M. Toi |
Sinisan, a traditional Chinese medicine, attenuates experimental chronic pancreatitis induced by trinitrobenzene sulfonic acid in rats |
Sinisan, a traditional Chinese medicine, attenuates experimental chronic pancreatitis induced by trinitrobenzene sulfonic acid in rats |
Sinisan, a traditional Chinese medicine, attenuates experimental chronic pancreatitis induced by trinitrobenzene sulfonic acid in rats |
Journal of Hepato-Biliary-Pancreatic Sciences, 18, 4, 551-558 |
Journal of Hepato-Biliary-Pancreatic Sciences, 18, 4, 551-558 |
Journal of Hepato-Biliary-Pancreatic Sciences, 18, 4, 551-558 |
2011 |
有 |
英語 |
|
公開 |
| M. Toi; E.P. Winer; T. Inamoto; J.R. Benson; J.F. Forbes; M. Mitsumori; J.F.R. Robertson; H. Sasano; G. Von Minckwitz; A. Yamauchi; V.S. Klimberg |
M. Toi; E.P. Winer; T. Inamoto; J.R. Benson; J.F. Forbes; M. Mitsumori; J.F.R. Robertson; H. Sasano; G. Von Minckwitz; A. Yamauchi; V.S. Klimberg |
M. Toi; E.P. Winer; T. Inamoto; J.R. Benson; J.F. Forbes; M. Mitsumori; J.F.R. Robertson; H. Sasano; G. Von Minckwitz; A. Yamauchi; V.S. Klimberg |
Identifying gaps in the locoregional management of early breast cancer: Highlights from the Kyoto consensus conference |
Identifying gaps in the locoregional management of early breast cancer: Highlights from the Kyoto consensus conference |
Identifying gaps in the locoregional management of early breast cancer: Highlights from the Kyoto consensus conference |
Annals of Surgical Oncology, 18, 10, 2885-2892 |
Annals of Surgical Oncology, 18, 10, 2885-2892 |
Annals of Surgical Oncology, 18, 10, 2885-2892 |
2011 |
有 |
英語 |
|
公開 |
| 福谷和彦,染田恭宏,卓雅一,浅尾恭史,小林秀一,八木隆行,山川誠,椎名 毅,杉江知治,戸井雅和 |
福谷和彦,染田恭宏,卓雅一,浅尾恭史,小林秀一,八木隆行,山川誠,椎名 毅,杉江知治,戸井雅和 |
福谷和彦,染田恭宏,卓雅一,浅尾恭史,小林秀一,八木隆行,山川誠,椎名 毅,杉江知治,戸井雅和 |
高深度イメージングを目指した両面照射型光音響イメージングシステムの評価 |
高深度イメージングを目指した両面照射型光音響イメージングシステムの評価 |
高深度イメージングを目指した両面照射型光音響イメージングシステムの評価 |
2011 BIOS(SPIE Photonic West) (2011.1.24) |
2011 BIOS(SPIE Photonic West) (2011.1.24) |
2011 BIOS(SPIE Photonic West) (2011.1.24) |
2011 |
有 |
日本語 |
|
公開 |
| M. Takada; M. Toi |
M. Takada; M. Toi |
M. Takada; M. Toi |
Surgery for breast cancer - From radical mastectomy to breast-conserving surgery |
Surgery for breast cancer - From radical mastectomy to breast-conserving surgery |
Surgery for breast cancer - From radical mastectomy to breast-conserving surgery |
Japanese Journal of Cancer and Chemotherapy, 38, 2, 173-178 |
Japanese Journal of Cancer and Chemotherapy, 38, 2, 173-178 |
Japanese Journal of Cancer and Chemotherapy, 38, 2, 173-178 |
2011 |
有 |
日本語 |
|
公開 |
| A. Tomotaki; S. Hirota; Y. Ohashi; A. Teramoto; M. Yokobori; M. Toi |
A. Tomotaki; S. Hirota; Y. Ohashi; A. Teramoto; M. Yokobori; M. Toi |
A. Tomotaki; S. Hirota; Y. Ohashi; A. Teramoto; M. Yokobori; M. Toi |
Participant proportion of population controls and matching for cases and controls: Lactic acid bacterium and breast cancer in the case-control study |
Participant proportion of population controls and matching for cases and controls: Lactic acid bacterium and breast cancer in the case-control study |
Participant proportion of population controls and matching for cases and controls: Lactic acid bacterium and breast cancer in the case-control study |
Japanese Pharmacology and Therapeutics, 39, SUPPL. 2, S211-SS221 |
Japanese Pharmacology and Therapeutics, 39, SUPPL. 2, S211-SS221 |
Japanese Pharmacology and Therapeutics, 39, SUPPL. 2, S211-SS221 |
2011 |
有 |
英語 |
|
公開 |
| C.C.P. Yiu; N. Chanplakorn; M.S.M. Chan; W.T.Y. Loo; L.W.C. Chow; M. Toi; S. Hironobu |
C.C.P. Yiu; N. Chanplakorn; M.S.M. Chan; W.T.Y. Loo; L.W.C. Chow; M. Toi; S. Hironobu |
C.C.P. Yiu; N. Chanplakorn; M.S.M. Chan; W.T.Y. Loo; L.W.C. Chow; M. Toi; S. Hironobu |
Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients |
Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients |
Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients |
Anticancer Research, 30, 9, 3465-3472 |
Anticancer Research, 30, 9, 3465-3472 |
Anticancer Research, 30, 9, 3465-3472 |
2010/09 |
有 |
英語 |
|
公開 |
| L. Chen; A. Endler; K. Uchida; S.-I. Horiguchi; Y. Morizane; O. Iijima; M. Toi; F. Shibasaki |
L. Chen; A. Endler; K. Uchida; S.-I. Horiguchi; Y. Morizane; O. Iijima; M. Toi; F. Shibasaki |
L. Chen; A. Endler; K. Uchida; S.-I. Horiguchi; Y. Morizane; O. Iijima; M. Toi; F. Shibasaki |
Int6/eIF3e silencing promotes functional blood vessel outgrowth and enhances wound healing by upregulating hypoxia-induced factor 2α expression |
Int6/eIF3e silencing promotes functional blood vessel outgrowth and enhances wound healing by upregulating hypoxia-induced factor 2α expression |
Int6/eIF3e silencing promotes functional blood vessel outgrowth and enhances wound healing by upregulating hypoxia-induced factor 2α expression |
Circulation, 122, 9, 910-919 |
Circulation, 122, 9, 910-919 |
Circulation, 122, 9, 910-919 |
2010/08/31 |
有 |
英語 |
|
公開 |
| M. Procter; T.M. Suter; E. De Azambuja; U. Dafni; V. Van Dooren; S. Muehlbauer; M.A. Climent; E. Rechberger; W.T.-W. Liu; M. Toi; R.C. Coombes; D. Dodwell; O. Pagani; J. Madrid; M. Hall; S.-C. Chen; C. Focan; M. Muschol; D.J. Van Veldhuisen; M.J. Piccart-Gebhart |
M. Procter; T.M. Suter; E. De Azambuja; U. Dafni; V. Van Dooren; S. Muehlbauer; M.A. Climent; E. Rechberger; W.T.-W. Liu; M. Toi; R.C. Coombes; D. Dodwell; O. Pagani; J. Madrid; M. Hall; S.-C. Chen; C. Focan; M. Muschol; D.J. Van Veldhuisen; M.J. Piccart-Gebhart |
M. Procter; T.M. Suter; E. De Azambuja; U. Dafni; V. Van Dooren; S. Muehlbauer; M.A. Climent; E. Rechberger; W.T.-W. Liu; M. Toi; R.C. Coombes; D. Dodwell; O. Pagani; J. Madrid; M. Hall; S.-C. Chen; C. Focan; M. Muschol; D.J. Van Veldhuisen; M.J. Piccart-Gebhart |
Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial |
Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial |
Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial |
Journal of Clinical Oncology, 28, 21, 3422-3428 |
Journal of Clinical Oncology, 28, 21, 3422-3428 |
Journal of Clinical Oncology, 28, 21, 3422-3428 |
2010/07/20 |
有 |
英語 |
|
公開 |
| M. Toi; H. Iwata; T. Yamanaka; N. Masuda; S. Ohno; S. Nakamura; T. Nakayama; M. Kashiwaba; S. Kamigaki; K. Kuroi; T. Ueno; K. Aogi |
M. Toi; H. Iwata; T. Yamanaka; N. Masuda; S. Ohno; S. Nakamura; T. Nakayama; M. Kashiwaba; S. Kamigaki; K. Kuroi; T. Ueno; K. Aogi |
M. Toi; H. Iwata; T. Yamanaka; N. Masuda; S. Ohno; S. Nakamura; T. Nakayama; M. Kashiwaba; S. Kamigaki; K. Kuroi; T. Ueno; K. Aogi |
Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population |
Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population |
Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population |
Cancer, 116, 13, 3112-3118 |
Cancer, 116, 13, 3112-3118 |
Cancer, 116, 13, 3112-3118 |
2010/07/01 |
有 |
英語 |
|
公開 |
| D. Kitagawa; S. Saji; S.-I. Horiguchi; Y. Satoh; K. Horiguchi; M. Toi; N. Funata; K. Kuroi |
D. Kitagawa; S. Saji; S.-I. Horiguchi; Y. Satoh; K. Horiguchi; M. Toi; N. Funata; K. Kuroi |
D. Kitagawa; S. Saji; S.-I. Horiguchi; Y. Satoh; K. Horiguchi; M. Toi; N. Funata; K. Kuroi |
Alternation of estrogen receptor and progesterone receptor expression in primary breast cancer patients treated with neoadjuvant chemotherapy |
Alternation of estrogen receptor and progesterone receptor expression in primary breast cancer patients treated with neoadjuvant chemotherapy |
Alternation of estrogen receptor and progesterone receptor expression in primary breast cancer patients treated with neoadjuvant chemotherapy |
Breast Journal, 16, 4, 435-436 |
Breast Journal, 16, 4, 435-436 |
Breast Journal, 16, 4, 435-436 |
2010/07 |
有 |
英語 |
|
公開 |
| S. Nakamura; H. Yagata; S. Ohno; H. Yamaguchi; H. Iwata; N. Tsunoda; Y. Ito; N. Tokudome; M. Toi; K. Kuroi; E. Suzuki |
S. Nakamura; H. Yagata; S. Ohno; H. Yamaguchi; H. Iwata; N. Tsunoda; Y. Ito; N. Tokudome; M. Toi; K. Kuroi; E. Suzuki |
S. Nakamura; H. Yagata; S. Ohno; H. Yamaguchi; H. Iwata; N. Tsunoda; Y. Ito; N. Tokudome; M. Toi; K. Kuroi; E. Suzuki |
Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer |
Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer |
Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer |
Breast Cancer, 17, 3, 199-204 |
Breast Cancer, 17, 3, 199-204 |
Breast Cancer, 17, 3, 199-204 |
2010/07 |
有 |
英語 |
|
公開 |
| N. Chanplakorn; P. Chanplakorn; T. Suzuki; K. Ono; M.S.M. Chan; Y. Miki; S. Saji; T. Ueno; M. Toi; H. Sasano |
N. Chanplakorn; P. Chanplakorn; T. Suzuki; K. Ono; M.S.M. Chan; Y. Miki; S. Saji; T. Ueno; M. Toi; H. Sasano |
N. Chanplakorn; P. Chanplakorn; T. Suzuki; K. Ono; M.S.M. Chan; Y. Miki; S. Saji; T. Ueno; M. Toi; H. Sasano |
Increased estrogen sulfatase (STS) and 17βhydroxysteroid dehydrogenase type l(17β-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients |
Increased estrogen sulfatase (STS) and 17βhydroxysteroid dehydrogenase type l(17β-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients |
Increased estrogen sulfatase (STS) and 17βhydroxysteroid dehydrogenase type l(17β-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients |
Breast Cancer Research and Treatment, 120, 3, 639-648 |
Breast Cancer Research and Treatment, 120, 3, 639-648 |
Breast Cancer Research and Treatment, 120, 3, 639-648 |
2010/04 |
有 |
英語 |
|
公開 |
| H. Ishiguro; M. Kondo; S.-L. Hoshi; M. Takada; S. Nakamura; S. Teramukai; K. Yanagihara; M. Toi |
H. Ishiguro; M. Kondo; S.-L. Hoshi; M. Takada; S. Nakamura; S. Teramukai; K. Yanagihara; M. Toi |
H. Ishiguro; M. Kondo; S.-L. Hoshi; M. Takada; S. Nakamura; S. Teramukai; K. Yanagihara; M. Toi |
Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan |
Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan |
Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan |
Clinical Therapeutics, 32, 2, 311-326 |
Clinical Therapeutics, 32, 2, 311-326 |
Clinical Therapeutics, 32, 2, 311-326 |
2010/02 |
有 |
英語 |
|
公開 |
| Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Chan MS, Miki Y, Saji S, Ueno T, Toi M, Sasano H. |
Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Chan MS, Miki Y, Saji S, Ueno T, Toi M, Sasano H. |
Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Chan MS, Miki Y, Saji S, Ueno T, Toi M, Sasano H. |
Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. |
Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. |
Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. |
Breast Cancer Res Treat 2010 Feb 12. [Epub] |
Breast Cancer Res Treat 2010 Feb 12. [Epub] |
Breast Cancer Res Treat 2010 Feb 12. [Epub] |
2010 |
有 |
英語 |
|
公開 |
| M. Toi; J. Sperinde; W. Huang; S. Saji; J. Winslow; X. Jin; Y. Tan; S. Ohno; S. Nakamura; H. Iwata; N. Masuda; K. Aogi; S. Morita; C. Petropoulos; M. Bates |
M. Toi; J. Sperinde; W. Huang; S. Saji; J. Winslow; X. Jin; Y. Tan; S. Ohno; S. Nakamura; H. Iwata; N. Masuda; K. Aogi; S. Morita; C. Petropoulos; M. Bates |
M. Toi; J. Sperinde; W. Huang; S. Saji; J. Winslow; X. Jin; Y. Tan; S. Ohno; S. Nakamura; H. Iwata; N. Masuda; K. Aogi; S. Morita; C. Petropoulos; M. Bates |
Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer |
Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer |
Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer |
BMC Cancer, 10 |
BMC Cancer, 10 |
BMC Cancer, 10 |
2010 |
有 |
英語 |
|
公開 |
| M. Toi; Y. Ohashi; A. Seow; T. Moriya; G. Tse; H. Sasano; B.W. Park; L.W. Chow; A.V. Laudico; C.H. Yip; E. Ueno; H. Ishiguro; H. Bando |
M. Toi; Y. Ohashi; A. Seow; T. Moriya; G. Tse; H. Sasano; B.W. Park; L.W. Chow; A.V. Laudico; C.H. Yip; E. Ueno; H. Ishiguro; H. Bando |
M. Toi; Y. Ohashi; A. Seow; T. Moriya; G. Tse; H. Sasano; B.W. Park; L.W. Chow; A.V. Laudico; C.H. Yip; E. Ueno; H. Ishiguro; H. Bando |
The breast cancer working group presentation was divided into three sections: The epidemiology, pathology and treatment of breast cancer |
The breast cancer working group presentation was divided into three sections: The epidemiology, pathology and treatment of breast cancer |
The breast cancer working group presentation was divided into three sections: The epidemiology, pathology and treatment of breast cancer |
Japanese Journal of Clinical Oncology, 40, SUPPL. 1, i13-i18 |
Japanese Journal of Clinical Oncology, 40, SUPPL. 1, i13-i18 |
Japanese Journal of Clinical Oncology, 40, SUPPL. 1, i13-i18 |
2010 |
有 |
英語 |
|
公開 |
| Y. Kimura; W. Tsuji; H. Yamashiro; M. Toi; T. Inamoto; Y. Tabata |
Y. Kimura; W. Tsuji; H. Yamashiro; M. Toi; T. Inamoto; Y. Tabata |
Y. Kimura; W. Tsuji; H. Yamashiro; M. Toi; T. Inamoto; Y. Tabata |
In situ adipogenesis in fat tissue augmented by collagen scaffold with gelatin microspheres containing basic fibroblast growth factor |
In situ adipogenesis in fat tissue augmented by collagen scaffold with gelatin microspheres containing basic fibroblast growth factor |
In situ adipogenesis in fat tissue augmented by collagen scaffold with gelatin microspheres containing basic fibroblast growth factor |
Journal of Tissue Engineering and Regenerative Medicine, 4, 1, 55-61 |
Journal of Tissue Engineering and Regenerative Medicine, 4, 1, 55-61 |
Journal of Tissue Engineering and Regenerative Medicine, 4, 1, 55-61 |
2010 |
有 |
英語 |
|
公開 |
| L.W.C. Chow; M. Toi |
L.W.C. Chow; M. Toi |
L.W.C. Chow; M. Toi |
Combat against cancer with science and medicine |
Combat against cancer with science and medicine |
Combat against cancer with science and medicine |
Expert Opinion on Investigational Drugs, 19, SUPPL. 1, S3-S4 |
Expert Opinion on Investigational Drugs, 19, SUPPL. 1, S3-S4 |
Expert Opinion on Investigational Drugs, 19, SUPPL. 1, S3-S4 |
2010 |
有 |
英語 |
|
公開 |
| M. Kimura; T. Tominaga; Y. Takatsuka; M. Toi; R. Abe; H. Koyama; S. Takashima; Y. Nomura; S. Miura; I. Kimijima; H. Tashiro; Y. Ohashi |
M. Kimura; T. Tominaga; Y. Takatsuka; M. Toi; R. Abe; H. Koyama; S. Takashima; Y. Nomura; S. Miura; I. Kimijima; H. Tashiro; Y. Ohashi |
M. Kimura; T. Tominaga; Y. Takatsuka; M. Toi; R. Abe; H. Koyama; S. Takashima; Y. Nomura; S. Miura; I. Kimijima; H. Tashiro; Y. Ohashi |
Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan |
Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan |
Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan |
Breast Cancer, 17, 3, 190-198 |
Breast Cancer, 17, 3, 190-198 |
Breast Cancer, 17, 3, 190-198 |
2010 |
有 |
英語 |
|
公開 |
| T. Shimbo; T. Fukui; C. Ishioka; K. Okamoto; T. Okamoto; S. Kameoka; A. Sato; M. Toi; K. Matsui; T. Mayumi; S. Saji; M. Miyazaki; Y. Takatsuka; K. Hirata |
T. Shimbo; T. Fukui; C. Ishioka; K. Okamoto; T. Okamoto; S. Kameoka; A. Sato; M. Toi; K. Matsui; T. Mayumi; S. Saji; M. Miyazaki; Y. Takatsuka; K. Hirata |
T. Shimbo; T. Fukui; C. Ishioka; K. Okamoto; T. Okamoto; S. Kameoka; A. Sato; M. Toi; K. Matsui; T. Mayumi; S. Saji; M. Miyazaki; Y. Takatsuka; K. Hirata |
Quality of guideline development assessed by the evaluation committee of the japan society of clinical oncology |
Quality of guideline development assessed by the evaluation committee of the japan society of clinical oncology |
Quality of guideline development assessed by the evaluation committee of the japan society of clinical oncology |
International Journal of Clinical Oncology, 15, 3, 227-233 |
International Journal of Clinical Oncology, 15, 3, 227-233 |
International Journal of Clinical Oncology, 15, 3, 227-233 |
2010 |
有 |
英語 |
|
公開 |
| Y. Kumagai; M. Toi; K. Kawada; T. Kawano |
Y. Kumagai; M. Toi; K. Kawada; T. Kawano |
Y. Kumagai; M. Toi; K. Kawada; T. Kawano |
Angiogenesis in superficial esophageal squamous cell carcinoma: Magnifying endoscopic observation and molecular analysis |
Angiogenesis in superficial esophageal squamous cell carcinoma: Magnifying endoscopic observation and molecular analysis |
Angiogenesis in superficial esophageal squamous cell carcinoma: Magnifying endoscopic observation and molecular analysis |
Digestive Endoscopy, 22, 4, 259-267 |
Digestive Endoscopy, 22, 4, 259-267 |
Digestive Endoscopy, 22, 4, 259-267 |
2010 |
有 |
英語 |
|
公開 |
| T. Sugie; K.A. Kassim; M. Takeuchi; T. Hashimoto; K. Yamagami; Y. Masai; M. Toi |
T. Sugie; K.A. Kassim; M. Takeuchi; T. Hashimoto; K. Yamagami; Y. Masai; M. Toi |
T. Sugie; K.A. Kassim; M. Takeuchi; T. Hashimoto; K. Yamagami; Y. Masai; M. Toi |
A novel method for sentinel lymph node biopsy by indocyanine green fluorescence technique in breast Cancer |
A novel method for sentinel lymph node biopsy by indocyanine green fluorescence technique in breast Cancer |
A novel method for sentinel lymph node biopsy by indocyanine green fluorescence technique in breast Cancer |
Cancers, 2, 2, 713-720 |
Cancers, 2, 2, 713-720 |
Cancers, 2, 2, 713-720 |
2010 |
有 |
英語 |
|
公開 |
| Y. Matsumura; H. Yamashiro; M. Toi |
Y. Matsumura; H. Yamashiro; M. Toi |
Y. Matsumura; H. Yamashiro; M. Toi |
Trastuzumab for cancer treatment: Present role and future perspective |
Trastuzumab for cancer treatment: Present role and future perspective |
Trastuzumab for cancer treatment: Present role and future perspective |
Biotherapy, 24, 2, 178-182 |
Biotherapy, 24, 2, 178-182 |
Biotherapy, 24, 2, 178-182 |
2010 |
有 |
日本語 |
|
公開 |
| K. Horiguchi; M. Toi; S.-I. Horiguchi; M. Sugimoto; Y. Naito; Y. Hayashi; T. Ueno; S. Ohno; N. Funata; K. Kuroi; M. Tomita; Y. Eishi |
K. Horiguchi; M. Toi; S.-I. Horiguchi; M. Sugimoto; Y. Naito; Y. Hayashi; T. Ueno; S. Ohno; N. Funata; K. Kuroi; M. Tomita; Y. Eishi |
K. Horiguchi; M. Toi; S.-I. Horiguchi; M. Sugimoto; Y. Naito; Y. Hayashi; T. Ueno; S. Ohno; N. Funata; K. Kuroi; M. Tomita; Y. Eishi |
Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients |
Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients |
Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients |
Journal of Medical and Dental Sciences, 57, 2, 165-175 |
Journal of Medical and Dental Sciences, 57, 2, 165-175 |
Journal of Medical and Dental Sciences, 57, 2, 165-175 |
2010 |
有 |
英語 |
|
公開 |
| S.-I. Horiguchi; T. Hishima; Y. Hayashi; Y. Shiozawa; K. Horiguchi; K. Kuroi; M. Toi; N. Funata; Y. Eishi |
S.-I. Horiguchi; T. Hishima; Y. Hayashi; Y. Shiozawa; K. Horiguchi; K. Kuroi; M. Toi; N. Funata; Y. Eishi |
S.-I. Horiguchi; T. Hishima; Y. Hayashi; Y. Shiozawa; K. Horiguchi; K. Kuroi; M. Toi; N. Funata; Y. Eishi |
HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma |
HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma |
HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma |
Journal of Medical and Dental Sciences, 57, 2, 155-163 |
Journal of Medical and Dental Sciences, 57, 2, 155-163 |
Journal of Medical and Dental Sciences, 57, 2, 155-163 |
2010 |
有 |
英語 |
|
公開 |
| H. Yamashiro; M. Toi |
H. Yamashiro; M. Toi |
H. Yamashiro; M. Toi |
[Molecular targeted therapy for breast cancer treatment, challenge to cure]. |
[Molecular targeted therapy for breast cancer treatment, challenge to cure]. |
[Molecular targeted therapy for breast cancer treatment, challenge to cure]. |
Nippon rinsho. Japanese journal of clinical medicine, 68, 10, 1854-1858 |
Nippon rinsho. Japanese journal of clinical medicine, 68, 10, 1854-1858 |
Nippon rinsho. Japanese journal of clinical medicine, 68, 10, 1854-1858 |
2010 |
有 |
英語 |
|
公開 |
| W. Tsuji; H. Yamashiro; M. Toi |
W. Tsuji; H. Yamashiro; M. Toi |
W. Tsuji; H. Yamashiro; M. Toi |
[Basic fibroblast growth factor (FGF-2)]. |
[Basic fibroblast growth factor (FGF-2)]. |
[Basic fibroblast growth factor (FGF-2)]. |
Nippon rinsho. Japanese journal of clinical medicine, 68 Suppl 7, 118-120 |
Nippon rinsho. Japanese journal of clinical medicine, 68 Suppl 7, 118-120 |
Nippon rinsho. Japanese journal of clinical medicine, 68 Suppl 7, 118-120 |
2010 |
有 |
英語 |
|
公開 |
| M. Toi |
M. Toi |
M. Toi |
[Current organ topics: chemotherapy of breast cancer]. |
[Current organ topics: chemotherapy of breast cancer]. |
[Current organ topics: chemotherapy of breast cancer]. |
Gan to kagaku ryoho. Cancer & chemotherapy, 37, 13, 2844- |
Gan to kagaku ryoho. Cancer & chemotherapy, 37, 13, 2844- |
Gan to kagaku ryoho. Cancer & chemotherapy, 37, 13, 2844- |
2010 |
有 |
英語 |
|
公開 |
| M. Toi; H. Iwata; Y. Fujiwara; Y. Ito; S. Nakamura; Y. Tokuda; T. Taguchi; Y. Rai; K. Aogi; T. Arai; J. Watanabe; T. Wakamatsu; K. Katsura; C.E. Ellis; R.C. Gagnon; K.E. Allen; Y. Sasaki; S. Takashima |
M. Toi; H. Iwata; Y. Fujiwara; Y. Ito; S. Nakamura; Y. Tokuda; T. Taguchi; Y. Rai; K. Aogi; T. Arai; J. Watanabe; T. Wakamatsu; K. Katsura; C.E. Ellis; R.C. Gagnon; K.E. Allen; Y. Sasaki; S. Takashima |
M. Toi; H. Iwata; Y. Fujiwara; Y. Ito; S. Nakamura; Y. Tokuda; T. Taguchi; Y. Rai; K. Aogi; T. Arai; J. Watanabe; T. Wakamatsu; K. Katsura; C.E. Ellis; R.C. Gagnon; K.E. Allen; Y. Sasaki; S. Takashima |
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: Efficacy, safety, and biomarker results from Japanese patients phase II studies |
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: Efficacy, safety, and biomarker results from Japanese patients phase II studies |
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: Efficacy, safety, and biomarker results from Japanese patients phase II studies |
British Journal of Cancer, 101, 10, 1676-1682 |
British Journal of Cancer, 101, 10, 1676-1682 |
British Journal of Cancer, 101, 10, 1676-1682 |
2009/11/10 |
有 |
英語 |
|
公開 |
| M. Kondo; S.-L. Hoshi; M. Toi |
M. Kondo; S.-L. Hoshi; M. Toi |
M. Kondo; S.-L. Hoshi; M. Toi |
Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan |
Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan |
Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan |
British Journal of Cancer, 100, 2, 281-290 |
British Journal of Cancer, 100, 2, 281-290 |
British Journal of Cancer, 100, 2, 281-290 |
2009/01/22 |
有 |
英語 |
|
公開 |
| W. Tsuji; T. Inamoto; H. Yamashiro; T. Ueno; H. Kato; Y. Kimura; Y. Tabata; M. Toi |
W. Tsuji; T. Inamoto; H. Yamashiro; T. Ueno; H. Kato; Y. Kimura; Y. Tabata; M. Toi |
W. Tsuji; T. Inamoto; H. Yamashiro; T. Ueno; H. Kato; Y. Kimura; Y. Tabata; M. Toi |
Adipogenesis induced by human adipose tissue-derived stem cells |
Adipogenesis induced by human adipose tissue-derived stem cells |
Adipogenesis induced by human adipose tissue-derived stem cells |
Tissue Engineering - Part A, 15, 1, 83-93 |
Tissue Engineering - Part A, 15, 1, 83-93 |
Tissue Engineering - Part A, 15, 1, 83-93 |
2009/01 |
有 |
英語 |
|
公開 |
| F. Chen; T. Fujinaga; K. Sato; M. Sonobe; T. Shoji; H. Sakai; R. Miyahara; T. Bando; K. Okubo; T. Hirata; M. Toi; H. Date |
F. Chen; T. Fujinaga; K. Sato; M. Sonobe; T. Shoji; H. Sakai; R. Miyahara; T. Bando; K. Okubo; T. Hirata; M. Toi; H. Date |
F. Chen; T. Fujinaga; K. Sato; M. Sonobe; T. Shoji; H. Sakai; R. Miyahara; T. Bando; K. Okubo; T. Hirata; M. Toi; H. Date |
Clinical features of surgical resection for pulmonary metastasis from breast cancer |
Clinical features of surgical resection for pulmonary metastasis from breast cancer |
Clinical features of surgical resection for pulmonary metastasis from breast cancer |
European Journal of Surgical Oncology, 35, 4, 393-397 |
European Journal of Surgical Oncology, 35, 4, 393-397 |
European Journal of Surgical Oncology, 35, 4, 393-397 |
2009 |
有 |
英語 |
|
公開 |
| T. Aruga; E. Suzuki; S. Saji; S.-I. Horiguchi; K. Horiguchi; S. Sekine; D. Kitagawa; N. Funata; M. Toi; K. Sugihara; K. Kuroi |
T. Aruga; E. Suzuki; S. Saji; S.-I. Horiguchi; K. Horiguchi; S. Sekine; D. Kitagawa; N. Funata; M. Toi; K. Sugihara; K. Kuroi |
T. Aruga; E. Suzuki; S. Saji; S.-I. Horiguchi; K. Horiguchi; S. Sekine; D. Kitagawa; N. Funata; M. Toi; K. Sugihara; K. Kuroi |
A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer |
A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer |
A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer |
Oncology Reports, 22, 2, 273-278 |
Oncology Reports, 22, 2, 273-278 |
Oncology Reports, 22, 2, 273-278 |
2009 |
有 |
英語 |
|
公開 |
| M. Toi; H. Yamashiro; W. Tsuji |
M. Toi; H. Yamashiro; W. Tsuji |
M. Toi; H. Yamashiro; W. Tsuji |
Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer |
Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer |
Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer |
Breast Cancer, 16, 3, 207-218 |
Breast Cancer, 16, 3, 207-218 |
Breast Cancer, 16, 3, 207-218 |
2009 |
有 |
英語 |
|
公開 |
| S. Noguchi; M. Toi |
S. Noguchi; M. Toi |
S. Noguchi; M. Toi |
From standardization to personalization in breast cancer treatment |
From standardization to personalization in breast cancer treatment |
From standardization to personalization in breast cancer treatment |
Breast Cancer, 16, 4, 241-242 |
Breast Cancer, 16, 4, 241-242 |
Breast Cancer, 16, 4, 241-242 |
2009 |
有 |
英語 |
|
公開 |
| A.M. Ali; M. Toi; T. Ueno |
A.M. Ali; M. Toi; T. Ueno |
A.M. Ali; M. Toi; T. Ueno |
Anti-angiogenic cancer therapy updates |
Anti-angiogenic cancer therapy updates |
Anti-angiogenic cancer therapy updates |
Current Molecular Medicine, 9, 8, 954-966 |
Current Molecular Medicine, 9, 8, 954-966 |
Current Molecular Medicine, 9, 8, 954-966 |
2009 |
有 |
英語 |
|
公開 |
| M. Kondo; S.-L. Hoshi; M. Toi |
M. Kondo; S.-L. Hoshi; M. Toi |
M. Kondo; S.-L. Hoshi; M. Toi |
Budget impact analysis of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan |
Budget impact analysis of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan |
Budget impact analysis of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan |
Japanese Journal of Clinical Oncology, 39, 11, 767-770 |
Japanese Journal of Clinical Oncology, 39, 11, 767-770 |
Japanese Journal of Clinical Oncology, 39, 11, 767-770 |
2009 |
有 |
英語 |
|
公開 |
| Md.Z. Dewan; M. Takada; H. Terunuma; X. Deng; S. Ahmed; N. Yamamoto; M. Toi |
Md.Z. Dewan; M. Takada; H. Terunuma; X. Deng; S. Ahmed; N. Yamamoto; M. Toi |
Md.Z. Dewan; M. Takada; H. Terunuma; X. Deng; S. Ahmed; N. Yamamoto; M. Toi |
Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients |
Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients |
Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients |
Biomedicine and Pharmacotherapy, 63, 9, 703-706 |
Biomedicine and Pharmacotherapy, 63, 9, 703-706 |
Biomedicine and Pharmacotherapy, 63, 9, 703-706 |
2009 |
有 |
英語 |
|
公開 |
| M. Muta; T. Yanagawa; Y. Sai; S. Saji; E. Suzuki; T. Aruga; K. Kuroi; G. Matsumoto; M. Toi; E. Nakashima |
M. Muta; T. Yanagawa; Y. Sai; S. Saji; E. Suzuki; T. Aruga; K. Kuroi; G. Matsumoto; M. Toi; E. Nakashima |
M. Muta; T. Yanagawa; Y. Sai; S. Saji; E. Suzuki; T. Aruga; K. Kuroi; G. Matsumoto; M. Toi; E. Nakashima |
Effect of low-dose paclitaxel and docetaxel on endothelial progenitor cells |
Effect of low-dose paclitaxel and docetaxel on endothelial progenitor cells |
Effect of low-dose paclitaxel and docetaxel on endothelial progenitor cells |
Oncology, 77, 3-4, 182-191 |
Oncology, 77, 3-4, 182-191 |
Oncology, 77, 3-4, 182-191 |
2009 |
有 |
英語 |
|
公開 |
| T. Sugie; Y. Tanaka; M. Toi |
T. Sugie; Y. Tanaka; M. Toi |
T. Sugie; Y. Tanaka; M. Toi |
New development in breast cancer therapy. III. Zoledronic acid and anti-tumor immunity in breast cancer |
New development in breast cancer therapy. III. Zoledronic acid and anti-tumor immunity in breast cancer |
New development in breast cancer therapy. III. Zoledronic acid and anti-tumor immunity in breast cancer |
Gan to kagaku ryoho. Cancer & chemotherapy, 36, 13, 2555-2559 |
Gan to kagaku ryoho. Cancer & chemotherapy, 36, 13, 2555-2559 |
Gan to kagaku ryoho. Cancer & chemotherapy, 36, 13, 2555-2559 |
2009 |
有 |
英語 |
|
公開 |
| M. Toi; H. Sasano; M.J. Ellis |
M. Toi; H. Sasano; M.J. Ellis |
M. Toi; H. Sasano; M.J. Ellis |
Future prospects of neoadjuvant endocrine therapy in postmenopausal breast cancer |
Future prospects of neoadjuvant endocrine therapy in postmenopausal breast cancer |
Future prospects of neoadjuvant endocrine therapy in postmenopausal breast cancer |
Japanese Journal of Cancer and Chemotherapy, 36, 6, 1035-1042 |
Japanese Journal of Cancer and Chemotherapy, 36, 6, 1035-1042 |
Japanese Journal of Cancer and Chemotherapy, 36, 6, 1035-1042 |
2009 |
有 |
日本語 |
|
公開 |
| H. Yamashiro; M. Toi |
H. Yamashiro; M. Toi |
H. Yamashiro; M. Toi |
Anti-HER2 antibody and small-molecule tyrosine kinase inhibitor therapy targeting EGFR signal pathway |
Anti-HER2 antibody and small-molecule tyrosine kinase inhibitor therapy targeting EGFR signal pathway |
Anti-HER2 antibody and small-molecule tyrosine kinase inhibitor therapy targeting EGFR signal pathway |
Japanese Journal of Cancer and Chemotherapy, 36, 7, 1067-1071 |
Japanese Journal of Cancer and Chemotherapy, 36, 7, 1067-1071 |
Japanese Journal of Cancer and Chemotherapy, 36, 7, 1067-1071 |
2009 |
有 |
日本語 |
|
公開 |
| T. Ueno; M. Toi |
T. Ueno; M. Toi |
T. Ueno; M. Toi |
Biomarker |
Biomarker |
Biomarker |
Japanese Journal of Cancer and Chemotherapy, 36, 1, 15-20 |
Japanese Journal of Cancer and Chemotherapy, 36, 1, 15-20 |
Japanese Journal of Cancer and Chemotherapy, 36, 1, 15-20 |
2009 |
有 |
英語 |
|
公開 |
| H. Ishiguro; I. Yano; M. Toi |
H. Ishiguro; I. Yano; M. Toi |
H. Ishiguro; I. Yano; M. Toi |
Important drug interactions for clinical oncologists |
Important drug interactions for clinical oncologists |
Important drug interactions for clinical oncologists |
Frontiers in Drug Design and Discovery, 4, 1, 97-121 |
Frontiers in Drug Design and Discovery, 4, 1, 97-121 |
Frontiers in Drug Design and Discovery, 4, 1, 97-121 |
2009 |
有 |
英語 |
|
公開 |
| H. Ishiguro; I. Yano; M. Toi |
H. Ishiguro; I. Yano; M. Toi |
H. Ishiguro; I. Yano; M. Toi |
Pharmacogenomic considerations in breast cancer management |
Pharmacogenomic considerations in breast cancer management |
Pharmacogenomic considerations in breast cancer management |
Frontiers in Drug Design and Discovery, 4, 1, 122-134 |
Frontiers in Drug Design and Discovery, 4, 1, 122-134 |
Frontiers in Drug Design and Discovery, 4, 1, 122-134 |
2009 |
有 |
英語 |
|
公開 |
| Kimura Y., Tsuji W., Yamashiro H., Toi M., Inamoto T., Tabata Y. |
Kimura Y., Tsuji W., Yamashiro H., Toi M., Inamoto T., Tabata Y. |
Kimura Y., Tsuji W., Yamashiro H., Toi M., Inamoto T., Tabata Y. |
In Situ adipose tissue regeneration augmented by collagen scaffold combined with gelatin microspheres containing basic fibroblast growth factor. |
In Situ adipose tissue regeneration augmented by collagen scaffold combined with gelatin microspheres containing basic fibroblast growth factor. |
In Situ adipose tissue regeneration augmented by collagen scaffold combined with gelatin microspheres containing basic fibroblast growth factor. |
The 2nd World Congress of the Tissue Engineering and Regenerative Medicine International Society （TERMIS-WC2009） （2009.08.31－09. 03 Seoul, Korea） |
The 2nd World Congress of the Tissue Engineering and Regenerative Medicine International Society （TERMIS-WC2009） （2009.08.31－09. 03 Seoul, Korea） |
The 2nd World Congress of the Tissue Engineering and Regenerative Medicine International Society （TERMIS-WC2009） （2009.08.31－09. 03 Seoul, Korea） |
2009 |
有 |
英語 |
|
公開 |
| M. Toi |
M. Toi |
M. Toi |
Long-term outcomes of aromatase inhibition for breast cancer |
Long-term outcomes of aromatase inhibition for breast cancer |
Long-term outcomes of aromatase inhibition for breast cancer |
The Lancet Oncology, 9, 1, 8-10 |
The Lancet Oncology, 9, 1, 8-10 |
The Lancet Oncology, 9, 1, 8-10 |
2008 |
有 |
英語 |
|
公開 |
| S. Saji; M. Toi; S. Morita; H. Iwata; Y. Ito; S. Ohno; T. Kobayashi; Y. Hozumi; J. Sakamoto |
S. Saji; M. Toi; S. Morita; H. Iwata; Y. Ito; S. Ohno; T. Kobayashi; Y. Hozumi; J. Sakamoto |
S. Saji; M. Toi; S. Morita; H. Iwata; Y. Ito; S. Ohno; T. Kobayashi; Y. Hozumi; J. Sakamoto |
Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer |
Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer |
Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer |
Oncology, 72, 5-6, 330-337 |
Oncology, 72, 5-6, 330-337 |
Oncology, 72, 5-6, 330-337 |
2008 |
有 |
英語 |
|
公開 |
| T. Ueno; G. Elmberger; T.E. Weaver; M. Toi; S. Linder |
T. Ueno; G. Elmberger; T.E. Weaver; M. Toi; S. Linder |
T. Ueno; G. Elmberger; T.E. Weaver; M. Toi; S. Linder |
The aspartic protease napsin a suppresses tumor growth independent of its catalytic activity |
The aspartic protease napsin a suppresses tumor growth independent of its catalytic activity |
The aspartic protease napsin a suppresses tumor growth independent of its catalytic activity |
Laboratory Investigation, 88, 3, 256-263 |
Laboratory Investigation, 88, 3, 256-263 |
Laboratory Investigation, 88, 3, 256-263 |
2008 |
有 |
英語 |
|
公開 |
| H. Yamashiro; M. Toi |
H. Yamashiro; M. Toi |
H. Yamashiro; M. Toi |
Update of evidence in chemotherapy for breast cancer |
Update of evidence in chemotherapy for breast cancer |
Update of evidence in chemotherapy for breast cancer |
International Journal of Clinical Oncology, 13, 1, 3-7 |
International Journal of Clinical Oncology, 13, 1, 3-7 |
International Journal of Clinical Oncology, 13, 1, 3-7 |
2008 |
有 |
英語 |
|
公開 |
| L.W.-C. Chow; A.Y.-S. Yip; W.T.-Y. Loo; M. Toi |
L.W.-C. Chow; A.Y.-S. Yip; W.T.-Y. Loo; M. Toi |
L.W.-C. Chow; A.Y.-S. Yip; W.T.-Y. Loo; M. Toi |
Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer |
Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer |
Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer |
Cancer Letters, 262, 2, 232-238 |
Cancer Letters, 262, 2, 232-238 |
Cancer Letters, 262, 2, 232-238 |
2008 |
有 |
英語 |
|
公開 |
| H. Ishiguro; T. Kitano; H. Yoshibayashi; M. Toi; T. Ueno; H. Yasuda; K. Yanagihara; C.L. Garbo; M. Fukushima |
H. Ishiguro; T. Kitano; H. Yoshibayashi; M. Toi; T. Ueno; H. Yasuda; K. Yanagihara; C.L. Garbo; M. Fukushima |
H. Ishiguro; T. Kitano; H. Yoshibayashi; M. Toi; T. Ueno; H. Yasuda; K. Yanagihara; C.L. Garbo; M. Fukushima |
Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim |
Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim |
Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim |
Annals of Oncology, 19, 5, 1019- |
Annals of Oncology, 19, 5, 1019- |
Annals of Oncology, 19, 5, 1019- |
2008 |
有 |
英語 |
|
公開 |
| S. Noguchi; M. Toi |
S. Noguchi; M. Toi |
S. Noguchi; M. Toi |
Molecular target therapy: Basics and clinical application |
Molecular target therapy: Basics and clinical application |
Molecular target therapy: Basics and clinical application |
Breast Cancer, 15, 1, 47-48 |
Breast Cancer, 15, 1, 47-48 |
Breast Cancer, 15, 1, 47-48 |
2008 |
有 |
英語 |
|
公開 |
| H. Yagata; S. Nakamura; M. Toi; H. Bando; S. Ohno; A. Kataoka |
H. Yagata; S. Nakamura; M. Toi; H. Bando; S. Ohno; A. Kataoka |
H. Yagata; S. Nakamura; M. Toi; H. Bando; S. Ohno; A. Kataoka |
Evaluation of circulating tumor cells in patients with breast cancer: Multi-institutional clinical trial in Japan |
Evaluation of circulating tumor cells in patients with breast cancer: Multi-institutional clinical trial in Japan |
Evaluation of circulating tumor cells in patients with breast cancer: Multi-institutional clinical trial in Japan |
International Journal of Clinical Oncology, 13, 3, 252-256 |
International Journal of Clinical Oncology, 13, 3, 252-256 |
International Journal of Clinical Oncology, 13, 3, 252-256 |
2008 |
有 |
英語 |
|
公開 |
| M. Toi; S. Nakamura; K. Kuroi; H. Iwata; S. Ohno; N. Masuda; M. Kusama; K. Yamazaki; K. Hisamatsu; Y. Sato; M. Kashiwaba; H. Kaise; M. Kurosumi; H. Tsuda; F. Akiyama; Y. Ohashi; Y. Takatsuka |
M. Toi; S. Nakamura; K. Kuroi; H. Iwata; S. Ohno; N. Masuda; M. Kusama; K. Yamazaki; K. Hisamatsu; Y. Sato; M. Kashiwaba; H. Kaise; M. Kurosumi; H. Tsuda; F. Akiyama; Y. Ohashi; Y. Takatsuka |
M. Toi; S. Nakamura; K. Kuroi; H. Iwata; S. Ohno; N. Masuda; M. Kusama; K. Yamazaki; K. Hisamatsu; Y. Sato; M. Kashiwaba; H. Kaise; M. Kurosumi; H. Tsuda; F. Akiyama; Y. Ohashi; Y. Takatsuka |
Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival |
Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival |
Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival |
Breast Cancer Research and Treatment, 110, 3, 531-539 |
Breast Cancer Research and Treatment, 110, 3, 531-539 |
Breast Cancer Research and Treatment, 110, 3, 531-539 |
2008 |
有 |
英語 |
|
公開 |
| L.W.-C. Chow; A.Y.-S. Yip; W.T.-Y. Loo; C.-K. Lam; M. Toi |
L.W.-C. Chow; A.Y.-S. Yip; W.T.-Y. Loo; C.-K. Lam; M. Toi |
L.W.-C. Chow; A.Y.-S. Yip; W.T.-Y. Loo; C.-K. Lam; M. Toi |
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer |
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer |
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer |
Journal of Steroid Biochemistry and Molecular Biology, 111, 1-2, 13-17 |
Journal of Steroid Biochemistry and Molecular Biology, 111, 1-2, 13-17 |
Journal of Steroid Biochemistry and Molecular Biology, 111, 1-2, 13-17 |
2008 |
有 |
英語 |
|
公開 |
| N. Tokudome; Y. Ito; K. Hatake; M. Toi; M. Sano; H. Iwata; Y. Sato; T. Saeki; K. Aogi; S. Takashima |
N. Tokudome; Y. Ito; K. Hatake; M. Toi; M. Sano; H. Iwata; Y. Sato; T. Saeki; K. Aogi; S. Takashima |
N. Tokudome; Y. Ito; K. Hatake; M. Toi; M. Sano; H. Iwata; Y. Sato; T. Saeki; K. Aogi; S. Takashima |
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II and pharmacokinetic study in Japan |
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II and pharmacokinetic study in Japan |
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II and pharmacokinetic study in Japan |
Anti-Cancer Drugs, 19, 7, 753-759 |
Anti-Cancer Drugs, 19, 7, 753-759 |
Anti-Cancer Drugs, 19, 7, 753-759 |
2008 |
有 |
英語 |
|
公開 |
| M. Kondo; S.L. Hoshi; H. Ishiguro; H. Yoshibayashi; M. Toi |
M. Kondo; S.L. Hoshi; H. Ishiguro; H. Yoshibayashi; M. Toi |
M. Kondo; S.L. Hoshi; H. Ishiguro; H. Yoshibayashi; M. Toi |
Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan |
Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan |
Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan |
Breast Cancer Research and Treatment, 112, 1, 175-187 |
Breast Cancer Research and Treatment, 112, 1, 175-187 |
Breast Cancer Research and Treatment, 112, 1, 175-187 |
2008 |
有 |
英語 |
|
公開 |
| M. Toi |
M. Toi |
M. Toi |
Novel targeting therapy concept for breast cancer treatment |
Novel targeting therapy concept for breast cancer treatment |
Novel targeting therapy concept for breast cancer treatment |
Folia Pharmacologica Japonica, 132, 3, 177-179 |
Folia Pharmacologica Japonica, 132, 3, 177-179 |
Folia Pharmacologica Japonica, 132, 3, 177-179 |
2008 |
有 |
英語 |
|
公開 |
| T. Kiba; T. Inamoto; T. Nishimura; M. Ueno; K. Yanagihara; S. Teramukai; H. Kato; M. Toi; M. Fukushima |
T. Kiba; T. Inamoto; T. Nishimura; M. Ueno; K. Yanagihara; S. Teramukai; H. Kato; M. Toi; M. Fukushima |
T. Kiba; T. Inamoto; T. Nishimura; M. Ueno; K. Yanagihara; S. Teramukai; H. Kato; M. Toi; M. Fukushima |
The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery |
The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery |
The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery |
BMC Cancer, 8 |
BMC Cancer, 8 |
BMC Cancer, 8 |
2008 |
有 |
英語 |
|
公開 |
| N. Honma; S. Saji; R. Kurabayashi; J. Aida; T. Arai; R. Horii; F. Akiyama; T. Iwase; N. Harada; M. Younes; M. Toi; K. Takubo; G. Sakamoto |
N. Honma; S. Saji; R. Kurabayashi; J. Aida; T. Arai; R. Horii; F. Akiyama; T. Iwase; N. Harada; M. Younes; M. Toi; K. Takubo; G. Sakamoto |
N. Honma; S. Saji; R. Kurabayashi; J. Aida; T. Arai; R. Horii; F. Akiyama; T. Iwase; N. Harada; M. Younes; M. Toi; K. Takubo; G. Sakamoto |
Oestrogen receptor-β1 but not oestrogen receptor-βcx is of prognostic value in apocrine carcinoma of the breast |
Oestrogen receptor-β1 but not oestrogen receptor-βcx is of prognostic value in apocrine carcinoma of the breast |
Oestrogen receptor-β1 but not oestrogen receptor-βcx is of prognostic value in apocrine carcinoma of the breast |
APMIS, 116, 10, 923-930 |
APMIS, 116, 10, 923-930 |
APMIS, 116, 10, 923-930 |
2008 |
有 |
英語 |
|
公開 |
| H. Yoshibayashi; H. Ishiguro; M. Takada; M. Takeuchi; H. Yamashiro; T. Ueno; H. Kato; K. Yoshikawa; S. Kanao; C. Yamauchi; Y. Mikami; M. Toi |
H. Yoshibayashi; H. Ishiguro; M. Takada; M. Takeuchi; H. Yamashiro; T. Ueno; H. Kato; K. Yoshikawa; S. Kanao; C. Yamauchi; Y. Mikami; M. Toi |
H. Yoshibayashi; H. Ishiguro; M. Takada; M. Takeuchi; H. Yamashiro; T. Ueno; H. Kato; K. Yoshikawa; S. Kanao; C. Yamauchi; Y. Mikami; M. Toi |
A case of primary breast cancer who responded remarkably to the neoadjuvant chemotherapy with the combination of docetaxel and cyclophosphamide |
A case of primary breast cancer who responded remarkably to the neoadjuvant chemotherapy with the combination of docetaxel and cyclophosphamide |
A case of primary breast cancer who responded remarkably to the neoadjuvant chemotherapy with the combination of docetaxel and cyclophosphamide |
Gan to kagaku ryoho. Cancer & chemotherapy, 35, 6, 987-990 |
Gan to kagaku ryoho. Cancer & chemotherapy, 35, 6, 987-990 |
Gan to kagaku ryoho. Cancer & chemotherapy, 35, 6, 987-990 |
2008 |
有 |
日本語 |
|
公開 |
| M. Takada; H. Ishiguro; M. Toi |
M. Takada; H. Ishiguro; M. Toi |
M. Takada; H. Ishiguro; M. Toi |
Treatment for breast cancer and endocrine neoplasm |
Treatment for breast cancer and endocrine neoplasm |
Treatment for breast cancer and endocrine neoplasm |
Gan to kagaku ryoho. Cancer & chemotherapy, 35, 13, 2344-2350 |
Gan to kagaku ryoho. Cancer & chemotherapy, 35, 13, 2344-2350 |
Gan to kagaku ryoho. Cancer & chemotherapy, 35, 13, 2344-2350 |
2008 |
有 |
英語 |
|
公開 |
| T. Oikawa; C. Onozawa; S. Kuranuki; Y. Igarashi; M. Sato; H. Ashino; M. Shimamura; M. Toi; S. Kurakata |
T. Oikawa; C. Onozawa; S. Kuranuki; Y. Igarashi; M. Sato; H. Ashino; M. Shimamura; M. Toi; S. Kurakata |
T. Oikawa; C. Onozawa; S. Kuranuki; Y. Igarashi; M. Sato; H. Ashino; M. Shimamura; M. Toi; S. Kurakata |
Dipalmitoylation of radicicol results in improved efficacy against tumor growth and angiogenesis in vivo |
Dipalmitoylation of radicicol results in improved efficacy against tumor growth and angiogenesis in vivo |
Dipalmitoylation of radicicol results in improved efficacy against tumor growth and angiogenesis in vivo |
Cancer Science, 98, 2, 219-225 |
Cancer Science, 98, 2, 219-225 |
Cancer Science, 98, 2, 219-225 |
2007 |
有 |
英語 |
|
公開 |
| T. Yamaguchi; H. Bando; T. Mori; K. Takahashi; H. Matsumoto; M. Yasutome; H.A. Weich; M. Toi |
T. Yamaguchi; H. Bando; T. Mori; K. Takahashi; H. Matsumoto; M. Yasutome; H.A. Weich; M. Toi |
T. Yamaguchi; H. Bando; T. Mori; K. Takahashi; H. Matsumoto; M. Yasutome; H.A. Weich; M. Toi |
Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: Association with progression and prognosis |
Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: Association with progression and prognosis |
Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: Association with progression and prognosis |
Cancer Science, 98, 3, 405-410 |
Cancer Science, 98, 3, 405-410 |
Cancer Science, 98, 3, 405-410 |
2007 |
有 |
英語 |
|
公開 |
| T. Saeki; T. Nomizu; M. Toi; Y. Ito; S. Noguchi; T. Kobayashi; T. Asaga; H. Minami; N. Yamamoto; K. Aogi; T. Ikeda; Y. Ohashi; W. Sato; T. Tsuruo |
T. Saeki; T. Nomizu; M. Toi; Y. Ito; S. Noguchi; T. Kobayashi; T. Asaga; H. Minami; N. Yamamoto; K. Aogi; T. Ikeda; Y. Ohashi; W. Sato; T. Tsuruo |
T. Saeki; T. Nomizu; M. Toi; Y. Ito; S. Noguchi; T. Kobayashi; T. Asaga; H. Minami; N. Yamamoto; K. Aogi; T. Ikeda; Y. Ohashi; W. Sato; T. Tsuruo |
Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer |
Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer |
Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer |
Journal of Clinical Oncology, 25, 4, 411-417 |
Journal of Clinical Oncology, 25, 4, 411-417 |
Journal of Clinical Oncology, 25, 4, 411-417 |
2007 |
有 |
英語 |
|
公開 |
| E. Suzuki; R. Niwa; S. Saji; M. Muta; M. Hirose; S. Iida; Y. Shiotsu; M. Satoh; K. Shitara; M. Kondo; M. Toi |
E. Suzuki; R. Niwa; S. Saji; M. Muta; M. Hirose; S. Iida; Y. Shiotsu; M. Satoh; K. Shitara; M. Kondo; M. Toi |
E. Suzuki; R. Niwa; S. Saji; M. Muta; M. Hirose; S. Iida; Y. Shiotsu; M. Satoh; K. Shitara; M. Kondo; M. Toi |
A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients |
A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients |
A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients |
Clinical Cancer Research, 13, 6, 1875-1882 |
Clinical Cancer Research, 13, 6, 1875-1882 |
Clinical Cancer Research, 13, 6, 1875-1882 |
2007 |
有 |
英語 |
|
公開 |
| E. Suzuki; M. Toi |
E. Suzuki; M. Toi |
E. Suzuki; M. Toi |
Improving the efficacy of trastuzumab in breast cancer |
Improving the efficacy of trastuzumab in breast cancer |
Improving the efficacy of trastuzumab in breast cancer |
Cancer Science, 98, 6, 767-771 |
Cancer Science, 98, 6, 767-771 |
Cancer Science, 98, 6, 767-771 |
2007 |
有 |
英語 |
|
公開 |
| M. Toi |
M. Toi |
M. Toi |
What does DNA methylation surrogate? |
What does DNA methylation surrogate? |
What does DNA methylation surrogate? |
Digestion, 75, 1, 53- |
Digestion, 75, 1, 53- |
Digestion, 75, 1, 53- |
2007 |
有 |
英語 |
|
公開 |
| M.H. Olofsson; T. Ueno; Y. Pan; R. Xu; F. Cai; H. Van Der Kuip; T.E. Muerdter; M. Sonnenberg; W.E. Aulitzky; S. Schwarz; E. Andersson; M.C. Shoshan; A.M. Havelka; M. Toi; S. Linder |
M.H. Olofsson; T. Ueno; Y. Pan; R. Xu; F. Cai; H. Van Der Kuip; T.E. Muerdter; M. Sonnenberg; W.E. Aulitzky; S. Schwarz; E. Andersson; M.C. Shoshan; A.M. Havelka; M. Toi; S. Linder |
M.H. Olofsson; T. Ueno; Y. Pan; R. Xu; F. Cai; H. Van Der Kuip; T.E. Muerdter; M. Sonnenberg; W.E. Aulitzky; S. Schwarz; E. Andersson; M.C. Shoshan; A.M. Havelka; M. Toi; S. Linder |
Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy |
Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy |
Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy |
Clinical Cancer Research, 13, 11, 3198-3206 |
Clinical Cancer Research, 13, 11, 3198-3206 |
Clinical Cancer Research, 13, 11, 3198-3206 |
2007 |
有 |
英語 |
|
公開 |
| Md.Z. Dewan; H. Terunuma; M. Takada; Y. Tanaka; H. Abe; T. Sata; M. Toi; N. Yamamoto |
Md.Z. Dewan; H. Terunuma; M. Takada; Y. Tanaka; H. Abe; T. Sata; M. Toi; N. Yamamoto |
Md.Z. Dewan; H. Terunuma; M. Takada; Y. Tanaka; H. Abe; T. Sata; M. Toi; N. Yamamoto |
Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo |
Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo |
Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo |
Breast Cancer Research and Treatment, 104, 3, 267-275 |
Breast Cancer Research and Treatment, 104, 3, 267-275 |
Breast Cancer Research and Treatment, 104, 3, 267-275 |
2007 |
有 |
英語 |
|
公開 |
| D. Kitagawa; M. Toi |
D. Kitagawa; M. Toi |
D. Kitagawa; M. Toi |
Current status and the perspective of treatment strategy for the patients with advanced or recurrent breast cancer |
Current status and the perspective of treatment strategy for the patients with advanced or recurrent breast cancer |
Current status and the perspective of treatment strategy for the patients with advanced or recurrent breast cancer |
Nippon rinsho. Japanese journal of clinical medicine, 65 Suppl 6, 396-401 |
Nippon rinsho. Japanese journal of clinical medicine, 65 Suppl 6, 396-401 |
Nippon rinsho. Japanese journal of clinical medicine, 65 Suppl 6, 396-401 |
2007 |
有 |
英語 |
|
公開 |
| H. Yamashiro; M. Toi |
H. Yamashiro; M. Toi |
H. Yamashiro; M. Toi |
Herceptin (trastuzumab) |
Herceptin (trastuzumab) |
Herceptin (trastuzumab) |
Gan to kagaku ryoho. Cancer & chemotherapy, 34, 8, 1173-1176 |
Gan to kagaku ryoho. Cancer & chemotherapy, 34, 8, 1173-1176 |
Gan to kagaku ryoho. Cancer & chemotherapy, 34, 8, 1173-1176 |
2007 |
有 |
日本語 |
|
公開 |
| M. Toi |
M. Toi |
M. Toi |
Lapatinib: A viewpoint |
Lapatinib: A viewpoint |
Lapatinib: A viewpoint |
Drugs, 67, 14, 2109- |
Drugs, 67, 14, 2109- |
Drugs, 67, 14, 2109- |
2007 |
有 |
英語 |
|
公開 |
| M. Toi; T. Ikeda; F. Akiyama; M. Kurosumi; H. Tsuda; G. Sakamoto; O. Abe |
M. Toi; T. Ikeda; F. Akiyama; M. Kurosumi; H. Tsuda; G. Sakamoto; O. Abe |
M. Toi; T. Ikeda; F. Akiyama; M. Kurosumi; H. Tsuda; G. Sakamoto; O. Abe |
Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy |
Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy |
Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy |
International Journal of Oncology, 31, 4, 899-906 |
International Journal of Oncology, 31, 4, 899-906 |
International Journal of Oncology, 31, 4, 899-906 |
2007 |
有 |
英語 |
|
公開 |
| S. Morita; M. Toi; S. Saji; H. Iwata; S. Ohno; Y. Ito; T. Kobayashi; Y. Hozumi; J. Sakamoto |
S. Morita; M. Toi; S. Saji; H. Iwata; S. Ohno; Y. Ito; T. Kobayashi; Y. Hozumi; J. Sakamoto |
S. Morita; M. Toi; S. Saji; H. Iwata; S. Ohno; Y. Ito; T. Kobayashi; Y. Hozumi; J. Sakamoto |
Practical application of the continual reassessment method to a phase I dose-finding trial in advanced breast cancer |
Practical application of the continual reassessment method to a phase I dose-finding trial in advanced breast cancer |
Practical application of the continual reassessment method to a phase I dose-finding trial in advanced breast cancer |
Drug Information Journal, 41, 6, 691-700 |
Drug Information Journal, 41, 6, 691-700 |
Drug Information Journal, 41, 6, 691-700 |
2007 |
有 |
英語 |
|
公開 |
| N. Masuda; M. Toi; Y. Takatsuka; S. Nakamura; H. Iwata; S. Ohno; K. Kuroi; M. Kusama; K. Hisamatsu; K. Yamazaki; S. Eisei; Y. Sato; H. Kaise; M. Kashiwaba; H. Iwase; M. Kurosumi; H. Tsuda; F. Akiyama |
N. Masuda; M. Toi; Y. Takatsuka; S. Nakamura; H. Iwata; S. Ohno; K. Kuroi; M. Kusama; K. Hisamatsu; K. Yamazaki; S. Eisei; Y. Sato; H. Kaise; M. Kashiwaba; H. Iwase; M. Kurosumi; H. Tsuda; F. Akiyama |
N. Masuda; M. Toi; Y. Takatsuka; S. Nakamura; H. Iwata; S. Ohno; K. Kuroi; M. Kusama; K. Hisamatsu; K. Yamazaki; S. Eisei; Y. Sato; H. Kaise; M. Kashiwaba; H. Iwase; M. Kurosumi; H. Tsuda; F. Akiyama |
Results of survey conducted on perioperative chemotherapy and supportive care in primary breast cancer (JBCRG01) |
Results of survey conducted on perioperative chemotherapy and supportive care in primary breast cancer (JBCRG01) |
Results of survey conducted on perioperative chemotherapy and supportive care in primary breast cancer (JBCRG01) |
Gan to kagaku ryoho. Cancer & chemotherapy, 34, 10, 1609-1615 |
Gan to kagaku ryoho. Cancer & chemotherapy, 34, 10, 1609-1615 |
Gan to kagaku ryoho. Cancer & chemotherapy, 34, 10, 1609-1615 |
2007 |
有 |
英語 |
|
公開 |
| M. Takada; M. Toi |
M. Takada; M. Toi |
M. Takada; M. Toi |
Primary systemic chemotherapy for breast cancer |
Primary systemic chemotherapy for breast cancer |
Primary systemic chemotherapy for breast cancer |
Gan to kagaku ryoho. Cancer & chemotherapy, 34, 11, 1730-1734 |
Gan to kagaku ryoho. Cancer & chemotherapy, 34, 11, 1730-1734 |
Gan to kagaku ryoho. Cancer & chemotherapy, 34, 11, 1730-1734 |
2007 |
有 |
日本語 |
|
公開 |
| M.Z. Dewan; J.-N. Uchihara; K. Terashima; M. Honda; T. Sata; M. Ito; N. Fujii; K. Uozumi; K. Tsukasaki; M. Tomonaga; Y. Kubuki; A. Okayama; M. Toi; N. Mori; N. Yamamoto |
M.Z. Dewan; J.-N. Uchihara; K. Terashima; M. Honda; T. Sata; M. Ito; N. Fujii; K. Uozumi; K. Tsukasaki; M. Tomonaga; Y. Kubuki; A. Okayama; M. Toi; N. Mori; N. Yamamoto |
M.Z. Dewan; J.-N. Uchihara; K. Terashima; M. Honda; T. Sata; M. Ito; N. Fujii; K. Uozumi; K. Tsukasaki; M. Tomonaga; Y. Kubuki; A. Okayama; M. Toi; N. Mori; N. Yamamoto |
Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir |
Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir |
Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir |
Blood, 107, 2, 716-724 |
Blood, 107, 2, 716-724 |
Blood, 107, 2, 716-724 |
2006 |
有 |
英語 |
|
公開 |
| M. Muta; G. Matsumoto; E. Nakashima; M. Toi |
M. Muta; G. Matsumoto; E. Nakashima; M. Toi |
M. Muta; G. Matsumoto; E. Nakashima; M. Toi |
Mechanical analysis of tumor growth regression by the cyclooxygenase-2 inhibitor, DFU, in a Walker256 rat tumor model: Importance of monocyte chemoattractant protein-1 modulation |
Mechanical analysis of tumor growth regression by the cyclooxygenase-2 inhibitor, DFU, in a Walker256 rat tumor model: Importance of monocyte chemoattractant protein-1 modulation |
Mechanical analysis of tumor growth regression by the cyclooxygenase-2 inhibitor, DFU, in a Walker256 rat tumor model: Importance of monocyte chemoattractant protein-1 modulation |
Clinical Cancer Research, 12, 1, 264-272 |
Clinical Cancer Research, 12, 1, 264-272 |
Clinical Cancer Research, 12, 1, 264-272 |
2006 |
有 |
英語 |
|
公開 |
| M. Kondo; M. Toi |
M. Kondo; M. Toi |
M. Kondo; M. Toi |
Cost-effective treatment options in first-line therapy for advanced breast cancer in Japan |
Cost-effective treatment options in first-line therapy for advanced breast cancer in Japan |
Cost-effective treatment options in first-line therapy for advanced breast cancer in Japan |
Expert Review of Anticancer Therapy, 6, 2, 197-204 |
Expert Review of Anticancer Therapy, 6, 2, 197-204 |
Expert Review of Anticancer Therapy, 6, 2, 197-204 |
2006 |
有 |
英語 |
|
公開 |
| T. Suzuki; M. Toi; S. Saji; K. Horiguchi; T. Aruga; E. Suzuki; S. Horiguchi; N. Funata; K. Karasawa; N. Kamata |
T. Suzuki; M. Toi; S. Saji; K. Horiguchi; T. Aruga; E. Suzuki; S. Horiguchi; N. Funata; K. Karasawa; N. Kamata |
T. Suzuki; M. Toi; S. Saji; K. Horiguchi; T. Aruga; E. Suzuki; S. Horiguchi; N. Funata; K. Karasawa; N. Kamata |
Early breast cancer |
Early breast cancer |
Early breast cancer |
International Journal of Clinical Oncology, 11, 2, 108-119 |
International Journal of Clinical Oncology, 11, 2, 108-119 |
International Journal of Clinical Oncology, 11, 2, 108-119 |
2006 |
有 |
英語 |
|
公開 |
| T. Saeki; T. Kimura; M. Toi; T. Taguchi |
T. Saeki; T. Kimura; M. Toi; T. Taguchi |
T. Saeki; T. Kimura; M. Toi; T. Taguchi |
A pilot phase II study of capecitabine in advanced or recurrent breast cancer. |
A pilot phase II study of capecitabine in advanced or recurrent breast cancer. |
A pilot phase II study of capecitabine in advanced or recurrent breast cancer. |
Breast cancer (Tokyo, Japan), 13, 1, 49-57 |
Breast cancer (Tokyo, Japan), 13, 1, 49-57 |
Breast cancer (Tokyo, Japan), 13, 1, 49-57 |
2006 |
有 |
英語 |
|
公開 |
| K. Kuroi; M. Toi; H. Tsuda; M. Kurosumi; F. Akiyama |
K. Kuroi; M. Toi; H. Tsuda; M. Kurosumi; F. Akiyama |
K. Kuroi; M. Toi; H. Tsuda; M. Kurosumi; F. Akiyama |
Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. |
Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. |
Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. |
Breast cancer (Tokyo, Japan), 13, 1, 38-48 |
Breast cancer (Tokyo, Japan), 13, 1, 38-48 |
Breast cancer (Tokyo, Japan), 13, 1, 38-48 |
2006 |
有 |
英語 |
|
公開 |
| M.Z. Dewan; S. Ahmed; Y. Iwasaki; K. Ohba; M. Toi; N. Yamamoto |
M.Z. Dewan; S. Ahmed; Y. Iwasaki; K. Ohba; M. Toi; N. Yamamoto |
M.Z. Dewan; S. Ahmed; Y. Iwasaki; K. Ohba; M. Toi; N. Yamamoto |
Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer |
Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer |
Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer |
Biomedicine and Pharmacotherapy, 60, 6, 273-276 |
Biomedicine and Pharmacotherapy, 60, 6, 273-276 |
Biomedicine and Pharmacotherapy, 60, 6, 273-276 |
2006 |
有 |
英語 |
|
公開 |
| T. Ueno; L.W.C. Chow; M. Toi |
T. Ueno; L.W.C. Chow; M. Toi |
T. Ueno; L.W.C. Chow; M. Toi |
Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients |
Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients |
Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients |
Biomedicine and Pharmacotherapy, 60, 6, 277-279 |
Biomedicine and Pharmacotherapy, 60, 6, 277-279 |
Biomedicine and Pharmacotherapy, 60, 6, 277-279 |
2006 |
有 |
英語 |
|
公開 |
| Md.Z. Dewan; H. Terunuma; M. Toi; Y. Tanaka; H. Katano; X. Deng; H. Abe; T. Nakasone; N. Mori; T. Sata; N. Yamamoto |
Md.Z. Dewan; H. Terunuma; M. Toi; Y. Tanaka; H. Katano; X. Deng; H. Abe; T. Nakasone; N. Mori; T. Sata; N. Yamamoto |
Md.Z. Dewan; H. Terunuma; M. Toi; Y. Tanaka; H. Katano; X. Deng; H. Abe; T. Nakasone; N. Mori; T. Sata; N. Yamamoto |
Potential role of natural killer cells in controlling growth and infiltration of AIDS-associated primary effusion lymphoma cells |
Potential role of natural killer cells in controlling growth and infiltration of AIDS-associated primary effusion lymphoma cells |
Potential role of natural killer cells in controlling growth and infiltration of AIDS-associated primary effusion lymphoma cells |
Cancer Science, 97, 12, 1381-1387 |
Cancer Science, 97, 12, 1381-1387 |
Cancer Science, 97, 12, 1381-1387 |
2006 |
有 |
英語 |
|
公開 |
| Y. Asami; H. Kakeya; G. Okada; M. Toi; H. Osada |
Y. Asami; H. Kakeya; G. Okada; M. Toi; H. Osada |
Y. Asami; H. Kakeya; G. Okada; M. Toi; H. Osada |
RK-95113, a new angiogenesis inhibitor produced by Aspergillus fumigatus |
RK-95113, a new angiogenesis inhibitor produced by Aspergillus fumigatus |
RK-95113, a new angiogenesis inhibitor produced by Aspergillus fumigatus |
Journal of Antibiotics, 59, 11, 724-728 |
Journal of Antibiotics, 59, 11, 724-728 |
Journal of Antibiotics, 59, 11, 724-728 |
2006 |
有 |
英語 |
|
公開 |
| H. Bando; H.A. Weich; S. Horiguchi; N. Funata; T. Ogawa; M. Toi |
H. Bando; H.A. Weich; S. Horiguchi; N. Funata; T. Ogawa; M. Toi |
H. Bando; H.A. Weich; S. Horiguchi; N. Funata; T. Ogawa; M. Toi |
The association between vascular endothelial growth factor-C, its corresponding receptor, VEGFR-3, and prognosis in primary breast cancer: A study with 193 cases |
The association between vascular endothelial growth factor-C, its corresponding receptor, VEGFR-3, and prognosis in primary breast cancer: A study with 193 cases |
The association between vascular endothelial growth factor-C, its corresponding receptor, VEGFR-3, and prognosis in primary breast cancer: A study with 193 cases |
Oncology Reports, 15, 3, 653-659 |
Oncology Reports, 15, 3, 653-659 |
Oncology Reports, 15, 3, 653-659 |
2006 |
有 |
英語 |
|
公開 |
| E. Suzuki; M. Toi |
E. Suzuki; M. Toi |
E. Suzuki; M. Toi |
Neoadjuvant Chemotherapy in breast cancer |
Neoadjuvant Chemotherapy in breast cancer |
Neoadjuvant Chemotherapy in breast cancer |
Nippon rinsho. Japanese journal of clinical medicine, 64, 3, 536-539 |
Nippon rinsho. Japanese journal of clinical medicine, 64, 3, 536-539 |
Nippon rinsho. Japanese journal of clinical medicine, 64, 3, 536-539 |
2006 |
有 |
英語 |
|
公開 |
| M. Toi; Y. Iino |
M. Toi; Y. Iino |
M. Toi; Y. Iino |
Who benefits from hormone therapy? |
Who benefits from hormone therapy? |
Who benefits from hormone therapy? |
Breast cancer (Tokyo, Japan), 13, 2, 117-122 |
Breast cancer (Tokyo, Japan), 13, 2, 117-122 |
Breast cancer (Tokyo, Japan), 13, 2, 117-122 |
2006 |
有 |
英語 |
|
公開 |
| G. Matsumoto; J.-I. Namekawa; M. Muta; T. Nakamura; H. Bando; K. Tohyama; M. Toi; K. Umezawa |
G. Matsumoto; J.-I. Namekawa; M. Muta; T. Nakamura; H. Bando; K. Tohyama; M. Toi; K. Umezawa |
G. Matsumoto; J.-I. Namekawa; M. Muta; T. Nakamura; H. Bando; K. Tohyama; M. Toi; K. Umezawa |
Targeting of nuclear factor κB pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: Antitumor and antiangiogenic potential in vivo |
Targeting of nuclear factor κB pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: Antitumor and antiangiogenic potential in vivo |
Targeting of nuclear factor κB pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: Antitumor and antiangiogenic potential in vivo |
Clinical Cancer Research, 11, 3, 1287-1293 |
Clinical Cancer Research, 11, 3, 1287-1293 |
Clinical Cancer Research, 11, 3, 1287-1293 |
2005 |
有 |
英語 |
|
公開 |
| M. Yasuno; T. Mori; M. Koike; K. Takahashi; M. Toi; T. Takizawa; S. Shimizu; T. Yamaguchi; H. Matsumoto |
M. Yasuno; T. Mori; M. Koike; K. Takahashi; M. Toi; T. Takizawa; S. Shimizu; T. Yamaguchi; H. Matsumoto |
M. Yasuno; T. Mori; M. Koike; K. Takahashi; M. Toi; T. Takizawa; S. Shimizu; T. Yamaguchi; H. Matsumoto |
Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma |
Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma |
Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma |
Oncology Reports, 13, 3, 405-412 |
Oncology Reports, 13, 3, 405-412 |
Oncology Reports, 13, 3, 405-412 |
2005 |
有 |
英語 |
|
公開 |
| I. Okubo; M. Kondo; M. Toi; T. Ochiai; S. Miki |
I. Okubo; M. Kondo; M. Toi; T. Ochiai; S. Miki |
I. Okubo; M. Kondo; M. Toi; T. Ochiai; S. Miki |
Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan. |
Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan. |
Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan. |
Gan to kagaku ryoho. Cancer & chemotherapy, 32, 3, 351-363 |
Gan to kagaku ryoho. Cancer & chemotherapy, 32, 3, 351-363 |
Gan to kagaku ryoho. Cancer & chemotherapy, 32, 3, 351-363 |
2005 |
有 |
英語 |
|
公開 |
| H. Bando; M. Toi |
H. Bando; M. Toi |
H. Bando; M. Toi |
VEGF (vascular endothelial growth factor) |
VEGF (vascular endothelial growth factor) |
VEGF (vascular endothelial growth factor) |
Nippon rinsho. Japanese journal of clinical medicine., 63 Suppl 8, 99-102 |
Nippon rinsho. Japanese journal of clinical medicine., 63 Suppl 8, 99-102 |
Nippon rinsho. Japanese journal of clinical medicine., 63 Suppl 8, 99-102 |
2005 |
有 |
英語 |
|
公開 |
| G. Matsumoto; M. Muta; K. Umezawa; T. Suzuki; K. Misumi; K. Tsuruta; A. Okamoto; M. Toi |
G. Matsumoto; M. Muta; K. Umezawa; T. Suzuki; K. Misumi; K. Tsuruta; A. Okamoto; M. Toi |
G. Matsumoto; M. Muta; K. Umezawa; T. Suzuki; K. Misumi; K. Tsuruta; A. Okamoto; M. Toi |
Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-κB inhibitor |
Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-κB inhibitor |
Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-κB inhibitor |
International Journal of Oncology, 27, 5, 1247-1255 |
International Journal of Oncology, 27, 5, 1247-1255 |
International Journal of Oncology, 27, 5, 1247-1255 |
2005 |
有 |
英語 |
|
公開 |
| M. Toi; M. Atiqur Rahman; H. Bando; L.W.C. Chow |
M. Toi; M. Atiqur Rahman; H. Bando; L.W.C. Chow |
M. Toi; M. Atiqur Rahman; H. Bando; L.W.C. Chow |
Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment |
Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment |
Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment |
Lancet Oncology, 6, 3, 158-166 |
Lancet Oncology, 6, 3, 158-166 |
Lancet Oncology, 6, 3, 158-166 |
2005 |
有 |
英語 |
|
公開 |
| H. Bando; H.A. Weich; M. Brokelmann; S. Horiguchi; N. Funata; T. Ogawa; M. Toi |
H. Bando; H.A. Weich; M. Brokelmann; S. Horiguchi; N. Funata; T. Ogawa; M. Toi |
H. Bando; H.A. Weich; M. Brokelmann; S. Horiguchi; N. Funata; T. Ogawa; M. Toi |
Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer |
Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer |
Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer |
British Journal of Cancer, 92, 3, 553-561 |
British Journal of Cancer, 92, 3, 553-561 |
British Journal of Cancer, 92, 3, 553-561 |
2005 |
有 |
英語 |
|
公開 |
| C. Nakanishi; M. Toi |
C. Nakanishi; M. Toi |
C. Nakanishi; M. Toi |
Nuclear factor-κB inhibitors as sensitizers to anticancer drugs |
Nuclear factor-κB inhibitors as sensitizers to anticancer drugs |
Nuclear factor-κB inhibitors as sensitizers to anticancer drugs |
Nature Reviews Cancer, 5, 4, 297-309 |
Nature Reviews Cancer, 5, 4, 297-309 |
Nature Reviews Cancer, 5, 4, 297-309 |
2005 |
有 |
英語 |
|
公開 |
| T. Saeki; S. Takashima; M. Terashima; A. Satoh; M. Toi; A. Osaki; T. Toge; S. Ohno; N. Nomura; Y. Fukuyama; W. Koizumi; T. Taguchi |
T. Saeki; S. Takashima; M. Terashima; A. Satoh; M. Toi; A. Osaki; T. Toge; S. Ohno; N. Nomura; Y. Fukuyama; W. Koizumi; T. Taguchi |
T. Saeki; S. Takashima; M. Terashima; A. Satoh; M. Toi; A. Osaki; T. Toge; S. Ohno; N. Nomura; Y. Fukuyama; W. Koizumi; T. Taguchi |
A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors |
A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors |
A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors |
International Journal of Clinical Oncology, 10, 1, 51-57 |
International Journal of Clinical Oncology, 10, 1, 51-57 |
International Journal of Clinical Oncology, 10, 1, 51-57 |
2005 |
有 |
英語 |
|
公開 |
| K. Hiramatsu; K. Takahashi; T. Yamaguchi; H. Matsumoto; H. Miyamoto; S. Tanaka; C. Tanaka; Y. Tamamori; M. Imajo; M. Kawaguchi; M. Toi; T. Mori; M. Kawakita |
K. Hiramatsu; K. Takahashi; T. Yamaguchi; H. Matsumoto; H. Miyamoto; S. Tanaka; C. Tanaka; Y. Tamamori; M. Imajo; M. Kawaguchi; M. Toi; T. Mori; M. Kawakita |
K. Hiramatsu; K. Takahashi; T. Yamaguchi; H. Matsumoto; H. Miyamoto; S. Tanaka; C. Tanaka; Y. Tamamori; M. Imajo; M. Kawaguchi; M. Toi; T. Mori; M. Kawakita |
N <sup>1</sup>,N <sup>12</sup>-diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers |
N <sup>1</sup>,N <sup>12</sup>-diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers |
N <sup>1</sup>,N <sup>12</sup>-diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers |
Clinical Cancer Research, 11, 8, 2986-2990 |
Clinical Cancer Research, 11, 8, 2986-2990 |
Clinical Cancer Research, 11, 8, 2986-2990 |
2005 |
有 |
英語 |
|
公開 |
| S. Saji; M. Kawakami; S.-I. Hayashi; N. Yoshida; M. Hirose; S.-I. Horiguchi; A. Itoh; N. Funata; S.L. Schreiber; M. Yoshida; M. Toi |
S. Saji; M. Kawakami; S.-I. Hayashi; N. Yoshida; M. Hirose; S.-I. Horiguchi; A. Itoh; N. Funata; S.L. Schreiber; M. Yoshida; M. Toi |
S. Saji; M. Kawakami; S.-I. Hayashi; N. Yoshida; M. Hirose; S.-I. Horiguchi; A. Itoh; N. Funata; S.L. Schreiber; M. Yoshida; M. Toi |
Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer |
Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer |
Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer |
Oncogene, 24, 28, 4531-4539 |
Oncogene, 24, 28, 4531-4539 |
Oncogene, 24, 28, 4531-4539 |
2005 |
有 |
英語 |
|
公開 |
| M. Toi; T. Saeki; K. Aogi; M. Sano; K. Hatake; T. Asaga; Y. Tokuda; S. Mitsuyama; M. Kimura; T. Kobayashi; M. Tamura; T. Tabei; E. Shin; R. Nishimura; S. Ohno; S. Takashima |
M. Toi; T. Saeki; K. Aogi; M. Sano; K. Hatake; T. Asaga; Y. Tokuda; S. Mitsuyama; M. Kimura; T. Kobayashi; M. Tamura; T. Tabei; E. Shin; R. Nishimura; S. Ohno; S. Takashima |
M. Toi; T. Saeki; K. Aogi; M. Sano; K. Hatake; T. Asaga; Y. Tokuda; S. Mitsuyama; M. Kimura; T. Kobayashi; M. Tamura; T. Tabei; E. Shin; R. Nishimura; S. Ohno; S. Takashima |
Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes |
Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes |
Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes |
Japanese Journal of Clinical Oncology, 35, 6, 310-315 |
Japanese Journal of Clinical Oncology, 35, 6, 310-315 |
Japanese Journal of Clinical Oncology, 35, 6, 310-315 |
2005 |
有 |
英語 |
|
公開 |
| M. Toi; Y. Takebayashi; L.W. Chow |
M. Toi; Y. Takebayashi; L.W. Chow |
M. Toi; Y. Takebayashi; L.W. Chow |
Translational research in breast cancer |
Translational research in breast cancer |
Translational research in breast cancer |
Breast Cancer, 12, 2, 86-90 |
Breast Cancer, 12, 2, 86-90 |
Breast Cancer, 12, 2, 86-90 |
2005 |
有 |
英語 |
|
公開 |
| H. Iwata; S. Nakamura; M. Toi; E. Shin; N. Masuda; S. Ohno; Y. Takatsuka; K. Hisamatsu; K. Yamazaki; M. Kusama; H. Kaise; Y. Sato; K. Kuroi; F. Akiyama; H. Tsuda; M. Kurosumi |
H. Iwata; S. Nakamura; M. Toi; E. Shin; N. Masuda; S. Ohno; Y. Takatsuka; K. Hisamatsu; K. Yamazaki; M. Kusama; H. Kaise; Y. Sato; K. Kuroi; F. Akiyama; H. Tsuda; M. Kurosumi |
H. Iwata; S. Nakamura; M. Toi; E. Shin; N. Masuda; S. Ohno; Y. Takatsuka; K. Hisamatsu; K. Yamazaki; M. Kusama; H. Kaise; Y. Sato; K. Kuroi; F. Akiyama; H. Tsuda; M. Kurosumi |
Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage Breast carcinoma |
Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage Breast carcinoma |
Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage Breast carcinoma |
Breast Cancer, 12, 2, 99-103 |
Breast Cancer, 12, 2, 99-103 |
Breast Cancer, 12, 2, 99-103 |
2005 |
有 |
英語 |
|
公開 |
| G. Gasparini; R. Longo; M. Toi; N. Ferrara |
G. Gasparini; R. Longo; M. Toi; N. Ferrara |
G. Gasparini; R. Longo; M. Toi; N. Ferrara |
Angiogenic inhibitors: A new therapeutic strategy in oncology |
Angiogenic inhibitors: A new therapeutic strategy in oncology |
Angiogenic inhibitors: A new therapeutic strategy in oncology |
Nature Clinical Practice Oncology, 2, 11, 562-577 |
Nature Clinical Practice Oncology, 2, 11, 562-577 |
Nature Clinical Practice Oncology, 2, 11, 562-577 |
2005 |
有 |
英語 |
|
公開 |
| S. Saji; M. Hirose; M. Toi |
S. Saji; M. Hirose; M. Toi |
S. Saji; M. Hirose; M. Toi |
Clinical significance of estrogen receptor β in breast cancer |
Clinical significance of estrogen receptor β in breast cancer |
Clinical significance of estrogen receptor β in breast cancer |
Cancer Chemotherapy and Pharmacology, 56, SUPPL. 7, s21-s26 |
Cancer Chemotherapy and Pharmacology, 56, SUPPL. 7, s21-s26 |
Cancer Chemotherapy and Pharmacology, 56, SUPPL. 7, s21-s26 |
2005 |
有 |
英語 |
|
公開 |
| M. Toi; K. Horiguchi; H. Bando; S. Saji; L.W.C. Chow |
M. Toi; K. Horiguchi; H. Bando; S. Saji; L.W.C. Chow |
M. Toi; K. Horiguchi; H. Bando; S. Saji; L.W.C. Chow |
Trastuzumab: Updates and future issues |
Trastuzumab: Updates and future issues |
Trastuzumab: Updates and future issues |
Cancer Chemotherapy and Pharmacology, 56, SUPPL. 7, s94-s99 |
Cancer Chemotherapy and Pharmacology, 56, SUPPL. 7, s94-s99 |
Cancer Chemotherapy and Pharmacology, 56, SUPPL. 7, s94-s99 |
2005 |
有 |
英語 |
|
公開 |
| K.S. Albain; J. de la Garza Salazar; T. Pienkowski; M. Aapro; J. Bergh; M. Caleffi; R. Coleman; W. Eiermann; F. Içli; M. Pegram; M. Piccart; R. Snyder; M. Toi; G.N. Hortobagyi |
K.S. Albain; J. de la Garza Salazar; T. Pienkowski; M. Aapro; J. Bergh; M. Caleffi; R. Coleman; W. Eiermann; F. Içli; M. Pegram; M. Piccart; R. Snyder; M. Toi; G.N. Hortobagyi |
K.S. Albain; J. de la Garza Salazar; T. Pienkowski; M. Aapro; J. Bergh; M. Caleffi; R. Coleman; W. Eiermann; F. Içli; M. Pegram; M. Piccart; R. Snyder; M. Toi; G.N. Hortobagyi |
Reducing the global breast cancer burden: The importance of patterns of care research |
Reducing the global breast cancer burden: The importance of patterns of care research |
Reducing the global breast cancer burden: The importance of patterns of care research |
Clinical Breast Cancer, 6, 5, 412-420 |
Clinical Breast Cancer, 6, 5, 412-420 |
Clinical Breast Cancer, 6, 5, 412-420 |
2005 |
有 |
英語 |
|
公開 |
| S. Ohno; M. Toi; K. Kuroi; S. Nakamura; H. Iwata; M. Kusama; N. Masuda; K. Yamazaki; K. Hisamatsu; Y. Sato; Y. Takatsuka; E. Shin; H. Kaise; M. Kurozumi; H. Tsuda; F. Akiyama |
S. Ohno; M. Toi; K. Kuroi; S. Nakamura; H. Iwata; M. Kusama; N. Masuda; K. Yamazaki; K. Hisamatsu; Y. Sato; Y. Takatsuka; E. Shin; H. Kaise; M. Kurozumi; H. Tsuda; F. Akiyama |
S. Ohno; M. Toi; K. Kuroi; S. Nakamura; H. Iwata; M. Kusama; N. Masuda; K. Yamazaki; K. Hisamatsu; Y. Sato; Y. Takatsuka; E. Shin; H. Kaise; M. Kurozumi; H. Tsuda; F. Akiyama |
Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer |
Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer |
Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S323-S324 |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S323-S324 |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S323-S324 |
2005 |
有 |
英語 |
|
公開 |
| Md.Z. Dewan; H. Terunuma; S. Ahmed; K. Ohba; M. Takada; Y. Tanaka; M. Toi; N. Yamamoto |
Md.Z. Dewan; H. Terunuma; S. Ahmed; K. Ohba; M. Takada; Y. Tanaka; M. Toi; N. Yamamoto |
Md.Z. Dewan; H. Terunuma; S. Ahmed; K. Ohba; M. Takada; Y. Tanaka; M. Toi; N. Yamamoto |
Natural killer cells in breast cancer cell growth and metastasis in SCID mice |
Natural killer cells in breast cancer cell growth and metastasis in SCID mice |
Natural killer cells in breast cancer cell growth and metastasis in SCID mice |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S375-S379 |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S375-S379 |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S375-S379 |
2005 |
有 |
英語 |
|
公開 |
| L.W.C. Chow; W.T.Y. Loo; C.C.Y. Wai; E.L.H. Lui; L. Zhu; M. Toi |
L.W.C. Chow; W.T.Y. Loo; C.C.Y. Wai; E.L.H. Lui; L. Zhu; M. Toi |
L.W.C. Chow; W.T.Y. Loo; C.C.Y. Wai; E.L.H. Lui; L. Zhu; M. Toi |
Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients |
Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients |
Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S298-S301 |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S298-S301 |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S298-S301 |
2005 |
有 |
英語 |
|
公開 |
| T. Ueno; M. Toi; S. Linder |
T. Ueno; M. Toi; S. Linder |
T. Ueno; M. Toi; S. Linder |
Detection of epithelial cell death in the body by cytokeratin 18 measurement |
Detection of epithelial cell death in the body by cytokeratin 18 measurement |
Detection of epithelial cell death in the body by cytokeratin 18 measurement |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S359-S362 |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S359-S362 |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S359-S362 |
2005 |
有 |
英語 |
|
公開 |
| L.W.C. Chow; C.W.L. Cheng; J.L.N. Wong; M. Toi |
L.W.C. Chow; C.W.L. Cheng; J.L.N. Wong; M. Toi |
L.W.C. Chow; C.W.L. Cheng; J.L.N. Wong; M. Toi |
Serum lipid profiles in patients receiving endocrine treatment for breast cancer - The results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial |
Serum lipid profiles in patients receiving endocrine treatment for breast cancer - The results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial |
Serum lipid profiles in patients receiving endocrine treatment for breast cancer - The results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S302-S305 |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S302-S305 |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S302-S305 |
2005 |
有 |
英語 |
|
公開 |
| K. Kuroi; M. Toi; H. Tsuda; M. Kurosumi; F. Akiyama |
K. Kuroi; M. Toi; H. Tsuda; M. Kurosumi; F. Akiyama |
K. Kuroi; M. Toi; H. Tsuda; M. Kurosumi; F. Akiyama |
Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer |
Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer |
Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S387-S392 |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S387-S392 |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S387-S392 |
2005 |
有 |
英語 |
|
公開 |
| L.W.C. Chow; M. Toi |
L.W.C. Chow; M. Toi |
L.W.C. Chow; M. Toi |
Translational research in oncology comes timely |
Translational research in oncology comes timely |
Translational research in oncology comes timely |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S263 |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S263 |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S263 |
2005 |
有 |
英語 |
|
公開 |
| M. Toi; H. Bando; H.A. Weich |
M. Toi; H. Bando; H.A. Weich |
M. Toi; H. Bando; H.A. Weich |
Vascular endothelial growth factor and its relationships with endogenous inhibitors in a breast cancer microenvironment manipulated by hormonal therapy: A hypothetical consideration |
Vascular endothelial growth factor and its relationships with endogenous inhibitors in a breast cancer microenvironment manipulated by hormonal therapy: A hypothetical consideration |
Vascular endothelial growth factor and its relationships with endogenous inhibitors in a breast cancer microenvironment manipulated by hormonal therapy: A hypothetical consideration |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S344-S347 |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S344-S347 |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S344-S347 |
2005 |
有 |
英語 |
|
公開 |
| L.W.C. Chow; W.T.Y. Loo; M. Toi |
L.W.C. Chow; W.T.Y. Loo; M. Toi |
L.W.C. Chow; W.T.Y. Loo; M. Toi |
Current directions for COX-2 inhibition in breast cancer |
Current directions for COX-2 inhibition in breast cancer |
Current directions for COX-2 inhibition in breast cancer |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S281-S284 |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S281-S284 |
Biomedicine and Pharmacotherapy, 59, SUPPL. 2, S281-S284 |
2005 |
有 |
英語 |
|
公開 |
| H.A. Weich; H. Bando; M. Brokelmann; P. Baumann; M. Toi; B. Barleon; K. Alitalo; B. Sipos; J. Sleeman |
H.A. Weich; H. Bando; M. Brokelmann; P. Baumann; M. Toi; B. Barleon; K. Alitalo; B. Sipos; J. Sleeman |
H.A. Weich; H. Bando; M. Brokelmann; P. Baumann; M. Toi; B. Barleon; K. Alitalo; B. Sipos; J. Sleeman |
Quantification of vascular endothelial growth factor-C (VEGF-C) by a novel ELISA |
Quantification of vascular endothelial growth factor-C (VEGF-C) by a novel ELISA |
Quantification of vascular endothelial growth factor-C (VEGF-C) by a novel ELISA |
Journal of Immunological Methods, 285, 2, 145-155 |
Journal of Immunological Methods, 285, 2, 145-155 |
Journal of Immunological Methods, 285, 2, 145-155 |
2004 |
有 |
英語 |
|
公開 |
| C. Nakanishi; T. Yamaguchi; T. Iijima; S. Saji; M. Toi; T. Mori; M. Miyaki |
C. Nakanishi; T. Yamaguchi; T. Iijima; S. Saji; M. Toi; T. Mori; M. Miyaki |
C. Nakanishi; T. Yamaguchi; T. Iijima; S. Saji; M. Toi; T. Mori; M. Miyaki |
Germline mutation of the LKB1/STK11 gene with loss of the normal allele in an aggressive breast cancer of Peutz-Jeghers syndrome. |
Germline mutation of the LKB1/STK11 gene with loss of the normal allele in an aggressive breast cancer of Peutz-Jeghers syndrome. |
Germline mutation of the LKB1/STK11 gene with loss of the normal allele in an aggressive breast cancer of Peutz-Jeghers syndrome. |
Oncology, 67, 5-6, 476-479 |
Oncology, 67, 5-6, 476-479 |
Oncology, 67, 5-6, 476-479 |
2004 |
有 |
英語 |
|
公開 |
| M. Toi; M. Takada; H. Bando; K. Toyama; H. Yamashiro; S. Horiguchi; S. Saji |
M. Toi; M. Takada; H. Bando; K. Toyama; H. Yamashiro; S. Horiguchi; S. Saji |
M. Toi; M. Takada; H. Bando; K. Toyama; H. Yamashiro; S. Horiguchi; S. Saji |
Current status of antibody therapy for breast cancer |
Current status of antibody therapy for breast cancer |
Current status of antibody therapy for breast cancer |
Breast Cancer, 11, 1, 10-14 |
Breast Cancer, 11, 1, 10-14 |
Breast Cancer, 11, 1, 10-14 |
2004 |
有 |
英語 |
|
公開 |
| S. Saji; M. Hirose; M. Toi |
S. Saji; M. Hirose; M. Toi |
S. Saji; M. Hirose; M. Toi |
Novel sensitizing agents: Potential contribution of COX-2 inhibitor for endocrine therapy of breast cancer |
Novel sensitizing agents: Potential contribution of COX-2 inhibitor for endocrine therapy of breast cancer |
Novel sensitizing agents: Potential contribution of COX-2 inhibitor for endocrine therapy of breast cancer |
Breast Cancer, 11, 2, 129-133 |
Breast Cancer, 11, 2, 129-133 |
Breast Cancer, 11, 2, 129-133 |
2004 |
有 |
英語 |
|
公開 |
| S. Morita; M. Toi; T. Kobayashi; Y. Ito; Y. Hozumi; S. Ohno; H. Iwata; J. Sakamoto |
S. Morita; M. Toi; T. Kobayashi; Y. Ito; Y. Hozumi; S. Ohno; H. Iwata; J. Sakamoto |
S. Morita; M. Toi; T. Kobayashi; Y. Ito; Y. Hozumi; S. Ohno; H. Iwata; J. Sakamoto |
Application of a continual reassessment method to a phase I clinical trial of capecitabine in combination with cyclophosphamide and epirubicin (CEX) for inoperable or recurrent breast cancer |
Application of a continual reassessment method to a phase I clinical trial of capecitabine in combination with cyclophosphamide and epirubicin (CEX) for inoperable or recurrent breast cancer |
Application of a continual reassessment method to a phase I clinical trial of capecitabine in combination with cyclophosphamide and epirubicin (CEX) for inoperable or recurrent breast cancer |
Japanese Journal of Clinical Oncology, 34, 2, 104-106 |
Japanese Journal of Clinical Oncology, 34, 2, 104-106 |
Japanese Journal of Clinical Oncology, 34, 2, 104-106 |
2004 |
有 |
英語 |
|
公開 |
| M. Toi; H. Bando; S. Horiguchi; M. Takada; A. Kataoka; T. Ueno; S. Saji; M. Muta; N. Funata; S. Ohno |
M. Toi; H. Bando; S. Horiguchi; M. Takada; A. Kataoka; T. Ueno; S. Saji; M. Muta; N. Funata; S. Ohno |
M. Toi; H. Bando; S. Horiguchi; M. Takada; A. Kataoka; T. Ueno; S. Saji; M. Muta; N. Funata; S. Ohno |
Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer |
Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer |
Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer |
British Journal of Cancer, 90, 12, 2338-2343 |
British Journal of Cancer, 90, 12, 2338-2343 |
British Journal of Cancer, 90, 12, 2338-2343 |
2004 |
有 |
英語 |
|
公開 |
| H. Bando; M. Brokelmann; M. Toi; K. Alitalo; J.P. Sleeman; B. Sipos; H.-J. Gröne; H.A. Weich |
H. Bando; M. Brokelmann; M. Toi; K. Alitalo; J.P. Sleeman; B. Sipos; H.-J. Gröne; H.A. Weich |
H. Bando; M. Brokelmann; M. Toi; K. Alitalo; J.P. Sleeman; B. Sipos; H.-J. Gröne; H.A. Weich |
Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues |
Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues |
Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues |
International Journal of Cancer, 111, 2, 184-191 |
International Journal of Cancer, 111, 2, 184-191 |
International Journal of Cancer, 111, 2, 184-191 |
2004 |
有 |
英語 |
|
公開 |
| Y. Asami; H. Kakeya; R. Onose; Y.-H. Chang; M. Toi; H. Osada |
Y. Asami; H. Kakeya; R. Onose; Y.-H. Chang; M. Toi; H. Osada |
Y. Asami; H. Kakeya; R. Onose; Y.-H. Chang; M. Toi; H. Osada |
RK-805, an endothelial-cell-growth inhibitor produced by Neosartorya sp., and a docking model with methionine aminopeptidase-2 |
RK-805, an endothelial-cell-growth inhibitor produced by Neosartorya sp., and a docking model with methionine aminopeptidase-2 |
RK-805, an endothelial-cell-growth inhibitor produced by Neosartorya sp., and a docking model with methionine aminopeptidase-2 |
Tetrahedron, 60, 33, 7085-7091 |
Tetrahedron, 60, 33, 7085-7091 |
Tetrahedron, 60, 33, 7085-7091 |
2004 |
有 |
英語 |
|
公開 |
| L. Zhu; L.W.C. Chow; W.T.Y. Loo; X.-Y. Guan; M. Toi |
L. Zhu; L.W.C. Chow; W.T.Y. Loo; X.-Y. Guan; M. Toi |
L. Zhu; L.W.C. Chow; W.T.Y. Loo; X.-Y. Guan; M. Toi |
Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: Subgroup analysis from celecoxib antiaromatase neoadjuvant trial |
Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: Subgroup analysis from celecoxib antiaromatase neoadjuvant trial |
Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: Subgroup analysis from celecoxib antiaromatase neoadjuvant trial |
Clinical Cancer Research, 10, 14, 4639-4644 |
Clinical Cancer Research, 10, 14, 4639-4644 |
Clinical Cancer Research, 10, 14, 4639-4644 |
2004 |
有 |
英語 |
|
公開 |
| M. Kawakami; S. Saji; M. Toi |
M. Kawakami; S. Saji; M. Toi |
M. Kawakami; S. Saji; M. Toi |
Controversies in endocrine therapy for breast cancer |
Controversies in endocrine therapy for breast cancer |
Controversies in endocrine therapy for breast cancer |
Gan to kagaku ryoho. Cancer & chemotherapy, 31, 2, 181-187 |
Gan to kagaku ryoho. Cancer & chemotherapy, 31, 2, 181-187 |
Gan to kagaku ryoho. Cancer & chemotherapy, 31, 2, 181-187 |
2004 |
有 |
英語 |
|
公開 |
| G. Matsumoto; M.A. Rahman; M. Muta; T. Nakamura; H. Bando; S. Saji; K. Tsuruta; A. Okamoto; M. Toi |
G. Matsumoto; M.A. Rahman; M. Muta; T. Nakamura; H. Bando; S. Saji; K. Tsuruta; A. Okamoto; M. Toi |
G. Matsumoto; M.A. Rahman; M. Muta; T. Nakamura; H. Bando; S. Saji; K. Tsuruta; A. Okamoto; M. Toi |
DFU, a selective COX-2 inhibitor, suppresses MCF-7 xenograft tumor growth in mice |
DFU, a selective COX-2 inhibitor, suppresses MCF-7 xenograft tumor growth in mice |
DFU, a selective COX-2 inhibitor, suppresses MCF-7 xenograft tumor growth in mice |
Oncology Reports, 12, 2, 281-285 |
Oncology Reports, 12, 2, 281-285 |
Oncology Reports, 12, 2, 281-285 |
2004 |
有 |
英語 |
|
公開 |
| T. Tominaga; M. Kimura; T. Asaga; M. Yoshida; H. Awane; H. Koyama; Y. Takatsuka; S. Mitsuyama; T. Ikeda; M. Ogita; H. Aoyama; M. Sano; R. Abe; T. Nishi; T. Wada; M. Danno; M. Toi; S. Takashima |
T. Tominaga; M. Kimura; T. Asaga; M. Yoshida; H. Awane; H. Koyama; Y. Takatsuka; S. Mitsuyama; T. Ikeda; M. Ogita; H. Aoyama; M. Sano; R. Abe; T. Nishi; T. Wada; M. Danno; M. Toi; S. Takashima |
T. Tominaga; M. Kimura; T. Asaga; M. Yoshida; H. Awane; H. Koyama; Y. Takatsuka; S. Mitsuyama; T. Ikeda; M. Ogita; H. Aoyama; M. Sano; R. Abe; T. Nishi; T. Wada; M. Danno; M. Toi; S. Takashima |
1-Hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: A randomized controlled trial |
1-Hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: A randomized controlled trial |
1-Hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: A randomized controlled trial |
Oncology Reports, 12, 4, 797-803 |
Oncology Reports, 12, 4, 797-803 |
Oncology Reports, 12, 4, 797-803 |
2004 |
有 |
英語 |
|
公開 |
| M. Takada; A. Kataoka; M. Toi; H. Bando; K. Toyama; S. Horiguchi; T. Ueno; S. Linder; S. Saji; Y. Hayashi; N. Funata; J. Kinoshita; S. Murakami; S. Ohono |
M. Takada; A. Kataoka; M. Toi; H. Bando; K. Toyama; S. Horiguchi; T. Ueno; S. Linder; S. Saji; Y. Hayashi; N. Funata; J. Kinoshita; S. Murakami; S. Ohono |
M. Takada; A. Kataoka; M. Toi; H. Bando; K. Toyama; S. Horiguchi; T. Ueno; S. Linder; S. Saji; Y. Hayashi; N. Funata; J. Kinoshita; S. Murakami; S. Ohono |
A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancer. |
A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancer. |
A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancer. |
International journal of oncology, 25, 2, 397-405 |
International journal of oncology, 25, 2, 397-405 |
International journal of oncology, 25, 2, 397-405 |
2004 |
有 |
英語 |
|
公開 |
| M. Kawakita; K. Hiramatsu; M. Sugimoto; K. Takahashi; M. Toi |
M. Kawakita; K. Hiramatsu; M. Sugimoto; K. Takahashi; M. Toi |
M. Kawakita; K. Hiramatsu; M. Sugimoto; K. Takahashi; M. Toi |
Clinical usefulness of urinary diacetylpolyamines as novel tumor markers |
Clinical usefulness of urinary diacetylpolyamines as novel tumor markers |
Clinical usefulness of urinary diacetylpolyamines as novel tumor markers |
Rinsho byori. The Japanese journal of clinical pathology, 52, 4, 321-327 |
Rinsho byori. The Japanese journal of clinical pathology, 52, 4, 321-327 |
Rinsho byori. The Japanese journal of clinical pathology, 52, 4, 321-327 |
2004 |
有 |
英語 |
|
公開 |
| H. Yamashiro; K. Toyama; H. Bando; S. Saji; M. Toi |
H. Yamashiro; K. Toyama; H. Bando; S. Saji; M. Toi |
H. Yamashiro; K. Toyama; H. Bando; S. Saji; M. Toi |
Trastuzumab treatment for breast cancer |
Trastuzumab treatment for breast cancer |
Trastuzumab treatment for breast cancer |
Nippon rinsho. Japanese journal of clinical medicine, 62, 7, 1305-1311 |
Nippon rinsho. Japanese journal of clinical medicine, 62, 7, 1305-1311 |
Nippon rinsho. Japanese journal of clinical medicine, 62, 7, 1305-1311 |
2004 |
有 |
英語 |
|
公開 |
| M. Kuwano; Y. Oda; H. Izumi; S.-J. Yang; T. Uchiumi; Y. Iwamoto; M. Toi; T. Fujii; H. Yamana; H. Kinoshita; T. Kamura; M. Tsuneyoshi; K. Yasumoto; K. Kohno |
M. Kuwano; Y. Oda; H. Izumi; S.-J. Yang; T. Uchiumi; Y. Iwamoto; M. Toi; T. Fujii; H. Yamana; H. Kinoshita; T. Kamura; M. Tsuneyoshi; K. Yasumoto; K. Kohno |
M. Kuwano; Y. Oda; H. Izumi; S.-J. Yang; T. Uchiumi; Y. Iwamoto; M. Toi; T. Fujii; H. Yamana; H. Kinoshita; T. Kamura; M. Tsuneyoshi; K. Yasumoto; K. Kohno |
The role of nuclear Y-box binding protein 1 as a global marker in drug resistance |
The role of nuclear Y-box binding protein 1 as a global marker in drug resistance |
The role of nuclear Y-box binding protein 1 as a global marker in drug resistance |
Molecular Cancer Therapeutics, 3, 11, 1485-1492 |
Molecular Cancer Therapeutics, 3, 11, 1485-1492 |
Molecular Cancer Therapeutics, 3, 11, 1485-1492 |
2004 |
有 |
英語 |
|
公開 |
| T. Tominaga; I. Adachi; Y. Sasaki; T. Tabei; T. Ikeda; Y. Takatsuka; M. Toi; T. Suwa; Y. Ohashi |
T. Tominaga; I. Adachi; Y. Sasaki; T. Tabei; T. Ikeda; Y. Takatsuka; M. Toi; T. Suwa; Y. Ohashi |
T. Tominaga; I. Adachi; Y. Sasaki; T. Tabei; T. Ikeda; Y. Takatsuka; M. Toi; T. Suwa; Y. Ohashi |
Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer |
Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer |
Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer |
Annals of Oncology, 14, 1, 62-70 |
Annals of Oncology, 14, 1, 62-70 |
Annals of Oncology, 14, 1, 62-70 |
2003 |
有 |
英語 |
|
公開 |
| O. Ogura; A. Kanzaki; H. Bando; T. Ogura; M. Toi; Y. Takebayashi |
O. Ogura; A. Kanzaki; H. Bando; T. Ogura; M. Toi; Y. Takebayashi |
O. Ogura; A. Kanzaki; H. Bando; T. Ogura; M. Toi; Y. Takebayashi |
Expression of thymidylate synthase and thymidine phosphorylase in human breast carcinoma: Implication for method to detect expression of these molecules in clinic |
Expression of thymidylate synthase and thymidine phosphorylase in human breast carcinoma: Implication for method to detect expression of these molecules in clinic |
Expression of thymidylate synthase and thymidine phosphorylase in human breast carcinoma: Implication for method to detect expression of these molecules in clinic |
Cancer Letters, 190, 1, 97-104 |
Cancer Letters, 190, 1, 97-104 |
Cancer Letters, 190, 1, 97-104 |
2003 |
有 |
英語 |
|
公開 |
| T. Tominaga; H. Koyama; T. Toge; S. Miura; K. Sugimachi; S. Yamaguchi; K. Hirata; Y. Monden; Y. Nomura; M. Toi; I. Kimijima; S. Noguchi; H. Sonoo; K. Asaishi; T. Ikeda; T. Morimoto; J. Ota; Y. Ohashi; O. Abe |
T. Tominaga; H. Koyama; T. Toge; S. Miura; K. Sugimachi; S. Yamaguchi; K. Hirata; Y. Monden; Y. Nomura; M. Toi; I. Kimijima; S. Noguchi; H. Sonoo; K. Asaishi; T. Ikeda; T. Morimoto; J. Ota; Y. Ohashi; O. Abe |
T. Tominaga; H. Koyama; T. Toge; S. Miura; K. Sugimachi; S. Yamaguchi; K. Hirata; Y. Monden; Y. Nomura; M. Toi; I. Kimijima; S. Noguchi; H. Sonoo; K. Asaishi; T. Ikeda; T. Morimoto; J. Ota; Y. Ohashi; O. Abe |
Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery |
Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery |
Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery |
Journal of Clinical Oncology, 21, 6, 991-998 |
Journal of Clinical Oncology, 21, 6, 991-998 |
Journal of Clinical Oncology, 21, 6, 991-998 |
2003 |
有 |
英語 |
|
公開 |
| H. Saji; M. Toi; S. Saji; M. Koike; K. Kohno; M. Kuwano |
H. Saji; M. Toi; S. Saji; M. Koike; K. Kohno; M. Kuwano |
H. Saji; M. Toi; S. Saji; M. Koike; K. Kohno; M. Kuwano |
Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma |
Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma |
Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma |
Cancer Letters, 190, 2, 191-197 |
Cancer Letters, 190, 2, 191-197 |
Cancer Letters, 190, 2, 191-197 |
2003 |
有 |
英語 |
|
公開 |
| K. Kuroi; H. Bando; S. Saji; M. Toi |
K. Kuroi; H. Bando; S. Saji; M. Toi |
K. Kuroi; H. Bando; S. Saji; M. Toi |
Weekly schedule of docetaxel in breast cancer: Evaluation of response and toxicity |
Weekly schedule of docetaxel in breast cancer: Evaluation of response and toxicity |
Weekly schedule of docetaxel in breast cancer: Evaluation of response and toxicity |
Breast Cancer, 10, 1, 10-14 |
Breast Cancer, 10, 1, 10-14 |
Breast Cancer, 10, 1, 10-14 |
2003 |
有 |
英語 |
|
公開 |
| H. Bando; M. Toi; K. Kitada; M. Koike |
H. Bando; M. Toi; K. Kitada; M. Koike |
H. Bando; M. Toi; K. Kitada; M. Koike |
Genes commonly upregulated by hypoxia in human breast cancer cells MCF-7 and MDA-MB-231 |
Genes commonly upregulated by hypoxia in human breast cancer cells MCF-7 and MDA-MB-231 |
Genes commonly upregulated by hypoxia in human breast cancer cells MCF-7 and MDA-MB-231 |
Biomedicine and Pharmacotherapy, 57, 8, 333-340 |
Biomedicine and Pharmacotherapy, 57, 8, 333-340 |
Biomedicine and Pharmacotherapy, 57, 8, 333-340 |
2003 |
有 |
英語 |
|
公開 |
| L.W.C. Chow; J.L.N. Wong; M. Toi |
L.W.C. Chow; J.L.N. Wong; M. Toi |
L.W.C. Chow; J.L.N. Wong; M. Toi |
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: Preliminary report |
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: Preliminary report |
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: Preliminary report |
Journal of Steroid Biochemistry and Molecular Biology, 86, 3-5, 443-447 |
Journal of Steroid Biochemistry and Molecular Biology, 86, 3-5, 443-447 |
Journal of Steroid Biochemistry and Molecular Biology, 86, 3-5, 443-447 |
2003 |
有 |
英語 |
|
公開 |
| M.A. Rahman; M. Toi |
M.A. Rahman; M. Toi |
M.A. Rahman; M. Toi |
Anti-angiogenic therapy in breast cancer |
Anti-angiogenic therapy in breast cancer |
Anti-angiogenic therapy in breast cancer |
Biomedicine and Pharmacotherapy, 57, 10, 463-470 |
Biomedicine and Pharmacotherapy, 57, 10, 463-470 |
Biomedicine and Pharmacotherapy, 57, 10, 463-470 |
2003 |
有 |
英語 |
|
公開 |
| T. Ueno; M. Toi; K. Bivén; H. Bando; T. Ogawa; S. Linder |
T. Ueno; M. Toi; K. Bivén; H. Bando; T. Ogawa; S. Linder |
T. Ueno; M. Toi; K. Bivén; H. Bando; T. Ogawa; S. Linder |
Measurement of an apoptotic product in the sera of breast cancer patients |
Measurement of an apoptotic product in the sera of breast cancer patients |
Measurement of an apoptotic product in the sera of breast cancer patients |
European Journal of Cancer, 39, 6, 769-774 |
European Journal of Cancer, 39, 6, 769-774 |
European Journal of Cancer, 39, 6, 769-774 |
2003 |
有 |
英語 |
|
公開 |
| M. Toi; H. Bando; C. Ramachandran; S.J. Melnick; A. Imai; R.S. Fife; R.E. Carr; T. Oikawa; E.P. Lansky |
M. Toi; H. Bando; C. Ramachandran; S.J. Melnick; A. Imai; R.S. Fife; R.E. Carr; T. Oikawa; E.P. Lansky |
M. Toi; H. Bando; C. Ramachandran; S.J. Melnick; A. Imai; R.S. Fife; R.E. Carr; T. Oikawa; E.P. Lansky |
Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo |
Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo |
Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo |
Angiogenesis, 6, 2, 121-128 |
Angiogenesis, 6, 2, 121-128 |
Angiogenesis, 6, 2, 121-128 |
2003 |
有 |
英語 |
|
公開 |
| K. Bivén; H. Erdal; M. Hägg; T. Ueno; R. Zhou; M. Lynch; B. Rowley; J. Wood; C. Zhang; M. Toi; M.C. Shoshan; S. Linder |
K. Bivén; H. Erdal; M. Hägg; T. Ueno; R. Zhou; M. Lynch; B. Rowley; J. Wood; C. Zhang; M. Toi; M.C. Shoshan; S. Linder |
K. Bivén; H. Erdal; M. Hägg; T. Ueno; R. Zhou; M. Lynch; B. Rowley; J. Wood; C. Zhang; M. Toi; M.C. Shoshan; S. Linder |
A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera |
A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera |
A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera |
Apoptosis, 8, 3, 263-268 |
Apoptosis, 8, 3, 263-268 |
Apoptosis, 8, 3, 263-268 |
2003 |
有 |
英語 |
|
公開 |
| M. Toi; H. Bando; S. Saji |
M. Toi; H. Bando; S. Saji |
M. Toi; H. Bando; S. Saji |
Decision tree and paradigms of primary breast cancer: Changes elicited by preoperative therapy |
Decision tree and paradigms of primary breast cancer: Changes elicited by preoperative therapy |
Decision tree and paradigms of primary breast cancer: Changes elicited by preoperative therapy |
Medical Science Monitor, 9, 5, RA90-RA95 |
Medical Science Monitor, 9, 5, RA90-RA95 |
Medical Science Monitor, 9, 5, RA90-RA95 |
2003 |
有 |
英語 |
|
公開 |
| K. Kuroi; M. Toi |
K. Kuroi; M. Toi |
K. Kuroi; M. Toi |
Male breast cancer |
Male breast cancer |
Male breast cancer |
Gan to kagaku ryoho. Cancer & chemotherapy, 30, 5, 599-605 |
Gan to kagaku ryoho. Cancer & chemotherapy, 30, 5, 599-605 |
Gan to kagaku ryoho. Cancer & chemotherapy, 30, 5, 599-605 |
2003 |
有 |
英語 |
|
公開 |
| Y. Yamamoto; J.-I. Yamashita; M. Toi; M. Muta; S. Nagai; N. Hanai; A. Furuya; Y. Osawa; S. Saji; M. Ogawa |
Y. Yamamoto; J.-I. Yamashita; M. Toi; M. Muta; S. Nagai; N. Hanai; A. Furuya; Y. Osawa; S. Saji; M. Ogawa |
Y. Yamamoto; J.-I. Yamashita; M. Toi; M. Muta; S. Nagai; N. Hanai; A. Furuya; Y. Osawa; S. Saji; M. Ogawa |
Immunohistochemical analysis of estrone sulfatase and aromatase in human breast cancer tissues |
Immunohistochemical analysis of estrone sulfatase and aromatase in human breast cancer tissues |
Immunohistochemical analysis of estrone sulfatase and aromatase in human breast cancer tissues |
Oncology Reports, 10, 4, 791-796 |
Oncology Reports, 10, 4, 791-796 |
Oncology Reports, 10, 4, 791-796 |
2003 |
有 |
英語 |
|
公開 |
| M. Muta; G. Matsumoto; K. Hiruma; S. Saji; E. Nakashima; M. Toi |
M. Muta; G. Matsumoto; K. Hiruma; S. Saji; E. Nakashima; M. Toi |
M. Muta; G. Matsumoto; K. Hiruma; S. Saji; E. Nakashima; M. Toi |
Impact of vasculogenesis on solid tumor growth in a rat model |
Impact of vasculogenesis on solid tumor growth in a rat model |
Impact of vasculogenesis on solid tumor growth in a rat model |
Oncology Reports, 10, 5, 1213-1218 |
Oncology Reports, 10, 5, 1213-1218 |
Oncology Reports, 10, 5, 1213-1218 |
2003 |
有 |
英語 |
|
公開 |
| G. Matsumoto; S. Nagai; M. Muta; K. Tsuruta; A. Okamoto; M. Toi |
G. Matsumoto; S. Nagai; M. Muta; K. Tsuruta; A. Okamoto; M. Toi |
G. Matsumoto; S. Nagai; M. Muta; K. Tsuruta; A. Okamoto; M. Toi |
Survival benefit of KRN7000 immune therapy in combination with TNP470 in hamster liver metastasis model of pancreatic cancer |
Survival benefit of KRN7000 immune therapy in combination with TNP470 in hamster liver metastasis model of pancreatic cancer |
Survival benefit of KRN7000 immune therapy in combination with TNP470 in hamster liver metastasis model of pancreatic cancer |
Oncology Reports, 10, 5, 1201-1206 |
Oncology Reports, 10, 5, 1201-1206 |
Oncology Reports, 10, 5, 1201-1206 |
2003 |
有 |
英語 |
|
公開 |
| K. Kuroi; H. Bando; S. Saji; M. Toi |
K. Kuroi; H. Bando; S. Saji; M. Toi |
K. Kuroi; H. Bando; S. Saji; M. Toi |
Protracted administration of weekly docetaxel in metastatic breast cancer |
Protracted administration of weekly docetaxel in metastatic breast cancer |
Protracted administration of weekly docetaxel in metastatic breast cancer |
Oncology Reports, 10, 5, 1479-1484 |
Oncology Reports, 10, 5, 1479-1484 |
Oncology Reports, 10, 5, 1479-1484 |
2003 |
有 |
英語 |
|
公開 |
| M. Muta; G. Matsumoto; K. Hiruma; E. Nakashima; M. Toi |
M. Muta; G. Matsumoto; K. Hiruma; E. Nakashima; M. Toi |
M. Muta; G. Matsumoto; K. Hiruma; E. Nakashima; M. Toi |
Study of cancer gene therapy using IL-12-secreting endothelial progenitor cells in a rat solid tumor model. |
Study of cancer gene therapy using IL-12-secreting endothelial progenitor cells in a rat solid tumor model. |
Study of cancer gene therapy using IL-12-secreting endothelial progenitor cells in a rat solid tumor model. |
Oncology reports, 10, 6, 1765-1769 |
Oncology reports, 10, 6, 1765-1769 |
Oncology reports, 10, 6, 1765-1769 |
2003 |
有 |
英語 |
|
公開 |
| G. Asai; N. Yamamoto; M. Toi; E. Shin; K. Nishiyama; T. Sekine; Y. Nomura; S. Takashima; M. Kimura; T. Tominaga |
G. Asai; N. Yamamoto; M. Toi; E. Shin; K. Nishiyama; T. Sekine; Y. Nomura; S. Takashima; M. Kimura; T. Tominaga |
G. Asai; N. Yamamoto; M. Toi; E. Shin; K. Nishiyama; T. Sekine; Y. Nomura; S. Takashima; M. Kimura; T. Tominaga |
Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast cancer |
Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast cancer |
Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast cancer |
Cancer Chemotherapy and Pharmacology, 49, 6, 468-472 |
Cancer Chemotherapy and Pharmacology, 49, 6, 468-472 |
Cancer Chemotherapy and Pharmacology, 49, 6, 468-472 |
2002 |
有 |
英語 |
|
公開 |
| S. Saji; Y. Omoto; C. Shimizu; S.-I. Horiguchi; T. Watanabe; N. Funata; S.-I. Hayashi; J.-A. Gustafsson; M. Toi |
S. Saji; Y. Omoto; C. Shimizu; S.-I. Horiguchi; T. Watanabe; N. Funata; S.-I. Hayashi; J.-A. Gustafsson; M. Toi |
S. Saji; Y. Omoto; C. Shimizu; S.-I. Horiguchi; T. Watanabe; N. Funata; S.-I. Hayashi; J.-A. Gustafsson; M. Toi |
Clinical impact of assay of estrogen receptorβcx in breast cancer |
Clinical impact of assay of estrogen receptorβcx in breast cancer |
Clinical impact of assay of estrogen receptorβcx in breast cancer |
Breast Cancer, 9, 4, 303-307 |
Breast Cancer, 9, 4, 303-307 |
Breast Cancer, 9, 4, 303-307 |
2002 |
有 |
英語 |
|
公開 |
| M. Toi; H. Bando; T. Ogawa; M. Muta; C. Hornig; H.A. Weich |
M. Toi; H. Bando; T. Ogawa; M. Muta; C. Hornig; H.A. Weich |
M. Toi; H. Bando; T. Ogawa; M. Muta; C. Hornig; H.A. Weich |
Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer |
Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer |
Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer |
International Journal of Cancer, 98, 1, 14-18 |
International Journal of Cancer, 98, 1, 14-18 |
International Journal of Cancer, 98, 1, 14-18 |
2002 |
有 |
英語 |
|
公開 |
| Y. Kumagai; M. Toi; H. Inoue |
Y. Kumagai; M. Toi; H. Inoue |
Y. Kumagai; M. Toi; H. Inoue |
Dynamism of tumour vasculature in the early phase of cancer progression: Outcomes from oesophageal cancer research |
Dynamism of tumour vasculature in the early phase of cancer progression: Outcomes from oesophageal cancer research |
Dynamism of tumour vasculature in the early phase of cancer progression: Outcomes from oesophageal cancer research |
Lancet Oncology, 3, 10, 604-610 |
Lancet Oncology, 3, 10, 604-610 |
Lancet Oncology, 3, 10, 604-610 |
2002 |
有 |
英語 |
|
公開 |
| S. Saji; M. Toi |
S. Saji; M. Toi |
S. Saji; M. Toi |
Aromatase inhibitors and other novel agents in breast cancer treatment |
Aromatase inhibitors and other novel agents in breast cancer treatment |
Aromatase inhibitors and other novel agents in breast cancer treatment |
Expert Opinion on Emerging Drugs, 7, 2, 303-319 |
Expert Opinion on Emerging Drugs, 7, 2, 303-319 |
Expert Opinion on Emerging Drugs, 7, 2, 303-319 |
2002 |
有 |
英語 |
|
公開 |
| A. Kanzaki; Y. Takebayashi; H. Bando; J.F. Eliason; S.-I. Watanabe; H. Miyashita; M. Fukumoto; M. Toi; T. Uchida |
A. Kanzaki; Y. Takebayashi; H. Bando; J.F. Eliason; S.-I. Watanabe; H. Miyashita; M. Fukumoto; M. Toi; T. Uchida |
A. Kanzaki; Y. Takebayashi; H. Bando; J.F. Eliason; S.-I. Watanabe; H. Miyashita; M. Fukumoto; M. Toi; T. Uchida |
Expression of uridine and thymidine phosphorylase genes in human breast carcinoma |
Expression of uridine and thymidine phosphorylase genes in human breast carcinoma |
Expression of uridine and thymidine phosphorylase genes in human breast carcinoma |
International Journal of Cancer, 97, 5, 631-635 |
International Journal of Cancer, 97, 5, 631-635 |
International Journal of Cancer, 97, 5, 631-635 |
2002 |
有 |
英語 |
|
公開 |
| A. Kanzaki; M. Toi; N. Neamati; H. Miyashita; M. Oubu; K. Nakayama; H. Bando; K. Ogawa; M. Mutoh; S. Mori; K. Terada; T. Sugiyama; M. Fukumoto; Y. Takebayashi |
A. Kanzaki; M. Toi; N. Neamati; H. Miyashita; M. Oubu; K. Nakayama; H. Bando; K. Ogawa; M. Mutoh; S. Mori; K. Terada; T. Sugiyama; M. Fukumoto; Y. Takebayashi |
A. Kanzaki; M. Toi; N. Neamati; H. Miyashita; M. Oubu; K. Nakayama; H. Bando; K. Ogawa; M. Mutoh; S. Mori; K. Terada; T. Sugiyama; M. Fukumoto; Y. Takebayashi |
Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human breast carcinoma |
Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human breast carcinoma |
Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human breast carcinoma |
Japanese Journal of Cancer Research, 93, 1, 70-77 |
Japanese Journal of Cancer Research, 93, 1, 70-77 |
Japanese Journal of Cancer Research, 93, 1, 70-77 |
2002 |
有 |
英語 |
|
公開 |
| H. Bando; G. Matsumoto; M. Bando; M. Muta; T. Ogawa; N. Funata; J. Nishihira; M. Koike; M. Toi |
H. Bando; G. Matsumoto; M. Bando; M. Muta; T. Ogawa; N. Funata; J. Nishihira; M. Koike; M. Toi |
H. Bando; G. Matsumoto; M. Bando; M. Muta; T. Ogawa; N. Funata; J. Nishihira; M. Koike; M. Toi |
Expression of macrophage migration inhibitory factor in human breast cancer: Association with nodal spread |
Expression of macrophage migration inhibitory factor in human breast cancer: Association with nodal spread |
Expression of macrophage migration inhibitory factor in human breast cancer: Association with nodal spread |
Japanese Journal of Cancer Research, 93, 4, 389-396 |
Japanese Journal of Cancer Research, 93, 4, 389-396 |
Japanese Journal of Cancer Research, 93, 4, 389-396 |
2002 |
有 |
英語 |
|
公開 |
| M. Toi |
M. Toi |
M. Toi |
Proinflammation in human tumor microenvironment: Its status and implication [1] |
Proinflammation in human tumor microenvironment: Its status and implication [1] |
Proinflammation in human tumor microenvironment: Its status and implication [1] |
Medical Science Monitor, 8, 7, LE25-LE26 |
Medical Science Monitor, 8, 7, LE25-LE26 |
Medical Science Monitor, 8, 7, LE25-LE26 |
2002 |
有 |
英語 |
|
公開 |
| T. Tominaga; M. Toi; Y. Ohashi |
T. Tominaga; M. Toi; Y. Ohashi |
T. Tominaga; M. Toi; Y. Ohashi |
Erratum: Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients (Clinical Breast Cancer (2002) vol. 3 (55-64)) |
Erratum: Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients (Clinical Breast Cancer (2002) vol. 3 (55-64)) |
Erratum: Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients (Clinical Breast Cancer (2002) vol. 3 (55-64)) |
Clinical Breast Cancer, 3, 2, 159- |
Clinical Breast Cancer, 3, 2, 159- |
Clinical Breast Cancer, 3, 2, 159- |
2002 |
有 |
英語 |
|
公開 |
| T. Tominaga; M. Toi; O. Abe; Y. Ohashi; J. Uchino; H. Hayasaka; R. Abe; M. Izuo; K. Enomoto; H. Watanabe; M. Yoshida; T. Taguchi; H. Koyama; T. Senoo; T. Toge; Y. Monden; T. Hattori; Y. Nomura; K. Sugimachi; K. Hirata; H. Nakazato; S. Miura; T. Morimoto; K. Asaishi; I. Kimijima; J. Ota; H. Sonoo; S. Yamaguchi |
T. Tominaga; M. Toi; O. Abe; Y. Ohashi; J. Uchino; H. Hayasaka; R. Abe; M. Izuo; K. Enomoto; H. Watanabe; M. Yoshida; T. Taguchi; H. Koyama; T. Senoo; T. Toge; Y. Monden; T. Hattori; Y. Nomura; K. Sugimachi; K. Hirata; H. Nakazato; S. Miura; T. Morimoto; K. Asaishi; I. Kimijima; J. Ota; H. Sonoo; S. Yamaguchi |
T. Tominaga; M. Toi; O. Abe; Y. Ohashi; J. Uchino; H. Hayasaka; R. Abe; M. Izuo; K. Enomoto; H. Watanabe; M. Yoshida; T. Taguchi; H. Koyama; T. Senoo; T. Toge; Y. Monden; T. Hattori; Y. Nomura; K. Sugimachi; K. Hirata; H. Nakazato; S. Miura; T. Morimoto; K. Asaishi; I. Kimijima; J. Ota; H. Sonoo; S. Yamaguchi |
The effect of adjuvant 5\\'-deoxy-5-fluorouridine in early stage breast cancer patients: results from a multicenter randomized controlled trial. |
The effect of adjuvant 5\\'-deoxy-5-fluorouridine in early stage breast cancer patients: results from a multicenter randomized controlled trial. |
The effect of adjuvant 5\\'-deoxy-5-fluorouridine in early stage breast cancer patients: results from a multicenter randomized controlled trial. |
International journal of oncology, 20, 3, 517-525 |
International journal of oncology, 20, 3, 517-525 |
International journal of oncology, 20, 3, 517-525 |
2002 |
有 |
英語 |
|
公開 |
| T. Watanabe; M. Sano; M. Toi; T. Saeki; K. Kanda; S. Miura; H. Inaji; H. Sono; H. Saeki; R. Nishimura; Y. Fujita |
T. Watanabe; M. Sano; M. Toi; T. Saeki; K. Kanda; S. Miura; H. Inaji; H. Sono; H. Saeki; R. Nishimura; Y. Fujita |
T. Watanabe; M. Sano; M. Toi; T. Saeki; K. Kanda; S. Miura; H. Inaji; H. Sono; H. Saeki; R. Nishimura; Y. Fujita |
Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents |
Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents |
Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents |
Japanese Journal of Cancer and Chemotherapy, 29, 7, 1211-1221 |
Japanese Journal of Cancer and Chemotherapy, 29, 7, 1211-1221 |
Japanese Journal of Cancer and Chemotherapy, 29, 7, 1211-1221 |
2002 |
有 |
英語 |
|
公開 |
| S. Saji; Y. Omoto; C. Shimizu; M. Warner; Y. Hayashi; S.-I. Horiguchi; T. Watanabe; S.-I. Hayashi; J.-Å. Gustafsson; M. Toi |
S. Saji; Y. Omoto; C. Shimizu; M. Warner; Y. Hayashi; S.-I. Horiguchi; T. Watanabe; S.-I. Hayashi; J.-Å. Gustafsson; M. Toi |
S. Saji; Y. Omoto; C. Shimizu; M. Warner; Y. Hayashi; S.-I. Horiguchi; T. Watanabe; S.-I. Hayashi; J.-Å. Gustafsson; M. Toi |
Expression of estrogen receptor (ER) βcx protein in ERα-positive breast cancer: Specific correlation with progesterone receptor |
Expression of estrogen receptor (ER) βcx protein in ERα-positive breast cancer: Specific correlation with progesterone receptor |
Expression of estrogen receptor (ER) βcx protein in ERα-positive breast cancer: Specific correlation with progesterone receptor |
Cancer Research, 62, 17, 4849-4853 |
Cancer Research, 62, 17, 4849-4853 |
Cancer Research, 62, 17, 4849-4853 |
2002 |
有 |
英語 |
|
公開 |
| C. Nakanishi; M. Toi; S. Saji; H. Bando |
C. Nakanishi; M. Toi; S. Saji; H. Bando |
C. Nakanishi; M. Toi; S. Saji; H. Bando |
Current indications for mastectomy in patients with breast cancer |
Current indications for mastectomy in patients with breast cancer |
Current indications for mastectomy in patients with breast cancer |
Nippon Geka Gakkai zasshi, 103, 11, 821-824 |
Nippon Geka Gakkai zasshi, 103, 11, 821-824 |
Nippon Geka Gakkai zasshi, 103, 11, 821-824 |
2002 |
有 |
英語 |
|
公開 |
| K. Tsuruta; A. Okamoto; M. Toi; H. Saji; T. Takahashi |
K. Tsuruta; A. Okamoto; M. Toi; H. Saji; T. Takahashi |
K. Tsuruta; A. Okamoto; M. Toi; H. Saji; T. Takahashi |
Impact of selective glisson transection on survival of hepatocellular carcinoma |
Impact of selective glisson transection on survival of hepatocellular carcinoma |
Impact of selective glisson transection on survival of hepatocellular carcinoma |
Hepato-Gastroenterology, 49, 48, 1607-1610 |
Hepato-Gastroenterology, 49, 48, 1607-1610 |
Hepato-Gastroenterology, 49, 48, 1607-1610 |
2002 |
有 |
英語 |
|
公開 |
| S. Saji; N. Okumura; H. Eguchi; S. Nakashima; A. Suzuki; M. Toi; Y. Nozawa; S. Saji; S.-I. Hayashi |
S. Saji; N. Okumura; H. Eguchi; S. Nakashima; A. Suzuki; M. Toi; Y. Nozawa; S. Saji; S.-I. Hayashi |
S. Saji; N. Okumura; H. Eguchi; S. Nakashima; A. Suzuki; M. Toi; Y. Nozawa; S. Saji; S.-I. Hayashi |
MDM2 enhances the function of estrogen receptor in human breast cancer cells |
MDM2 enhances the function of estrogen receptor in human breast cancer cells |
MDM2 enhances the function of estrogen receptor in human breast cancer cells |
Biochemical and Biophysical Research Communications, 281, 1, 259-265 |
Biochemical and Biophysical Research Communications, 281, 1, 259-265 |
Biochemical and Biophysical Research Communications, 281, 1, 259-265 |
2001 |
有 |
英語 |
|
公開 |
| A. Mandic; K. Viktorsson; M. Molin; G. Akusjärvi; H. Eguchi; S.-I. Hayashi; M. Toi; J. Hansson; S. Linder; M.C. Shoshan |
A. Mandic; K. Viktorsson; M. Molin; G. Akusjärvi; H. Eguchi; S.-I. Hayashi; M. Toi; J. Hansson; S. Linder; M.C. Shoshan |
A. Mandic; K. Viktorsson; M. Molin; G. Akusjärvi; H. Eguchi; S.-I. Hayashi; M. Toi; J. Hansson; S. Linder; M.C. Shoshan |
Cisplatin induces the proapoptotic conformation of Bak in a ΔMEKK1-dependent manner |
Cisplatin induces the proapoptotic conformation of Bak in a ΔMEKK1-dependent manner |
Cisplatin induces the proapoptotic conformation of Bak in a ΔMEKK1-dependent manner |
Molecular and Cellular Biology, 21, 11, 3684-3691 |
Molecular and Cellular Biology, 21, 11, 3684-3691 |
Molecular and Cellular Biology, 21, 11, 3684-3691 |
2001 |
有 |
英語 |
|
公開 |
| K. Hattori; M. Muta; M. Toi; H. Iizasa; M. Shinsei; T. Terasaki; M. Obinata; M. Ueda; E. Nakashima |
K. Hattori; M. Muta; M. Toi; H. Iizasa; M. Shinsei; T. Terasaki; M. Obinata; M. Ueda; E. Nakashima |
K. Hattori; M. Muta; M. Toi; H. Iizasa; M. Shinsei; T. Terasaki; M. Obinata; M. Ueda; E. Nakashima |
Establishment of bone marrow-derived endothelial cell lines from ts-SV40 T-antigen gene transgenic rats |
Establishment of bone marrow-derived endothelial cell lines from ts-SV40 T-antigen gene transgenic rats |
Establishment of bone marrow-derived endothelial cell lines from ts-SV40 T-antigen gene transgenic rats |
Pharmaceutical Research, 18, 1, 9-15 |
Pharmaceutical Research, 18, 1, 9-15 |
Pharmaceutical Research, 18, 1, 9-15 |
2001 |
有 |
英語 |
|
公開 |
| G. Gasparini; M. Toi; E. Biganzoli; R. Dittadi; M. Fanelli; A. Morabito; P. Boracchi; M. Gion |
G. Gasparini; M. Toi; E. Biganzoli; R. Dittadi; M. Fanelli; A. Morabito; P. Boracchi; M. Gion |
G. Gasparini; M. Toi; E. Biganzoli; R. Dittadi; M. Fanelli; A. Morabito; P. Boracchi; M. Gion |
Thrombospondin-1 and -2 in node-negative breast cancer: Correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis |
Thrombospondin-1 and -2 in node-negative breast cancer: Correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis |
Thrombospondin-1 and -2 in node-negative breast cancer: Correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis |
Oncology, 60, 1, 72-80 |
Oncology, 60, 1, 72-80 |
Oncology, 60, 1, 72-80 |
2001 |
有 |
英語 |
|
公開 |
| M. Toi; T. Matsumoto; H. Bando |
M. Toi; T. Matsumoto; H. Bando |
M. Toi; T. Matsumoto; H. Bando |
Vascular endothelial growth factor: Its prognostic, predictive, and therapeutic implications |
Vascular endothelial growth factor: Its prognostic, predictive, and therapeutic implications |
Vascular endothelial growth factor: Its prognostic, predictive, and therapeutic implications |
Lancet Oncology, 2, 11, 667-673 |
Lancet Oncology, 2, 11, 667-673 |
Lancet Oncology, 2, 11, 667-673 |
2001 |
有 |
英語 |
|
公開 |
| H. Saji; M. Koike; T. Yamori; S. Saji; M. Seiki; K. Matsushima; M. Toi |
H. Saji; M. Koike; T. Yamori; S. Saji; M. Seiki; K. Matsushima; M. Toi |
H. Saji; M. Koike; T. Yamori; S. Saji; M. Seiki; K. Matsushima; M. Toi |
Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma |
Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma |
Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma |
Cancer, 92, 5, 1085-1091 |
Cancer, 92, 5, 1085-1091 |
Cancer, 92, 5, 1085-1091 |
2001 |
有 |
英語 |
|
公開 |
| M. Toi; H. Bando; S. Saji |
M. Toi; H. Bando; S. Saji |
M. Toi; H. Bando; S. Saji |
Aromatase and aromatase inhibitors |
Aromatase and aromatase inhibitors |
Aromatase and aromatase inhibitors |
Breast Cancer, 8, 4, 329-332 |
Breast Cancer, 8, 4, 329-332 |
Breast Cancer, 8, 4, 329-332 |
2001 |
有 |
英語 |
|
公開 |
| S. Umemura; G. Sakamoto; H. Sasano; H. Tsuda; F. Akiyama; M. Kurosumi; Y. Tokuda; T. Watanabe; M. Toi; T. Hasegawa; R. Yoshiyuki Osamura |
S. Umemura; G. Sakamoto; H. Sasano; H. Tsuda; F. Akiyama; M. Kurosumi; Y. Tokuda; T. Watanabe; M. Toi; T. Hasegawa; R. Yoshiyuki Osamura |
S. Umemura; G. Sakamoto; H. Sasano; H. Tsuda; F. Akiyama; M. Kurosumi; Y. Tokuda; T. Watanabe; M. Toi; T. Hasegawa; R. Yoshiyuki Osamura |
Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (pathological committee for optimal use of trastuzumab) |
Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (pathological committee for optimal use of trastuzumab) |
Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (pathological committee for optimal use of trastuzumab) |
Breast Cancer, 8, 4, 316-320 |
Breast Cancer, 8, 4, 316-320 |
Breast Cancer, 8, 4, 316-320 |
2001 |
有 |
英語 |
|
公開 |
| K. Nakayama; A. Kanzaki; Y. Takebayashi; M. Toi; H. Bando; T. Nabei; K. Miyazaki; M. Fukumoto |
K. Nakayama; A. Kanzaki; Y. Takebayashi; M. Toi; H. Bando; T. Nabei; K. Miyazaki; M. Fukumoto |
K. Nakayama; A. Kanzaki; Y. Takebayashi; M. Toi; H. Bando; T. Nabei; K. Miyazaki; M. Fukumoto |
Different features of angiogenesis between ovarian and breast carcinoma |
Different features of angiogenesis between ovarian and breast carcinoma |
Different features of angiogenesis between ovarian and breast carcinoma |
Cancer Letters, 170, 2, 161-167 |
Cancer Letters, 170, 2, 161-167 |
Cancer Letters, 170, 2, 161-167 |
2001 |
有 |
英語 |
|
公開 |
| A. Kanzaki; M. Toi; K. Nakayama; H. Bando; M. Mutoh; T. Uchida; M. Fukumoto; Y. Takebayashi |
A. Kanzaki; M. Toi; K. Nakayama; H. Bando; M. Mutoh; T. Uchida; M. Fukumoto; Y. Takebayashi |
A. Kanzaki; M. Toi; K. Nakayama; H. Bando; M. Mutoh; T. Uchida; M. Fukumoto; Y. Takebayashi |
Expression of multidrug resistance-related transporters in human breast carcinoma |
Expression of multidrug resistance-related transporters in human breast carcinoma |
Expression of multidrug resistance-related transporters in human breast carcinoma |
Japanese Journal of Cancer Research, 92, 4, 452-458 |
Japanese Journal of Cancer Research, 92, 4, 452-458 |
Japanese Journal of Cancer Research, 92, 4, 452-458 |
2001 |
有 |
英語 |
|
公開 |
| K. Kuroi; M. Toi |
K. Kuroi; M. Toi |
K. Kuroi; M. Toi |
Circulating angiogenesis regulators in cancer patients |
Circulating angiogenesis regulators in cancer patients |
Circulating angiogenesis regulators in cancer patients |
International Journal of Biological Markers, 16, 1, 5-26 |
International Journal of Biological Markers, 16, 1, 5-26 |
International Journal of Biological Markers, 16, 1, 5-26 |
2001 |
有 |
英語 |
|
公開 |
| N. Tsuneyoshi; K. Fukudome; S.-I. Horiguchi; X. Ye; M. Matsuzaki; M. Toi; K. Suzuki; M. Kimoto |
N. Tsuneyoshi; K. Fukudome; S.-I. Horiguchi; X. Ye; M. Matsuzaki; M. Toi; K. Suzuki; M. Kimoto |
N. Tsuneyoshi; K. Fukudome; S.-I. Horiguchi; X. Ye; M. Matsuzaki; M. Toi; K. Suzuki; M. Kimoto |
Expression and anticoagulant function of the endothelial cell protein C receptor (EPCR) in cancer cell lines |
Expression and anticoagulant function of the endothelial cell protein C receptor (EPCR) in cancer cell lines |
Expression and anticoagulant function of the endothelial cell protein C receptor (EPCR) in cancer cell lines |
Thrombosis and Haemostasis, 85, 2, 356-361 |
Thrombosis and Haemostasis, 85, 2, 356-361 |
Thrombosis and Haemostasis, 85, 2, 356-361 |
2001 |
有 |
英語 |
|
公開 |
| O. Ohno; Y. Shima; Y. Ikeda; S.I. Kondo; K. Kato; M. Toi; K. Umezawa |
O. Ohno; Y. Shima; Y. Ikeda; S.I. Kondo; K. Kato; M. Toi; K. Umezawa |
O. Ohno; Y. Shima; Y. Ikeda; S.I. Kondo; K. Kato; M. Toi; K. Umezawa |
Selective growth inhibition by sangivamycin of human umbilical vein endothelial cells. |
Selective growth inhibition by sangivamycin of human umbilical vein endothelial cells. |
Selective growth inhibition by sangivamycin of human umbilical vein endothelial cells. |
International journal of oncology, 18, 5, 1009-1015 |
International journal of oncology, 18, 5, 1009-1015 |
International journal of oncology, 18, 5, 1009-1015 |
2001 |
有 |
英語 |
|
公開 |
| G. Matsumoto; S. Nagai; M. Toi; S. Ishiyama; K. Kuroi; K. Turuta; A. Okamoto; T. Takahashi |
G. Matsumoto; S. Nagai; M. Toi; S. Ishiyama; K. Kuroi; K. Turuta; A. Okamoto; T. Takahashi |
G. Matsumoto; S. Nagai; M. Toi; S. Ishiyama; K. Kuroi; K. Turuta; A. Okamoto; T. Takahashi |
KRN7000 inhibit hepatic metastasis of pancreatic cancer |
KRN7000 inhibit hepatic metastasis of pancreatic cancer |
KRN7000 inhibit hepatic metastasis of pancreatic cancer |
Nippon Geka Gakkai zasshi, 102, 5, 421- |
Nippon Geka Gakkai zasshi, 102, 5, 421- |
Nippon Geka Gakkai zasshi, 102, 5, 421- |
2001 |
有 |
英語 |
|
公開 |
| K. Kuroi; H. Bando; S. Nagai; C. Tanaka; K. Hayashi; M. Toi |
K. Kuroi; H. Bando; S. Nagai; C. Tanaka; K. Hayashi; M. Toi |
K. Kuroi; H. Bando; S. Nagai; C. Tanaka; K. Hayashi; M. Toi |
Efficacy of weekly docetaxel therapy for advanced or recurrent breast cancer |
Efficacy of weekly docetaxel therapy for advanced or recurrent breast cancer |
Efficacy of weekly docetaxel therapy for advanced or recurrent breast cancer |
Japanese Journal of Cancer and Chemotherapy, 28, 6, 797-802 |
Japanese Journal of Cancer and Chemotherapy, 28, 6, 797-802 |
Japanese Journal of Cancer and Chemotherapy, 28, 6, 797-802 |
2001 |
有 |
英語 |
|
公開 |
| K. Kuroi; C. Tanaka; M. Toi |
K. Kuroi; C. Tanaka; M. Toi |
K. Kuroi; C. Tanaka; M. Toi |
Clinical significance of plasma nucleosome levels in cancer patients. |
Clinical significance of plasma nucleosome levels in cancer patients. |
Clinical significance of plasma nucleosome levels in cancer patients. |
International journal of oncology, 19, 1, 143-148 |
International journal of oncology, 19, 1, 143-148 |
International journal of oncology, 19, 1, 143-148 |
2001 |
有 |
英語 |
|
公開 |
| M. Shitashige; M. Toi; T. Yano; M. Shibata; Y. Matsuo; F. Shibasaki |
M. Shitashige; M. Toi; T. Yano; M. Shibata; Y. Matsuo; F. Shibasaki |
M. Shitashige; M. Toi; T. Yano; M. Shibata; Y. Matsuo; F. Shibasaki |
Dissociation of Bax from a Bcl-2/Bax heterodimer triggered by phosphorylation of serine 70 of Bcl-2<sup>1</sup> |
Dissociation of Bax from a Bcl-2/Bax heterodimer triggered by phosphorylation of serine 70 of Bcl-2<sup>1</sup> |
Dissociation of Bax from a Bcl-2/Bax heterodimer triggered by phosphorylation of serine 70 of Bcl-2<sup>1</sup> |
Journal of Biochemistry, 130, 6, 741-748 |
Journal of Biochemistry, 130, 6, 741-748 |
Journal of Biochemistry, 130, 6, 741-748 |
2001 |
有 |
英語 |
|
公開 |
| M. Toi; Y. Bando; S. Saji; T. Matsumoto |
M. Toi; Y. Bando; S. Saji; T. Matsumoto |
M. Toi; Y. Bando; S. Saji; T. Matsumoto |
Tumor angiogenesis and hypoxia |
Tumor angiogenesis and hypoxia |
Tumor angiogenesis and hypoxia |
Biotherapy, 15, 6, 663-668 |
Biotherapy, 15, 6, 663-668 |
Biotherapy, 15, 6, 663-668 |
2001 |
有 |
英語 |
|
公開 |
| H. Kodama; I. To; J. Ishiwata; Y. Shinohara; N. Katayanagi; K. Kubota; T. Murakami; K. Kuroi; K. Hayashi; M. Toi |
H. Kodama; I. To; J. Ishiwata; Y. Shinohara; N. Katayanagi; K. Kubota; T. Murakami; K. Kuroi; K. Hayashi; M. Toi |
H. Kodama; I. To; J. Ishiwata; Y. Shinohara; N. Katayanagi; K. Kubota; T. Murakami; K. Kuroi; K. Hayashi; M. Toi |
MEN2A incidentally detected by high level of CEA and family history |
MEN2A incidentally detected by high level of CEA and family history |
MEN2A incidentally detected by high level of CEA and family history |
[Zasshi] Journal. Nihon Naika Gakkai, 90, 4, 683-686 |
[Zasshi] Journal. Nihon Naika Gakkai, 90, 4, 683-686 |
[Zasshi] Journal. Nihon Naika Gakkai, 90, 4, 683-686 |
2001 |
有 |
英語 |
|
公開 |
| J. Kurebayashi; H. Sonoo; H. Inaji; R. Nishimura; Y. Iino; M. Toi; S. Kobayashi; T. Saeki |
J. Kurebayashi; H. Sonoo; H. Inaji; R. Nishimura; Y. Iino; M. Toi; S. Kobayashi; T. Saeki |
J. Kurebayashi; H. Sonoo; H. Inaji; R. Nishimura; Y. Iino; M. Toi; S. Kobayashi; T. Saeki |
Endocrine therapies for patients with recurrent breast cancer: Predictive factors for responses to first- and second-line endocrine therapies |
Endocrine therapies for patients with recurrent breast cancer: Predictive factors for responses to first- and second-line endocrine therapies |
Endocrine therapies for patients with recurrent breast cancer: Predictive factors for responses to first- and second-line endocrine therapies |
Oncology, 59, SUPPL. 1, 31-37 |
Oncology, 59, SUPPL. 1, 31-37 |
Oncology, 59, SUPPL. 1, 31-37 |
2000 |
有 |
英語 |
|
公開 |
| H. Eguchi; K. Suga; H. Saji; M. Toi; K. Nakachi; S.-I. Hayashi |
H. Eguchi; K. Suga; H. Saji; M. Toi; K. Nakachi; S.-I. Hayashi |
H. Eguchi; K. Suga; H. Saji; M. Toi; K. Nakachi; S.-I. Hayashi |
Different expression patterns of Bcl-2 family genes in breast cancer by estrogen receptor status with special reference to pro-apoptotic Bak gene |
Different expression patterns of Bcl-2 family genes in breast cancer by estrogen receptor status with special reference to pro-apoptotic Bak gene |
Different expression patterns of Bcl-2 family genes in breast cancer by estrogen receptor status with special reference to pro-apoptotic Bak gene |
Cell Death and Differentiation, 7, 5, 439-446 |
Cell Death and Differentiation, 7, 5, 439-446 |
Cell Death and Differentiation, 7, 5, 439-446 |
2000 |
有 |
英語 |
|
公開 |
| T. Ueno; M. Toi; M. Koike; S. Nakamura; T. Tominaga |
T. Ueno; M. Toi; M. Koike; S. Nakamura; T. Tominaga |
T. Ueno; M. Toi; M. Koike; S. Nakamura; T. Tominaga |
Tissue factor expression in breast cancer tissues: Its correlation with prognosis and plasma concentration |
Tissue factor expression in breast cancer tissues: Its correlation with prognosis and plasma concentration |
Tissue factor expression in breast cancer tissues: Its correlation with prognosis and plasma concentration |
British Journal of Cancer, 83, 2, 164-170 |
British Journal of Cancer, 83, 2, 164-170 |
British Journal of Cancer, 83, 2, 164-170 |
2000 |
有 |
英語 |
|
公開 |
| S. Nagai; M. Toi |
S. Nagai; M. Toi |
S. Nagai; M. Toi |
Interleukin-4 and breast cancer |
Interleukin-4 and breast cancer |
Interleukin-4 and breast cancer |
Breast Cancer, 7, 3, 181-186 |
Breast Cancer, 7, 3, 181-186 |
Breast Cancer, 7, 3, 181-186 |
2000 |
有 |
英語 |
|
公開 |
| M. Toi; H. Bando; K. Kuroi |
M. Toi; H. Bando; K. Kuroi |
M. Toi; H. Bando; K. Kuroi |
The predictive value of angiogenesis for adjuvant therapy in breast cancer |
The predictive value of angiogenesis for adjuvant therapy in breast cancer |
The predictive value of angiogenesis for adjuvant therapy in breast cancer |
Breast Cancer, 7, 4, 311-314 |
Breast Cancer, 7, 4, 311-314 |
Breast Cancer, 7, 4, 311-314 |
2000 |
有 |
英語 |
|
公開 |
| K. Mori; M. Hasegawa; M. Nishida; H. Toma; M. Fukuda; T. Kubota; N. Nagasue; H. Yamana; K. Hirakawa-YS Chung; T. Ikeda; K. Takasaki; M. Oka; M. Kameyama; M. Toi; H. Fujii; M. Kitamura; M. Murai; H. Sasaki; S. Ozono; H. Makuuchi; Y. Shimada; Y. Onishi; S. Aoyagi; K. Mizutani; M. Ogawa; A. Nakao; H. Kinoshita; T. Tono; H. Imamoto; Y. Nakashima; T. Manabe |
K. Mori; M. Hasegawa; M. Nishida; H. Toma; M. Fukuda; T. Kubota; N. Nagasue; H. Yamana; K. Hirakawa-YS Chung; T. Ikeda; K. Takasaki; M. Oka; M. Kameyama; M. Toi; H. Fujii; M. Kitamura; M. Murai; H. Sasaki; S. Ozono; H. Makuuchi; Y. Shimada; Y. Onishi; S. Aoyagi; K. Mizutani; M. Ogawa; A. Nakao; H. Kinoshita; T. Tono; H. Imamoto; Y. Nakashima; T. Manabe |
K. Mori; M. Hasegawa; M. Nishida; H. Toma; M. Fukuda; T. Kubota; N. Nagasue; H. Yamana; K. Hirakawa-YS Chung; T. Ikeda; K. Takasaki; M. Oka; M. Kameyama; M. Toi; H. Fujii; M. Kitamura; M. Murai; H. Sasaki; S. Ozono; H. Makuuchi; Y. Shimada; Y. Onishi; S. Aoyagi; K. Mizutani; M. Ogawa; A. Nakao; H. Kinoshita; T. Tono; H. Imamoto; Y. Nakashima; T. Manabe |
Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. |
Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. |
Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. |
International journal of oncology, 17, 1, 33-38 |
International journal of oncology, 17, 1, 33-38 |
International journal of oncology, 17, 1, 33-38 |
2000 |
有 |
英語 |
|
公開 |
| M. Miyaki; T. Iijima; K. Hosono; R. Ishii; M. Yasuno; T. Mori; M. Toi; T. Hishima; N. Shitara; K. Tamura; J. Utsunomiya; N. Kobayashi; T. Kuroki; T. Iwama |
M. Miyaki; T. Iijima; K. Hosono; R. Ishii; M. Yasuno; T. Mori; M. Toi; T. Hishima; N. Shitara; K. Tamura; J. Utsunomiya; N. Kobayashi; T. Kuroki; T. Iwama |
M. Miyaki; T. Iijima; K. Hosono; R. Ishii; M. Yasuno; T. Mori; M. Toi; T. Hishima; N. Shitara; K. Tamura; J. Utsunomiya; N. Kobayashi; T. Kuroki; T. Iwama |
Somatic mutations of LKB1 and β-catenin genes in gastrointestinal polyps from patients with Peutz-Jeghers syndrome |
Somatic mutations of LKB1 and β-catenin genes in gastrointestinal polyps from patients with Peutz-Jeghers syndrome |
Somatic mutations of LKB1 and β-catenin genes in gastrointestinal polyps from patients with Peutz-Jeghers syndrome |
Cancer Research, 60, 22, 6311-6313 |
Cancer Research, 60, 22, 6311-6313 |
Cancer Research, 60, 22, 6311-6313 |
2000 |
有 |
英語 |
|
公開 |
| M. Tozaki; M. Toi; Y. Miyamoto; K. Fukuda |
M. Tozaki; M. Toi; Y. Miyamoto; K. Fukuda |
M. Tozaki; M. Toi; Y. Miyamoto; K. Fukuda |
Power Doppler sonography of breast masses: Correlation of Doppler spectral parameters with tumor angiogenesis and histologic growth pattern |
Power Doppler sonography of breast masses: Correlation of Doppler spectral parameters with tumor angiogenesis and histologic growth pattern |
Power Doppler sonography of breast masses: Correlation of Doppler spectral parameters with tumor angiogenesis and histologic growth pattern |
Journal of Ultrasound in Medicine, 19, 9, 593-600 |
Journal of Ultrasound in Medicine, 19, 9, 593-600 |
Journal of Ultrasound in Medicine, 19, 9, 593-600 |
2000 |
有 |
英語 |
|
公開 |
| T. Ueno; M. Toi; H. Saji; M. Muta; H. Bando; K. Kuroi; M. Koike; H. Inadera; K. Matsushima |
T. Ueno; M. Toi; H. Saji; M. Muta; H. Bando; K. Kuroi; M. Koike; H. Inadera; K. Matsushima |
T. Ueno; M. Toi; H. Saji; M. Muta; H. Bando; K. Kuroi; M. Koike; H. Inadera; K. Matsushima |
Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer |
Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer |
Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer |
Clinical Cancer Research, 6, 8, 3282-3289 |
Clinical Cancer Research, 6, 8, 3282-3289 |
Clinical Cancer Research, 6, 8, 3282-3289 |
2000 |
有 |
英語 |
|
公開 |
| C. Tanaka; M. Toi |
C. Tanaka; M. Toi |
C. Tanaka; M. Toi |
Capecitabine for treatment of advanced breast cancers |
Capecitabine for treatment of advanced breast cancers |
Capecitabine for treatment of advanced breast cancers |
Nippon rinsho. Japanese journal of clinical medicine, 58 Suppl, 279-283 |
Nippon rinsho. Japanese journal of clinical medicine, 58 Suppl, 279-283 |
Nippon rinsho. Japanese journal of clinical medicine, 58 Suppl, 279-283 |
2000 |
有 |
英語 |
|
公開 |
| K. Kuroi; M. Toi |
K. Kuroi; M. Toi |
K. Kuroi; M. Toi |
Angiogenesis as a prognostic factor of breast cancers |
Angiogenesis as a prognostic factor of breast cancers |
Angiogenesis as a prognostic factor of breast cancers |
Nippon rinsho. Japanese journal of clinical medicine, 58 Suppl, 435-441 |
Nippon rinsho. Japanese journal of clinical medicine, 58 Suppl, 435-441 |
Nippon rinsho. Japanese journal of clinical medicine, 58 Suppl, 435-441 |
2000 |
有 |
英語 |
|
公開 |
| M. Toi; G. Matsumoto; H. Bando; K. Kuroi |
M. Toi; G. Matsumoto; H. Bando; K. Kuroi |
M. Toi; G. Matsumoto; H. Bando; K. Kuroi |
Antiangiogenesis therapy and hormone therapy--their resemblance and applications of prognostic and predictive factors |
Antiangiogenesis therapy and hormone therapy--their resemblance and applications of prognostic and predictive factors |
Antiangiogenesis therapy and hormone therapy--their resemblance and applications of prognostic and predictive factors |
Japanese Journal of Cancer and Chemotherapy, 27, 8, 1212-1216 |
Japanese Journal of Cancer and Chemotherapy, 27, 8, 1212-1216 |
Japanese Journal of Cancer and Chemotherapy, 27, 8, 1212-1216 |
2000 |
有 |
英語 |
|
公開 |
| M. Toi; G. Matsumoto |
M. Toi; G. Matsumoto |
M. Toi; G. Matsumoto |
Isolated tumor cells and micrometastasis--clinical behavior and therapeutic implications |
Isolated tumor cells and micrometastasis--clinical behavior and therapeutic implications |
Isolated tumor cells and micrometastasis--clinical behavior and therapeutic implications |
Japanese Journal of Cancer and Chemotherapy, 27, 9, 1315-1336 |
Japanese Journal of Cancer and Chemotherapy, 27, 9, 1315-1336 |
Japanese Journal of Cancer and Chemotherapy, 27, 9, 1315-1336 |
2000 |
有 |
英語 |
|
公開 |
| M. Seki; M. Toi; K. Kobayashi; K. Shitara; K. Umezawa; B.K. Seon; M. Kan; J.S. Rhim |
M. Seki; M. Toi; K. Kobayashi; K. Shitara; K. Umezawa; B.K. Seon; M. Kan; J.S. Rhim |
M. Seki; M. Toi; K. Kobayashi; K. Shitara; K. Umezawa; B.K. Seon; M. Kan; J.S. Rhim |
Differential behavior of VEGF receptor expression and response to TNP-470 in two immortalized human endothelial cell lines. |
Differential behavior of VEGF receptor expression and response to TNP-470 in two immortalized human endothelial cell lines. |
Differential behavior of VEGF receptor expression and response to TNP-470 in two immortalized human endothelial cell lines. |
International journal of oncology, 17, 3, 525-533 |
International journal of oncology, 17, 3, 525-533 |
International journal of oncology, 17, 3, 525-533 |
2000 |
有 |
英語 |
|
公開 |
| H. Bando; M. Toi |
H. Bando; M. Toi |
H. Bando; M. Toi |
Tumor angiogenesis, macrophages, and cytokines |
Tumor angiogenesis, macrophages, and cytokines |
Tumor angiogenesis, macrophages, and cytokines |
Advances in Experimental Medicine and Biology, 476, 267-284 |
Advances in Experimental Medicine and Biology, 476, 267-284 |
Advances in Experimental Medicine and Biology, 476, 267-284 |
2000 |
有 |
英語 |
|
公開 |
| K. Kuroi; C. Tanaka; M. Toi |
K. Kuroi; C. Tanaka; M. Toi |
K. Kuroi; C. Tanaka; M. Toi |
Plasma nucleosome levels in node-negative breast cancer patients |
Plasma nucleosome levels in node-negative breast cancer patients |
Plasma nucleosome levels in node-negative breast cancer patients |
Breast Cancer, 6, 4, 361-364 |
Breast Cancer, 6, 4, 361-364 |
Breast Cancer, 6, 4, 361-364 |
1999 |
有 |
英語 |
|
公開 |
| H. Sonoo; J. Kurebayashi; Y. Lino; H. Inaji; T. Watanabe; M. Toi; S. Kobayashi; B. Sato; M. Yoshimoto |
H. Sonoo; J. Kurebayashi; Y. Lino; H. Inaji; T. Watanabe; M. Toi; S. Kobayashi; B. Sato; M. Yoshimoto |
H. Sonoo; J. Kurebayashi; Y. Lino; H. Inaji; T. Watanabe; M. Toi; S. Kobayashi; B. Sato; M. Yoshimoto |
Current status and controversial issues concerning endocrine therapy for patients with recurrent breast cancer in Japan |
Current status and controversial issues concerning endocrine therapy for patients with recurrent breast cancer in Japan |
Current status and controversial issues concerning endocrine therapy for patients with recurrent breast cancer in Japan |
Breast Cancer, 6, 4, 344-350 |
Breast Cancer, 6, 4, 344-350 |
Breast Cancer, 6, 4, 344-350 |
1999 |
有 |
英語 |
|
公開 |
| T. Ueno; M. Toi; T. Tominaga |
T. Ueno; M. Toi; T. Tominaga |
T. Ueno; M. Toi; T. Tominaga |
Circulating soluble Fas concentration in breast cancer patients |
Circulating soluble Fas concentration in breast cancer patients |
Circulating soluble Fas concentration in breast cancer patients |
Clinical Cancer Research, 5, 11, 3529-3533 |
Clinical Cancer Research, 5, 11, 3529-3533 |
Clinical Cancer Research, 5, 11, 3529-3533 |
1999 |
有 |
英語 |
|
公開 |
| S.-I. Kumeda; A. Deguchi; M. Toi; S. Omura; K. Umezawa |
S.-I. Kumeda; A. Deguchi; M. Toi; S. Omura; K. Umezawa |
S.-I. Kumeda; A. Deguchi; M. Toi; S. Omura; K. Umezawa |
Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells |
Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells |
Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells |
Anticancer Research, 19, 5 B, 3961-3968 |
Anticancer Research, 19, 5 B, 3961-3968 |
Anticancer Research, 19, 5 B, 3961-3968 |
1999 |
有 |
英語 |
|
公開 |
| M. Toi; M. Seki |
M. Toi; M. Seki |
M. Toi; M. Seki |
Assessment of angiogenesis inhibitors using cultured endothelial cells |
Assessment of angiogenesis inhibitors using cultured endothelial cells |
Assessment of angiogenesis inhibitors using cultured endothelial cells |
Biotherapy, 13, 6, 675-678 |
Biotherapy, 13, 6, 675-678 |
Biotherapy, 13, 6, 675-678 |
1999 |
有 |
英語 |
|
公開 |
| M. Toi; T. Ueno; H. Matsumoto; H. Saji; N. Funata; M. Koike; T. Tominaga |
M. Toi; T. Ueno; H. Matsumoto; H. Saji; N. Funata; M. Koike; T. Tominaga |
M. Toi; T. Ueno; H. Matsumoto; H. Saji; N. Funata; M. Koike; T. Tominaga |
Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer |
Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer |
Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer |
Clinical Cancer Research, 5, 5, 1131-1137 |
Clinical Cancer Research, 5, 5, 1131-1137 |
Clinical Cancer Research, 5, 5, 1131-1137 |
1999 |
有 |
英語 |
|
公開 |
| G. Gasparini; M. Toi; R. Miceli; P.B. Vermeulen; R. Dittadi; E. Biganzoli; A. Morabito; M. Fanelli; C. Gatti; H. Suzuki; T. Tominaga; L.Y. Dirix; M. Gion |
G. Gasparini; M. Toi; R. Miceli; P.B. Vermeulen; R. Dittadi; E. Biganzoli; A. Morabito; M. Fanelli; C. Gatti; H. Suzuki; T. Tominaga; L.Y. Dirix; M. Gion |
G. Gasparini; M. Toi; R. Miceli; P.B. Vermeulen; R. Dittadi; E. Biganzoli; A. Morabito; M. Fanelli; C. Gatti; H. Suzuki; T. Tominaga; L.Y. Dirix; M. Gion |
Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy |
Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy |
Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy |
Cancer Journal from Scientific American, 5, 2, 101-111 |
Cancer Journal from Scientific American, 5, 2, 101-111 |
Cancer Journal from Scientific American, 5, 2, 101-111 |
1999 |
有 |
英語 |
|
公開 |
| M. Toi; H. Saji |
M. Toi; H. Saji |
M. Toi; H. Saji |
Thymidine phosphorylase targeting treatment |
Thymidine phosphorylase targeting treatment |
Thymidine phosphorylase targeting treatment |
Biotherapy, 13, 2, 166-172 |
Biotherapy, 13, 2, 166-172 |
Biotherapy, 13, 2, 166-172 |
1999 |
有 |
英語 |
|
公開 |
| S. Saji; S. Nakashima; S.-I. Hayashi; M. Toi; S. Saji; Y. Nozawa |
S. Saji; S. Nakashima; S.-I. Hayashi; M. Toi; S. Saji; Y. Nozawa |
S. Saji; S. Nakashima; S.-I. Hayashi; M. Toi; S. Saji; Y. Nozawa |
Overexpression of MDM2 in MCF-7 promotes both growth advantage and p53 accumulation in response to estradiol |
Overexpression of MDM2 in MCF-7 promotes both growth advantage and p53 accumulation in response to estradiol |
Overexpression of MDM2 in MCF-7 promotes both growth advantage and p53 accumulation in response to estradiol |
Japanese Journal of Cancer Research, 90, 2, 210-218 |
Japanese Journal of Cancer Research, 90, 2, 210-218 |
Japanese Journal of Cancer Research, 90, 2, 210-218 |
1999 |
有 |
英語 |
|
公開 |
| S. Ishigaki; M. Toi; T. Ueno; H. Matsumoto; M. Muta; M. Koike; M. Seiki |
S. Ishigaki; M. Toi; T. Ueno; H. Matsumoto; M. Muta; M. Koike; M. Seiki |
S. Ishigaki; M. Toi; T. Ueno; H. Matsumoto; M. Muta; M. Koike; M. Seiki |
Significance of membrane type 1 matrix metalloproteinase expression in breast cancer |
Significance of membrane type 1 matrix metalloproteinase expression in breast cancer |
Significance of membrane type 1 matrix metalloproteinase expression in breast cancer |
Japanese Journal of Cancer Research, 90, 5, 516-522 |
Japanese Journal of Cancer Research, 90, 5, 516-522 |
Japanese Journal of Cancer Research, 90, 5, 516-522 |
1999 |
有 |
英語 |
|
公開 |
| S. Nagai; M. Toi; K. Kuroi; K. Hayashi; T. Tominaga |
S. Nagai; M. Toi; K. Kuroi; K. Hayashi; T. Tominaga |
S. Nagai; M. Toi; K. Kuroi; K. Hayashi; T. Tominaga |
Docetaxel as a single agent in cases of advanced/recurrent breast cancer previously treated with anthracycline |
Docetaxel as a single agent in cases of advanced/recurrent breast cancer previously treated with anthracycline |
Docetaxel as a single agent in cases of advanced/recurrent breast cancer previously treated with anthracycline |
Gan to kagaku ryoho. Cancer & chemotherapy, 26, 13, 2037-2042 |
Gan to kagaku ryoho. Cancer & chemotherapy, 26, 13, 2037-2042 |
Gan to kagaku ryoho. Cancer & chemotherapy, 26, 13, 2037-2042 |
1999 |
有 |
英語 |
|
公開 |
| M. Toi; M. Gion; H. Saji; M. Asano; R. Dittadi; S. Gilberti; N. Locopo; G. Gasparini |
M. Toi; M. Gion; H. Saji; M. Asano; R. Dittadi; S. Gilberti; N. Locopo; G. Gasparini |
M. Toi; M. Gion; H. Saji; M. Asano; R. Dittadi; S. Gilberti; N. Locopo; G. Gasparini |
Endogenous interleukin-12: relationship with angiogenic factors, hormone receptors and nodal status in human breast carcinoma. |
Endogenous interleukin-12: relationship with angiogenic factors, hormone receptors and nodal status in human breast carcinoma. |
Endogenous interleukin-12: relationship with angiogenic factors, hormone receptors and nodal status in human breast carcinoma. |
International journal of oncology, 15, 6, 1169-1175 |
International journal of oncology, 15, 6, 1169-1175 |
International journal of oncology, 15, 6, 1169-1175 |
1999 |
有 |
英語 |
|
公開 |
| M. Toi; S. Ishigaki; T. Tominaga |
M. Toi; S. Ishigaki; T. Tominaga |
M. Toi; S. Ishigaki; T. Tominaga |
Metalloproteinases and tissue inhibitors of metalloproteinases |
Metalloproteinases and tissue inhibitors of metalloproteinases |
Metalloproteinases and tissue inhibitors of metalloproteinases |
Breast Cancer Research and Treatment, 52, 1-3, 113-124 |
Breast Cancer Research and Treatment, 52, 1-3, 113-124 |
Breast Cancer Research and Treatment, 52, 1-3, 113-124 |
1998 |
有 |
英語 |
|
公開 |
| S. Umemura; K. Komaki; S. Noguchi; E. Shiba; M. Toi; I. Kimijima; H. Itoh; Y.R. Osamura |
S. Umemura; K. Komaki; S. Noguchi; E. Shiba; M. Toi; I. Kimijima; H. Itoh; Y.R. Osamura |
S. Umemura; K. Komaki; S. Noguchi; E. Shiba; M. Toi; I. Kimijima; H. Itoh; Y.R. Osamura |
Prognostic factors for node-negative breast cancers: Results of a study program by the Japanese breast cancer society |
Prognostic factors for node-negative breast cancers: Results of a study program by the Japanese breast cancer society |
Prognostic factors for node-negative breast cancers: Results of a study program by the Japanese breast cancer society |
Breast Cancer, 5, 3, 243-249 |
Breast Cancer, 5, 3, 243-249 |
Breast Cancer, 5, 3, 243-249 |
1998 |
有 |
英語 |
|
公開 |
| Y. Lino; M. Toi |
Y. Lino; M. Toi |
Y. Lino; M. Toi |
Chemoendocrine therapy: Basic science and clinical aspects |
Chemoendocrine therapy: Basic science and clinical aspects |
Chemoendocrine therapy: Basic science and clinical aspects |
Breast Cancer, 5, 4, 344-346 |
Breast Cancer, 5, 4, 344-346 |
Breast Cancer, 5, 4, 344-346 |
1998 |
有 |
英語 |
|
公開 |
| M. Kitamura; M. Toi; K. Arai; Y. Iwasaki; H. Suzuki; K. Matsuo |
M. Kitamura; M. Toi; K. Arai; Y. Iwasaki; H. Suzuki; K. Matsuo |
M. Kitamura; M. Toi; K. Arai; Y. Iwasaki; H. Suzuki; K. Matsuo |
Concentrations of vascular endothelial growth factor in the sera of gastric cancer patients |
Concentrations of vascular endothelial growth factor in the sera of gastric cancer patients |
Concentrations of vascular endothelial growth factor in the sera of gastric cancer patients |
Oncology Reports, 5, 6, 1419-1424 |
Oncology Reports, 5, 6, 1419-1424 |
Oncology Reports, 5, 6, 1419-1424 |
1998 |
有 |
英語 |
|
公開 |
| A. Suzuki; M. Toi; Y. Yamamoto; S. Saji; M. Muta; T. Tominaga |
A. Suzuki; M. Toi; Y. Yamamoto; S. Saji; M. Muta; T. Tominaga |
A. Suzuki; M. Toi; Y. Yamamoto; S. Saji; M. Muta; T. Tominaga |
Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma |
Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma |
Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma |
Japanese Journal of Cancer Research, 89, 2, 221-227 |
Japanese Journal of Cancer Research, 89, 2, 221-227 |
Japanese Journal of Cancer Research, 89, 2, 221-227 |
1998 |
有 |
英語 |
|
公開 |
| M. Toi; T. Taniguchi; T. Ueno; M. Asano; N. Funata; K. Sekiguchi; H. Iwanari; T. Tominaga |
M. Toi; T. Taniguchi; T. Ueno; M. Asano; N. Funata; K. Sekiguchi; H. Iwanari; T. Tominaga |
M. Toi; T. Taniguchi; T. Ueno; M. Asano; N. Funata; K. Sekiguchi; H. Iwanari; T. Tominaga |
Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer |
Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer |
Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer |
Clinical Cancer Research, 4, 3, 659-664 |
Clinical Cancer Research, 4, 3, 659-664 |
Clinical Cancer Research, 4, 3, 659-664 |
1998 |
有 |
英語 |
|
公開 |
| G. Gasparini; M. Toi; P. Verderio; G. Ranieri; S. Dante; E. Bonoldi; P. Boracchi; M. Fanelli; T. Tominaga |
G. Gasparini; M. Toi; P. Verderio; G. Ranieri; S. Dante; E. Bonoldi; P. Boracchi; M. Fanelli; T. Tominaga |
G. Gasparini; M. Toi; P. Verderio; G. Ranieri; S. Dante; E. Bonoldi; P. Boracchi; M. Fanelli; T. Tominaga |
Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: Subanalysis in node-positive and node- negative patients |
Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: Subanalysis in node-positive and node- negative patients |
Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: Subanalysis in node-positive and node- negative patients |
International Journal of Oncology, 12, 5, 1117-1125 |
International Journal of Oncology, 12, 5, 1117-1125 |
International Journal of Oncology, 12, 5, 1117-1125 |
1998 |
有 |
英語 |
|
公開 |
| T. Kurizaki; M. Toi; T. Tominaga |
T. Kurizaki; M. Toi; T. Tominaga |
T. Kurizaki; M. Toi; T. Tominaga |
Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma |
Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma |
Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma |
Oncology Reports, 5, 3, 673-677 |
Oncology Reports, 5, 3, 673-677 |
Oncology Reports, 5, 3, 673-677 |
1998 |
有 |
英語 |
|
公開 |
| M. Toi |
M. Toi |
M. Toi |
Antiangiogenic therapy |
Antiangiogenic therapy |
Antiangiogenic therapy |
Gan to kagaku ryoho. Cancer & chemotherapy, 25, 13, 2003-2009 |
Gan to kagaku ryoho. Cancer & chemotherapy, 25, 13, 2003-2009 |
Gan to kagaku ryoho. Cancer & chemotherapy, 25, 13, 2003-2009 |
1998 |
有 |
英語 |
|
公開 |
| K. Tsuruta; M. Toi; M. Kondo; A. Okamoto |
K. Tsuruta; M. Toi; M. Kondo; A. Okamoto |
K. Tsuruta; M. Toi; M. Kondo; A. Okamoto |
Removal of primary tumor might alter the growth rate of metastatic tumor in hepatocellular carcinoma |
Removal of primary tumor might alter the growth rate of metastatic tumor in hepatocellular carcinoma |
Removal of primary tumor might alter the growth rate of metastatic tumor in hepatocellular carcinoma |
Cancer Journal, 10, 1, 53-55 |
Cancer Journal, 10, 1, 53-55 |
Cancer Journal, 10, 1, 53-55 |
1997 |
有 |
英語 |
|
公開 |
| M. Toi |
M. Toi |
M. Toi |
The increase of apoptosis and the decrease of proliferation by angiogenesis inhibitor in rat mammary tumors |
The increase of apoptosis and the decrease of proliferation by angiogenesis inhibitor in rat mammary tumors |
The increase of apoptosis and the decrease of proliferation by angiogenesis inhibitor in rat mammary tumors |
Oncology Reports, 4, 1, 111-114 |
Oncology Reports, 4, 1, 111-114 |
Oncology Reports, 4, 1, 111-114 |
1997 |
有 |
英語 |
|
公開 |
| M. Toi; S. Saji; A. Suzuki; Y. Yamamoto; T. Tominaga |
M. Toi; S. Saji; A. Suzuki; Y. Yamamoto; T. Tominaga |
M. Toi; S. Saji; A. Suzuki; Y. Yamamoto; T. Tominaga |
MDM2 in breast cancer |
MDM2 in breast cancer |
MDM2 in breast cancer |
Breast Cancer, 4, 4, 264-268 |
Breast Cancer, 4, 4, 264-268 |
Breast Cancer, 4, 4, 264-268 |
1997 |
有 |
英語 |
|
公開 |
| G. Gasparini; M. Toi; M. Gion; P. Verderio; R. Dittadi; M. Hanatani; I. Matsubara; O. Vinante; E. Bonoldi; P. Boracchi; C. Gatti; H. Suzuki; T. Tominaga |
G. Gasparini; M. Toi; M. Gion; P. Verderio; R. Dittadi; M. Hanatani; I. Matsubara; O. Vinante; E. Bonoldi; P. Boracchi; C. Gatti; H. Suzuki; T. Tominaga |
G. Gasparini; M. Toi; M. Gion; P. Verderio; R. Dittadi; M. Hanatani; I. Matsubara; O. Vinante; E. Bonoldi; P. Boracchi; C. Gatti; H. Suzuki; T. Tominaga |
Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma |
Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma |
Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma |
Journal of the National Cancer Institute, 89, 2, 139-147 |
Journal of the National Cancer Institute, 89, 2, 139-147 |
Journal of the National Cancer Institute, 89, 2, 139-147 |
1997 |
有 |
英語 |
|
公開 |
| T. Taniguchi; M. Kitamura; K. Arai; Y. Iwasaki; Y. Yamamoto; A. Igari; M. Toi |
T. Taniguchi; M. Kitamura; K. Arai; Y. Iwasaki; Y. Yamamoto; A. Igari; M. Toi |
T. Taniguchi; M. Kitamura; K. Arai; Y. Iwasaki; Y. Yamamoto; A. Igari; M. Toi |
Increase in the circulating level of hepatocyte growth factor in gastric cancer patients |
Increase in the circulating level of hepatocyte growth factor in gastric cancer patients |
Increase in the circulating level of hepatocyte growth factor in gastric cancer patients |
British Journal of Cancer, 75, 5, 673-677 |
British Journal of Cancer, 75, 5, 673-677 |
British Journal of Cancer, 75, 5, 673-677 |
1997 |
有 |
英語 |
|
公開 |
| M. Toi; S. Tanaka; M. Bando; K. Hayashi; T. Tominaga |
M. Toi; S. Tanaka; M. Bando; K. Hayashi; T. Tominaga |
M. Toi; S. Tanaka; M. Bando; K. Hayashi; T. Tominaga |
Outcome of surgical resection for chest wall recurrence in breast cancer patients |
Outcome of surgical resection for chest wall recurrence in breast cancer patients |
Outcome of surgical resection for chest wall recurrence in breast cancer patients |
Journal of Surgical Oncology, 64, 1, 23-26 |
Journal of Surgical Oncology, 64, 1, 23-26 |
Journal of Surgical Oncology, 64, 1, 23-26 |
1997 |
有 |
英語 |
|
公開 |
| M. Toi; M. Gion; E. Biganzoli; R. Dittadi; P. Boracchi; R. Miceli; S. Meli; K. Mori; T. Tominaga; G. Gasparini |
M. Toi; M. Gion; E. Biganzoli; R. Dittadi; P. Boracchi; R. Miceli; S. Meli; K. Mori; T. Tominaga; G. Gasparini |
M. Toi; M. Gion; E. Biganzoli; R. Dittadi; P. Boracchi; R. Miceli; S. Meli; K. Mori; T. Tominaga; G. Gasparini |
Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: Prognostic implications |
Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: Prognostic implications |
Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: Prognostic implications |
Angiogenesis, 1, 1, 71-83 |
Angiogenesis, 1, 1, 71-83 |
Angiogenesis, 1, 1, 71-83 |
1997 |
有 |
英語 |
|
公開 |
| M. Toi; S. Saji; T. Tominaga |
M. Toi; S. Saji; T. Tominaga |
M. Toi; S. Saji; T. Tominaga |
Novel target of biotherapy: Angiogenesis |
Novel target of biotherapy: Angiogenesis |
Novel target of biotherapy: Angiogenesis |
Biotherapy, 11, 6, 738-742 |
Biotherapy, 11, 6, 738-742 |
Biotherapy, 11, 6, 738-742 |
1997 |
有 |
英語 |
|
公開 |
| K. Abe; K. Suzuki; N. Kamata; Y. Yokoyama; T. Ushimi; T. Masumoto; M. Koike; M. Toi |
K. Abe; K. Suzuki; N. Kamata; Y. Yokoyama; T. Ushimi; T. Masumoto; M. Koike; M. Toi |
K. Abe; K. Suzuki; N. Kamata; Y. Yokoyama; T. Ushimi; T. Masumoto; M. Koike; M. Toi |
Case report ; pulmonary thromboembolism due to medroxyprogesterone acetate |
Case report ; pulmonary thromboembolism due to medroxyprogesterone acetate |
Case report ; pulmonary thromboembolism due to medroxyprogesterone acetate |
Japanese Journal of Clinical Radiology, 42, 6, 719-722 |
Japanese Journal of Clinical Radiology, 42, 6, 719-722 |
Japanese Journal of Clinical Radiology, 42, 6, 719-722 |
1997 |
有 |
英語 |
|
公開 |
| T. Narita; N. Kimura; C. Mitsuoka; M. Toi; M. Sato; N. Matsuura; K. Matsumoto; T. Nakamura; R. Kannagi |
T. Narita; N. Kimura; C. Mitsuoka; M. Toi; M. Sato; N. Matsuura; K. Matsumoto; T. Nakamura; R. Kannagi |
T. Narita; N. Kimura; C. Mitsuoka; M. Toi; M. Sato; N. Matsuura; K. Matsumoto; T. Nakamura; R. Kannagi |
Biological and clinical significance of hepatocyte growth factor in breast cancer |
Biological and clinical significance of hepatocyte growth factor in breast cancer |
Biological and clinical significance of hepatocyte growth factor in breast cancer |
International Journal of Oncology, 11, 6, 1305-1310 |
International Journal of Oncology, 11, 6, 1305-1310 |
International Journal of Oncology, 11, 6, 1305-1310 |
1997 |
有 |
英語 |
|
公開 |
| T. Narita; C. Mitsuoka; N. Kimura; M. Toi; T. Nakashio; K. Sekiguchi; H. Iwanari; R. Kannagi |
T. Narita; C. Mitsuoka; N. Kimura; M. Toi; T. Nakashio; K. Sekiguchi; H. Iwanari; R. Kannagi |
T. Narita; C. Mitsuoka; N. Kimura; M. Toi; T. Nakashio; K. Sekiguchi; H. Iwanari; R. Kannagi |
Increased concentration of hepatocyte growth factor in the sera of patients with gastrointestinal cancer |
Increased concentration of hepatocyte growth factor in the sera of patients with gastrointestinal cancer |
Increased concentration of hepatocyte growth factor in the sera of patients with gastrointestinal cancer |
Oncology Reports, 4, 6, 1239-1241 |
Oncology Reports, 4, 6, 1239-1241 |
Oncology Reports, 4, 6, 1239-1241 |
1997 |
有 |
英語 |
|
公開 |
| N. Nagaya; M. Toi; S. Sunahara; F. Kurimoto; T. Tominaga |
N. Nagaya; M. Toi; S. Sunahara; F. Kurimoto; T. Tominaga |
N. Nagaya; M. Toi; S. Sunahara; F. Kurimoto; T. Tominaga |
Determination of intratumoral estrone (E<sub>1</sub>) and estradiol (E<sub>2</sub>) in primary breast cancer tissues by sensitive HPLC-RIA |
Determination of intratumoral estrone (E<sub>1</sub>) and estradiol (E<sub>2</sub>) in primary breast cancer tissues by sensitive HPLC-RIA |
Determination of intratumoral estrone (E<sub>1</sub>) and estradiol (E<sub>2</sub>) in primary breast cancer tissues by sensitive HPLC-RIA |
Japanese Journal of Cancer and Chemotherapy, 24, 3, 329-336 |
Japanese Journal of Cancer and Chemotherapy, 24, 3, 329-336 |
Japanese Journal of Cancer and Chemotherapy, 24, 3, 329-336 |
1997 |
有 |
英語 |
|
公開 |
| M. Toi; S. Kondo; H. Suzuki; Y. Yamamoto; K. Inada; T. Imazawa; T. Taniguchi; T. Tominaga |
M. Toi; S. Kondo; H. Suzuki; Y. Yamamoto; K. Inada; T. Imazawa; T. Taniguchi; T. Tominaga |
M. Toi; S. Kondo; H. Suzuki; Y. Yamamoto; K. Inada; T. Imazawa; T. Taniguchi; T. Tominaga |
Quantitative analysis of vascular endothelial growth factor in primary breast cancer |
Quantitative analysis of vascular endothelial growth factor in primary breast cancer |
Quantitative analysis of vascular endothelial growth factor in primary breast cancer |
Cancer, 77, 6, 1101-1106 |
Cancer, 77, 6, 1101-1106 |
Cancer, 77, 6, 1101-1106 |
1996 |
有 |
英語 |
|
公開 |
| K. Inada; T. Tominaga; M. Toi; Y. Yamamoto; M. Abe; J.-I. Yamashita; M. Ogawa |
K. Inada; T. Tominaga; M. Toi; Y. Yamamoto; M. Abe; J.-I. Yamashita; M. Ogawa |
K. Inada; T. Tominaga; M. Toi; Y. Yamamoto; M. Abe; J.-I. Yamashita; M. Ogawa |
Protective effect of leuprolide acetate on 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinogenesis in rats |
Protective effect of leuprolide acetate on 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinogenesis in rats |
Protective effect of leuprolide acetate on 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinogenesis in rats |
European Journal of Surgical Oncology, 22, 6, 583-587 |
European Journal of Surgical Oncology, 22, 6, 583-587 |
European Journal of Surgical Oncology, 22, 6, 583-587 |
1996 |
有 |
英語 |
|
公開 |
| M. Toi; T. Taniguchi; Y. Yamamoto; T. Kurisaki; H. Suzuki; T. Tominaga |
M. Toi; T. Taniguchi; Y. Yamamoto; T. Kurisaki; H. Suzuki; T. Tominaga |
M. Toi; T. Taniguchi; Y. Yamamoto; T. Kurisaki; H. Suzuki; T. Tominaga |
Clinical significance of the determination of angiogenic factors |
Clinical significance of the determination of angiogenic factors |
Clinical significance of the determination of angiogenic factors |
European Journal of Cancer Part A, 32, 14, 2513-2519 |
European Journal of Cancer Part A, 32, 14, 2513-2519 |
European Journal of Cancer Part A, 32, 14, 2513-2519 |
1996 |
有 |
英語 |
|
公開 |
| P.E. Vermeulen; G. Gasparini; S.B. Fox; M. Toi; L. Martin; P. McCulloch; F. Pezzella; G. Viale; N. Weidner; A.L. Harris; L.Y. Dirix |
P.E. Vermeulen; G. Gasparini; S.B. Fox; M. Toi; L. Martin; P. McCulloch; F. Pezzella; G. Viale; N. Weidner; A.L. Harris; L.Y. Dirix |
P.E. Vermeulen; G. Gasparini; S.B. Fox; M. Toi; L. Martin; P. McCulloch; F. Pezzella; G. Viale; N. Weidner; A.L. Harris; L.Y. Dirix |
Quantification of angiogenesis in solid human tumours: An international consensus on the methodology and criteria of evaluation |
Quantification of angiogenesis in solid human tumours: An international consensus on the methodology and criteria of evaluation |
Quantification of angiogenesis in solid human tumours: An international consensus on the methodology and criteria of evaluation |
European Journal of Cancer Part A, 32, 14, 2474-2484 |
European Journal of Cancer Part A, 32, 14, 2474-2484 |
European Journal of Cancer Part A, 32, 14, 2474-2484 |
1996 |
有 |
英語 |
|
公開 |
| K. Umezawa; T. Taniguchi; M. Toi; T. Ohse; N. Tsutsumi; T. Yamamoto; T. Koyano; M. Ishizuka |
K. Umezawa; T. Taniguchi; M. Toi; T. Ohse; N. Tsutsumi; T. Yamamoto; T. Koyano; M. Ishizuka |
K. Umezawa; T. Taniguchi; M. Toi; T. Ohse; N. Tsutsumi; T. Yamamoto; T. Koyano; M. Ishizuka |
Growth inhibition of K-ras-expressing tumours by a new vinca alkaloid, conophylline, in nude mice |
Growth inhibition of K-ras-expressing tumours by a new vinca alkaloid, conophylline, in nude mice |
Growth inhibition of K-ras-expressing tumours by a new vinca alkaloid, conophylline, in nude mice |
Drugs under Experimental and Clinical Research, 22, 2, 35-40 |
Drugs under Experimental and Clinical Research, 22, 2, 35-40 |
Drugs under Experimental and Clinical Research, 22, 2, 35-40 |
1996 |
有 |
英語 |
|
公開 |
| Y. Yamamoto; M. Toi; T. Tominaga |
Y. Yamamoto; M. Toi; T. Tominaga |
Y. Yamamoto; M. Toi; T. Tominaga |
Prediction of the effect of 5\\'-deoxy-5-fluorouridine by the status of angiogenic enzyme thymidine phosphorylase expression in recurrent breast cancer patients |
Prediction of the effect of 5\\'-deoxy-5-fluorouridine by the status of angiogenic enzyme thymidine phosphorylase expression in recurrent breast cancer patients |
Prediction of the effect of 5\\'-deoxy-5-fluorouridine by the status of angiogenic enzyme thymidine phosphorylase expression in recurrent breast cancer patients |
Oncology Reports, 3, 5, 863-865 |
Oncology Reports, 3, 5, 863-865 |
Oncology Reports, 3, 5, 863-865 |
1996 |
有 |
英語 |
|
公開 |
| T. Tominaga; M. Toi; Y. Yamamoto |
T. Tominaga; M. Toi; Y. Yamamoto |
T. Tominaga; M. Toi; Y. Yamamoto |
Tumor angiogenesis as a key prognostic factor in breast cancer |
Tumor angiogenesis as a key prognostic factor in breast cancer |
Tumor angiogenesis as a key prognostic factor in breast cancer |
Biotherapy, 10, 7, 958-962 |
Biotherapy, 10, 7, 958-962 |
Biotherapy, 10, 7, 958-962 |
1996 |
有 |
英語 |
|
公開 |
| M. Toi; T. Tominaga |
M. Toi; T. Tominaga |
M. Toi; T. Tominaga |
Breast cancer angiogenesis |
Breast cancer angiogenesis |
Breast cancer angiogenesis |
Japanese Journal of Cancer and Chemotherapy, 23, 6, 659-666 |
Japanese Journal of Cancer and Chemotherapy, 23, 6, 659-666 |
Japanese Journal of Cancer and Chemotherapy, 23, 6, 659-666 |
1996 |
有 |
英語 |
|
公開 |
| S. Saji; M. Toi; T. Tominaga |
S. Saji; M. Toi; T. Tominaga |
S. Saji; M. Toi; T. Tominaga |
The importance of tumor angiogenesis as a prognostic indicator in primary breast cancer |
The importance of tumor angiogenesis as a prognostic indicator in primary breast cancer |
The importance of tumor angiogenesis as a prognostic indicator in primary breast cancer |
Nippon Geka Gakkai zasshi, 97, 5, 368-374 |
Nippon Geka Gakkai zasshi, 97, 5, 368-374 |
Nippon Geka Gakkai zasshi, 97, 5, 368-374 |
1996 |
有 |
英語 |
|
公開 |
| M. Toi; Y. Yamamoto; T. Taniguchi; S. Saji; K. Hayashi; T. Tominaga |
M. Toi; Y. Yamamoto; T. Taniguchi; S. Saji; K. Hayashi; T. Tominaga |
M. Toi; Y. Yamamoto; T. Taniguchi; S. Saji; K. Hayashi; T. Tominaga |
Regulation of endothelial growth factor expressions in breast cancer. |
Regulation of endothelial growth factor expressions in breast cancer. |
Regulation of endothelial growth factor expressions in breast cancer. |
Gan to kagaku ryoho. Cancer & chemotherapy, 23 Suppl 1, 75-79 |
Gan to kagaku ryoho. Cancer & chemotherapy, 23 Suppl 1, 75-79 |
Gan to kagaku ryoho. Cancer & chemotherapy, 23 Suppl 1, 75-79 |
1996 |
有 |
英語 |
|
公開 |
| Y. Yamamoto; M. Toi; S. Kondo; T. Matsumoto; H. Suzuki; M. Kitamura; K. Tsuruta; T. Taniguchi; A. Okamoto; T. Mori; M. Yoshida; T. Ikeda; T. Tominaga |
Y. Yamamoto; M. Toi; S. Kondo; T. Matsumoto; H. Suzuki; M. Kitamura; K. Tsuruta; T. Taniguchi; A. Okamoto; T. Mori; M. Yoshida; T. Ikeda; T. Tominaga |
Y. Yamamoto; M. Toi; S. Kondo; T. Matsumoto; H. Suzuki; M. Kitamura; K. Tsuruta; T. Taniguchi; A. Okamoto; T. Mori; M. Yoshida; T. Ikeda; T. Tominaga |
Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients |
Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients |
Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients |
Clinical Cancer Research, 2, 5, 821-826 |
Clinical Cancer Research, 2, 5, 821-826 |
Clinical Cancer Research, 2, 5, 821-826 |
1996 |
有 |
英語 |
|
公開 |
| M. Toi; S. Hoshina; T. Taniguchi; Y. Yamamoto; H. ishitsuka; T. Tominaga |
M. Toi; S. Hoshina; T. Taniguchi; Y. Yamamoto; H. ishitsuka; T. Tominaga |
M. Toi; S. Hoshina; T. Taniguchi; Y. Yamamoto; H. ishitsuka; T. Tominaga |
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer |
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer |
Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer |
International Journal of Cancer, 64, 2, 79-82 |
International Journal of Cancer, 64, 2, 79-82 |
International Journal of Cancer, 64, 2, 79-82 |
1995 |
有 |
英語 |
|
公開 |
| M. Toi; K. Inada; H. Suzuki; T. Tominaga |
M. Toi; K. Inada; H. Suzuki; T. Tominaga |
M. Toi; K. Inada; H. Suzuki; T. Tominaga |
Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression |
Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression |
Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression |
Breast Cancer Research and Treatment, 36, 2, 193-204 |
Breast Cancer Research and Treatment, 36, 2, 193-204 |
Breast Cancer Research and Treatment, 36, 2, 193-204 |
1995 |
有 |
英語 |
|
公開 |
| M. Toi; T. Taniguchi; K. Hayashi; T. Tominaga |
M. Toi; T. Taniguchi; K. Hayashi; T. Tominaga |
M. Toi; T. Taniguchi; K. Hayashi; T. Tominaga |
The effect of combination treatment consisted of 5\\'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patients |
The effect of combination treatment consisted of 5\\'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patients |
The effect of combination treatment consisted of 5\\'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patients |
Japanese Journal of Cancer and Chemotherapy, 22, 6, 799-804 |
Japanese Journal of Cancer and Chemotherapy, 22, 6, 799-804 |
Japanese Journal of Cancer and Chemotherapy, 22, 6, 799-804 |
1995 |
有 |
英語 |
|
公開 |
| Y. Yamamoto; M. Toi; R. Yamada; T. Tominaga |
Y. Yamamoto; M. Toi; R. Yamada; T. Tominaga |
Y. Yamamoto; M. Toi; R. Yamada; T. Tominaga |
Combination effect of an angiogenesis inhibitor AGM-1470 with 5\\'-deoxy-5-fluorouridine, and with hormonal drugs in DMBA-induced rat mammary tumors |
Combination effect of an angiogenesis inhibitor AGM-1470 with 5\\'-deoxy-5-fluorouridine, and with hormonal drugs in DMBA-induced rat mammary tumors |
Combination effect of an angiogenesis inhibitor AGM-1470 with 5\\'-deoxy-5-fluorouridine, and with hormonal drugs in DMBA-induced rat mammary tumors |
Oncology Reports, 2, 5, 793-796 |
Oncology Reports, 2, 5, 793-796 |
Oncology Reports, 2, 5, 793-796 |
1995 |
有 |
英語 |
|
公開 |
| M. Toi; K. Inada; S. Hoshina; H. Suzuki; S. Kondo; T. Tominaga |
M. Toi; K. Inada; S. Hoshina; H. Suzuki; S. Kondo; T. Tominaga |
M. Toi; K. Inada; S. Hoshina; H. Suzuki; S. Kondo; T. Tominaga |
Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer |
Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer |
Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer |
Clinical Cancer Research, 1, 9, 961-964 |
Clinical Cancer Research, 1, 9, 961-964 |
Clinical Cancer Research, 1, 9, 961-964 |
1995 |
有 |
英語 |
|
公開 |
| T. Taniguchi; M. Toi; K. Inada; T. Imazawa; Y. Yamamoto; T. Tominaga |
T. Taniguchi; M. Toi; K. Inada; T. Imazawa; Y. Yamamoto; T. Tominaga |
T. Taniguchi; M. Toi; K. Inada; T. Imazawa; Y. Yamamoto; T. Tominaga |
Serum concentrations of hepatocyte growth factor in breast cancer patients |
Serum concentrations of hepatocyte growth factor in breast cancer patients |
Serum concentrations of hepatocyte growth factor in breast cancer patients |
Clinical Cancer Research, 1, 9, 1031-1034 |
Clinical Cancer Research, 1, 9, 1031-1034 |
Clinical Cancer Research, 1, 9, 1031-1034 |
1995 |
有 |
英語 |
|
公開 |
| M. Toi |
M. Toi |
M. Toi |
Endothelial growth factors: A target for antiangiogenesis |
Endothelial growth factors: A target for antiangiogenesis |
Endothelial growth factors: A target for antiangiogenesis |
Cancer Journal, 8, 6, 315-319 |
Cancer Journal, 8, 6, 315-319 |
Cancer Journal, 8, 6, 315-319 |
1995 |
有 |
英語 |
|
公開 |
| M. Toi; T. Tominaga; A. Osaki; T. Toge |
M. Toi; T. Tominaga; A. Osaki; T. Toge |
M. Toi; T. Tominaga; A. Osaki; T. Toge |
Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study |
Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study |
Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study |
Breast Cancer Research and Treatment, 29, 1, 51-58 |
Breast Cancer Research and Treatment, 29, 1, 51-58 |
Breast Cancer Research and Treatment, 29, 1, 51-58 |
1994 |
有 |
英語 |
|
公開 |
| T. Taniguchi; M. Toi; T. Tominaga |
T. Taniguchi; M. Toi; T. Tominaga |
T. Taniguchi; M. Toi; T. Tominaga |
Increase in the circulating level of hepatocyte growth factor in breast cancer patients with distant metastases |
Increase in the circulating level of hepatocyte growth factor in breast cancer patients with distant metastases |
Increase in the circulating level of hepatocyte growth factor in breast cancer patients with distant metastases |
Oncology Reports, 1, 6, 1199-1201 |
Oncology Reports, 1, 6, 1199-1201 |
Oncology Reports, 1, 6, 1199-1201 |
1994 |
有 |
英語 |
|
公開 |
| M. Kitamura; K. Takahashi; T. Tominaga; M. Toi |
M. Kitamura; K. Takahashi; T. Tominaga; M. Toi |
M. Kitamura; K. Takahashi; T. Tominaga; M. Toi |
Preventive effect of whole peptidoglycan (WPG) on the occurrence of rat mammary tumors induced by 7,12-dimethylbenz(a)anthracene (DMBA) |
Preventive effect of whole peptidoglycan (WPG) on the occurrence of rat mammary tumors induced by 7,12-dimethylbenz(a)anthracene (DMBA) |
Preventive effect of whole peptidoglycan (WPG) on the occurrence of rat mammary tumors induced by 7,12-dimethylbenz(a)anthracene (DMBA) |
Oncology Reports, 1, 2, 309-312 |
Oncology Reports, 1, 2, 309-312 |
Oncology Reports, 1, 2, 309-312 |
1994 |
有 |
英語 |
|
公開 |
| M. Toi; T. Takayanagi; R. Souma; T. Tominaga |
M. Toi; T. Takayanagi; R. Souma; T. Tominaga |
M. Toi; T. Takayanagi; R. Souma; T. Tominaga |
Inhibition of vascular endothelial growth factor induced cell growth by an angiogenesis inhibitor AGM-1470 in capillary endothelial cells |
Inhibition of vascular endothelial growth factor induced cell growth by an angiogenesis inhibitor AGM-1470 in capillary endothelial cells |
Inhibition of vascular endothelial growth factor induced cell growth by an angiogenesis inhibitor AGM-1470 in capillary endothelial cells |
Oncology Reports, 1, 2, 423-426 |
Oncology Reports, 1, 2, 423-426 |
Oncology Reports, 1, 2, 423-426 |
1994 |
有 |
英語 |
|
公開 |
| M. Toi; K. Hayashi; T. Tominaga |
M. Toi; K. Hayashi; T. Tominaga |
M. Toi; K. Hayashi; T. Tominaga |
Feasibility of adjuvant high-dose CAF (cyclophosphamide, adriamycin, 5-FU) therapy for primary breast cancer patients |
Feasibility of adjuvant high-dose CAF (cyclophosphamide, adriamycin, 5-FU) therapy for primary breast cancer patients |
Feasibility of adjuvant high-dose CAF (cyclophosphamide, adriamycin, 5-FU) therapy for primary breast cancer patients |
Japanese Journal of Cancer and Chemotherapy, 21, 12, 2057-2060 |
Japanese Journal of Cancer and Chemotherapy, 21, 12, 2057-2060 |
Japanese Journal of Cancer and Chemotherapy, 21, 12, 2057-2060 |
1994 |
有 |
英語 |
|
公開 |
| T. Taniguchi; M. Toi; T. Tominaga |
T. Taniguchi; M. Toi; T. Tominaga |
T. Taniguchi; M. Toi; T. Tominaga |
Rapid induction of hepatocyte growth factor by heparin [3] |
Rapid induction of hepatocyte growth factor by heparin [3] |
Rapid induction of hepatocyte growth factor by heparin [3] |
Lancet, 344, 8920, 470- |
Lancet, 344, 8920, 470- |
Lancet, 344, 8920, 470- |
1994 |
有 |
英語 |
|
公開 |
| M. Toi; S. Hoshima; T. Takayanagi; T. Tominaga |
M. Toi; S. Hoshima; T. Takayanagi; T. Tominaga |
M. Toi; S. Hoshima; T. Takayanagi; T. Tominaga |
Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer |
Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer |
Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer |
Japanese Journal of Cancer Research, 85, 10, 1045-1049 |
Japanese Journal of Cancer Research, 85, 10, 1045-1049 |
Japanese Journal of Cancer Research, 85, 10, 1045-1049 |
1994 |
有 |
英語 |
|
公開 |
| K. Inada; M. Toi; T. Imazawa; S. Hoshina; K. Hayashi; T. Tominaga |
K. Inada; M. Toi; T. Imazawa; S. Hoshina; K. Hayashi; T. Tominaga |
K. Inada; M. Toi; T. Imazawa; S. Hoshina; K. Hayashi; T. Tominaga |
Significance of overexpression of p53 protein in human breast cancer |
Significance of overexpression of p53 protein in human breast cancer |
Significance of overexpression of p53 protein in human breast cancer |
Japanese Journal of Cancer and Chemotherapy, 21, 6, 817-821 |
Japanese Journal of Cancer and Chemotherapy, 21, 6, 817-821 |
Japanese Journal of Cancer and Chemotherapy, 21, 6, 817-821 |
1994 |
有 |
英語 |
|
公開 |
| M. Toi; S. Hoshina; Y. Yamamoto; T. Ishii; K. Hayashi; T. Tominaga |
M. Toi; S. Hoshina; Y. Yamamoto; T. Ishii; K. Hayashi; T. Tominaga |
M. Toi; S. Hoshina; Y. Yamamoto; T. Ishii; K. Hayashi; T. Tominaga |
Tumor angiogenesis in breast cancer: significance of vessel density as a prognostic indicator |
Tumor angiogenesis in breast cancer: significance of vessel density as a prognostic indicator |
Tumor angiogenesis in breast cancer: significance of vessel density as a prognostic indicator |
Japanese Journal of Cancer and Chemotherapy, 21 Suppl 2, 178-182 |
Japanese Journal of Cancer and Chemotherapy, 21 Suppl 2, 178-182 |
Japanese Journal of Cancer and Chemotherapy, 21 Suppl 2, 178-182 |
1994 |
有 |
英語 |
|
公開 |
| T. Oikawa; H. Ito; H. Ashino; M. Toi; T. Tominaga; I. Morita; S.-i. Murota |
T. Oikawa; H. Ito; H. Ashino; M. Toi; T. Tominaga; I. Morita; S.-i. Murota |
T. Oikawa; H. Ito; H. Ashino; M. Toi; T. Tominaga; I. Morita; S.-i. Murota |
Radicol, a microbial cell differentiation modulator, inhibits in vivo angiogenesis |
Radicol, a microbial cell differentiation modulator, inhibits in vivo angiogenesis |
Radicol, a microbial cell differentiation modulator, inhibits in vivo angiogenesis |
European Journal of Pharmacology, 241, 2-3, 221-227 |
European Journal of Pharmacology, 241, 2-3, 221-227 |
European Journal of Pharmacology, 241, 2-3, 221-227 |
1993 |
有 |
英語 |
|
公開 |
| M. Toi; J. Kashitani; T. Tominaga |
M. Toi; J. Kashitani; T. Tominaga |
M. Toi; J. Kashitani; T. Tominaga |
Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma |
Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma |
Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma |
International Journal of Cancer, 55, 3, 371-374 |
International Journal of Cancer, 55, 3, 371-374 |
International Journal of Cancer, 55, 3, 371-374 |
1993 |
有 |
英語 |
|
公開 |
| M. Toi; A.L. Harris; R. Bicknell |
M. Toi; A.L. Harris; R. Bicknell |
M. Toi; A.L. Harris; R. Bicknell |
cDNA transfection followed by the isolation of a MCF-7 breast cell line resistant to tamoxifen in vitro and in vivo |
cDNA transfection followed by the isolation of a MCF-7 breast cell line resistant to tamoxifen in vitro and in vivo |
cDNA transfection followed by the isolation of a MCF-7 breast cell line resistant to tamoxifen in vitro and in vivo |
British Journal of Cancer, 68, 6, 1088-1096 |
British Journal of Cancer, 68, 6, 1088-1096 |
British Journal of Cancer, 68, 6, 1088-1096 |
1993 |
有 |
英語 |
|
公開 |
| K. Kuroi; A. Osaki; H. Yamada; M. Toi; T. Toge; Y. Takimoto; A. Kuramoto; K. Arihiro; K. Inai |
K. Kuroi; A. Osaki; H. Yamada; M. Toi; T. Toge; Y. Takimoto; A. Kuramoto; K. Arihiro; K. Inai |
K. Kuroi; A. Osaki; H. Yamada; M. Toi; T. Toge; Y. Takimoto; A. Kuramoto; K. Arihiro; K. Inai |
Primary squamous cell carcinoma of the breast after cured Hodgkin\\'s disease |
Primary squamous cell carcinoma of the breast after cured Hodgkin\\'s disease |
Primary squamous cell carcinoma of the breast after cured Hodgkin\\'s disease |
Surgery Today, 23, 1, 81-84 |
Surgery Today, 23, 1, 81-84 |
Surgery Today, 23, 1, 81-84 |
1993 |
有 |
英語 |
|
公開 |
| M. Toi; Y. Yamamoto; T. Imazawa; T. Takayanagi; K. Akutsu; T. Tominaga |
M. Toi; Y. Yamamoto; T. Imazawa; T. Takayanagi; K. Akutsu; T. Tominaga |
M. Toi; Y. Yamamoto; T. Imazawa; T. Takayanagi; K. Akutsu; T. Tominaga |
Antitumor effect of the angiogenesis inhibitor AGM-1470 and its combination effect with tamoxifen in DMBA induced mammary tumors in rats |
Antitumor effect of the angiogenesis inhibitor AGM-1470 and its combination effect with tamoxifen in DMBA induced mammary tumors in rats |
Antitumor effect of the angiogenesis inhibitor AGM-1470 and its combination effect with tamoxifen in DMBA induced mammary tumors in rats |
International Journal of Oncology, 3, 3, 525-528 |
International Journal of Oncology, 3, 3, 525-528 |
International Journal of Oncology, 3, 3, 525-528 |
1993 |
有 |
英語 |
|
公開 |
| T. Tominaga; M. Toi; T. Shirasaka |
T. Tominaga; M. Toi; T. Shirasaka |
T. Tominaga; M. Toi; T. Shirasaka |
Enhanced inhibition of thymidylate synthase by 5-fluorouracil and [6S] leucovorin combination therapy for breast cancer |
Enhanced inhibition of thymidylate synthase by 5-fluorouracil and [6S] leucovorin combination therapy for breast cancer |
Enhanced inhibition of thymidylate synthase by 5-fluorouracil and [6S] leucovorin combination therapy for breast cancer |
Anticancer Research, 13, 6 B, 2425-2427 |
Anticancer Research, 13, 6 B, 2425-2427 |
Anticancer Research, 13, 6 B, 2425-2427 |
1993 |
有 |
英語 |
|
公開 |
| M. Toi; T. Hattori; M. Akagi; K. Inokuchi; K. Orita; K. Sugimachi; K. Dohi; Y. Nomura; Y. Monden; Y. Hamada; T. Morimoto; N. Ogawa |
M. Toi; T. Hattori; M. Akagi; K. Inokuchi; K. Orita; K. Sugimachi; K. Dohi; Y. Nomura; Y. Monden; Y. Hamada; T. Morimoto; N. Ogawa |
M. Toi; T. Hattori; M. Akagi; K. Inokuchi; K. Orita; K. Sugimachi; K. Dohi; Y. Nomura; Y. Monden; Y. Hamada; T. Morimoto; N. Ogawa |
Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer: 5-year results from the Nishi-Nippon group of the adjuvant chemoendocrine therapy for breast cancer organization |
Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer: 5-year results from the Nishi-Nippon group of the adjuvant chemoendocrine therapy for breast cancer organization |
Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer: 5-year results from the Nishi-Nippon group of the adjuvant chemoendocrine therapy for breast cancer organization |
Cancer, 70, 10, 2475-2483 |
Cancer, 70, 10, 2475-2483 |
Cancer, 70, 10, 2475-2483 |
1992 |
有 |
英語 |
|
公開 |
| A. Osaki; M. Toi; H. Yamada; H. Kawami; K. Kuroi; T. Toge |
A. Osaki; M. Toi; H. Yamada; H. Kawami; K. Kuroi; T. Toge |
A. Osaki; M. Toi; H. Yamada; H. Kawami; K. Kuroi; T. Toge |
Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients |
Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients |
Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients |
The American Journal of Surgery, 164, 4, 323-326 |
The American Journal of Surgery, 164, 4, 323-326 |
The American Journal of Surgery, 164, 4, 323-326 |
1992 |
有 |
英語 |
|
公開 |
| M. Toi; R. Bicknell; A.L. Harris |
M. Toi; R. Bicknell; A.L. Harris |
M. Toi; R. Bicknell; A.L. Harris |
Inhibition of colon and breast carcinoma cell growth by interleukin-4 |
Inhibition of colon and breast carcinoma cell growth by interleukin-4 |
Inhibition of colon and breast carcinoma cell growth by interleukin-4 |
Cancer Research, 52, 2, 275-279 |
Cancer Research, 52, 2, 275-279 |
Cancer Research, 52, 2, 275-279 |
1992 |
有 |
英語 |
|
公開 |
| M. Toi; A. Osaki; H. Yamada; T. Toge |
M. Toi; A. Osaki; H. Yamada; T. Toge |
M. Toi; A. Osaki; H. Yamada; T. Toge |
Epidermal growth factor receptor expression as a prognostic indicator in breast cancer |
Epidermal growth factor receptor expression as a prognostic indicator in breast cancer |
Epidermal growth factor receptor expression as a prognostic indicator in breast cancer |
European Journal of Cancer and Clinical Oncology, 27, 8, 977-980 |
European Journal of Cancer and Clinical Oncology, 27, 8, 977-980 |
European Journal of Cancer and Clinical Oncology, 27, 8, 977-980 |
1991 |
有 |
英語 |
|
公開 |
| M. Toi; A.L. Harris; R. Bicknell |
M. Toi; A.L. Harris; R. Bicknell |
M. Toi; A.L. Harris; R. Bicknell |
Interleukin-4 is a potent mitogen for capillary endothelium |
Interleukin-4 is a potent mitogen for capillary endothelium |
Interleukin-4 is a potent mitogen for capillary endothelium |
Biochemical and Biophysical Research Communications, 174, 3, 1287-1293 |
Biochemical and Biophysical Research Communications, 174, 3, 1287-1293 |
Biochemical and Biophysical Research Communications, 174, 3, 1287-1293 |
1991 |
有 |
英語 |
|
公開 |
| H. Mukaida; M. Toi; T. Hirai; Y. Yamashita; T. Toge |
H. Mukaida; M. Toi; T. Hirai; Y. Yamashita; T. Toge |
H. Mukaida; M. Toi; T. Hirai; Y. Yamashita; T. Toge |
Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer |
Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer |
Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer |
Cancer, 68, 1, 142-148 |
Cancer, 68, 1, 142-148 |
Cancer, 68, 1, 142-148 |
1991 |
有 |
英語 |
|
公開 |
| K. Yoshinaka; M. Yagi; S. Ohtagaki; M. Toi; T. Toge |
K. Yoshinaka; M. Yagi; S. Ohtagaki; M. Toi; T. Toge |
K. Yoshinaka; M. Yagi; S. Ohtagaki; M. Toi; T. Toge |
5\\'-deoxy-5-fluorouridine (5\\'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer |
5\\'-deoxy-5-fluorouridine (5\\'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer |
5\\'-deoxy-5-fluorouridine (5\\'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer |
Japanese Journal of Cancer and Chemotherapy, 18, 1, 115-118 |
Japanese Journal of Cancer and Chemotherapy, 18, 1, 115-118 |
Japanese Journal of Cancer and Chemotherapy, 18, 1, 115-118 |
1991 |
有 |
英語 |
|
公開 |
| K. Umezaza; M. Toi |
K. Umezaza; M. Toi |
K. Umezaza; M. Toi |
Inhibitors of growth factor functions, possible antineoplastic agents |
Inhibitors of growth factor functions, possible antineoplastic agents |
Inhibitors of growth factor functions, possible antineoplastic agents |
Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 36, 7, 1429-1435 |
Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 36, 7, 1429-1435 |
Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 36, 7, 1429-1435 |
1991 |
有 |
英語 |
|
公開 |
| H. Mukaida; T. Yamamoto; T. Hirai; M. Toi; T. Nakamura; T. Wada; Y. Yamashita; K. Kawano; M. Niimoto |
H. Mukaida; T. Yamamoto; T. Hirai; M. Toi; T. Nakamura; T. Wada; Y. Yamashita; K. Kawano; M. Niimoto |
H. Mukaida; T. Yamamoto; T. Hirai; M. Toi; T. Nakamura; T. Wada; Y. Yamashita; K. Kawano; M. Niimoto |
Expression of human epidermal growth factor and its receptor in esophageal cancer |
Expression of human epidermal growth factor and its receptor in esophageal cancer |
Expression of human epidermal growth factor and its receptor in esophageal cancer |
The Japanese Journal of Surgery, 20, 3, 275-282 |
The Japanese Journal of Surgery, 20, 3, 275-282 |
The Japanese Journal of Surgery, 20, 3, 275-282 |
1990 |
有 |
英語 |
|
公開 |
| M. Toi; T. Wada; H. Yamada; A. Ohsaki; A. Yamamoto; T. Nakamura; M. Nimoto; T. Hattori |
M. Toi; T. Wada; H. Yamada; A. Ohsaki; A. Yamamoto; T. Nakamura; M. Nimoto; T. Hattori |
M. Toi; T. Wada; H. Yamada; A. Ohsaki; A. Yamamoto; T. Nakamura; M. Nimoto; T. Hattori |
Growth fractions of breast cancer in relation to epidermal growth factor receptor and estrogen receptor |
Growth fractions of breast cancer in relation to epidermal growth factor receptor and estrogen receptor |
Growth fractions of breast cancer in relation to epidermal growth factor receptor and estrogen receptor |
The Japanese Journal of Surgery, 20, 3, 327-330 |
The Japanese Journal of Surgery, 20, 3, 327-330 |
The Japanese Journal of Surgery, 20, 3, 327-330 |
1990 |
有 |
英語 |
|
公開 |
| M. Niimoto; T. Saeki; M. Toi; M. Nishiyama; T. Hirai; E. Yanagawa; T. Hattori |
M. Niimoto; T. Saeki; M. Toi; M. Nishiyama; T. Hirai; E. Yanagawa; T. Hattori |
M. Niimoto; T. Saeki; M. Toi; M. Nishiyama; T. Hirai; E. Yanagawa; T. Hattori |
Prospective randomized controlled study on bestatin in resectable gastric cancer -Third report- |
Prospective randomized controlled study on bestatin in resectable gastric cancer -Third report- |
Prospective randomized controlled study on bestatin in resectable gastric cancer -Third report- |
The Japanese Journal of Surgery, 20, 2, 186-191 |
The Japanese Journal of Surgery, 20, 2, 186-191 |
The Japanese Journal of Surgery, 20, 2, 186-191 |
1990 |
有 |
英語 |
|
公開 |
| M. Toi; H. Mukaida; T. Wada; N. Hirabayashi; T. Toge; T. Hori; K. Umezawa |
M. Toi; H. Mukaida; T. Wada; N. Hirabayashi; T. Toge; T. Hori; K. Umezawa |
M. Toi; H. Mukaida; T. Wada; N. Hirabayashi; T. Toge; T. Hori; K. Umezawa |
Antineoplastic effect of erbstatin on human mammary and esophageal tumors in athymic nude mice |
Antineoplastic effect of erbstatin on human mammary and esophageal tumors in athymic nude mice |
Antineoplastic effect of erbstatin on human mammary and esophageal tumors in athymic nude mice |
European Journal of Cancer and Clinical Oncology, 26, 6, 722-724 |
European Journal of Cancer and Clinical Oncology, 26, 6, 722-724 |
European Journal of Cancer and Clinical Oncology, 26, 6, 722-724 |
1990 |
有 |
英語 |
|
公開 |
| M. Toi; T. Nakamura; H. Mukaida; T. Wada; A. Osaki; H. Yamada; T. Toge; M. Niimoto; T. Hattori |
M. Toi; T. Nakamura; H. Mukaida; T. Wada; A. Osaki; H. Yamada; T. Toge; M. Niimoto; T. Hattori |
M. Toi; T. Nakamura; H. Mukaida; T. Wada; A. Osaki; H. Yamada; T. Toge; M. Niimoto; T. Hattori |
Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer |
Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer |
Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer |
Cancer, 65, 9, 1980-1984 |
Cancer, 65, 9, 1980-1984 |
Cancer, 65, 9, 1980-1984 |
1990 |
有 |
英語 |
|
公開 |
| S.-i. Suehiro; Y. Hamada; M. Toi; T. Nakamura; M. Niimoto; T. Hattori |
S.-i. Suehiro; Y. Hamada; M. Toi; T. Nakamura; M. Niimoto; T. Hattori |
S.-i. Suehiro; Y. Hamada; M. Toi; T. Nakamura; M. Niimoto; T. Hattori |
Nuclear DNA content in breast carcinoma with special reference to the parameters of malignant potentiality |
Nuclear DNA content in breast carcinoma with special reference to the parameters of malignant potentiality |
Nuclear DNA content in breast carcinoma with special reference to the parameters of malignant potentiality |
The Japanese Journal of Surgery, 20, 1, 115-118 |
The Japanese Journal of Surgery, 20, 1, 115-118 |
The Japanese Journal of Surgery, 20, 1, 115-118 |
1990 |
有 |
英語 |
|
公開 |
| E. Miyahara; M. Toi; T. Wada; H. Yamada; A. Osaki; E. Yanagawa; T. Toge |
E. Miyahara; M. Toi; T. Wada; H. Yamada; A. Osaki; E. Yanagawa; T. Toge |
E. Miyahara; M. Toi; T. Wada; H. Yamada; A. Osaki; E. Yanagawa; T. Toge |
The expression of NCC-ST-439, a tumor marker, in human breast cancer patients |
The expression of NCC-ST-439, a tumor marker, in human breast cancer patients |
The expression of NCC-ST-439, a tumor marker, in human breast cancer patients |
Gan no rinsho. Japan journal of cancer clinics, 36, 11, 2023-2026 |
Gan no rinsho. Japan journal of cancer clinics, 36, 11, 2023-2026 |
Gan no rinsho. Japan journal of cancer clinics, 36, 11, 2023-2026 |
1990 |
有 |
英語 |
|
公開 |
| M. Toi; Y. Hamada; T. Nakamura; H. Mukaida; S. Suehiro; T. Wada; T. Toge; M. Niimoto; T. Hattori |
M. Toi; Y. Hamada; T. Nakamura; H. Mukaida; S. Suehiro; T. Wada; T. Toge; M. Niimoto; T. Hattori |
M. Toi; Y. Hamada; T. Nakamura; H. Mukaida; S. Suehiro; T. Wada; T. Toge; M. Niimoto; T. Hattori |
Immunocytochemical and biochemical analysis of epidermal growth factor receptor expression in human breast cancer tissues: Relationship to estrogen receptor and lymphatic invasion |
Immunocytochemical and biochemical analysis of epidermal growth factor receptor expression in human breast cancer tissues: Relationship to estrogen receptor and lymphatic invasion |
Immunocytochemical and biochemical analysis of epidermal growth factor receptor expression in human breast cancer tissues: Relationship to estrogen receptor and lymphatic invasion |
International Journal of Cancer, 43, 2, 220-225 |
International Journal of Cancer, 43, 2, 220-225 |
International Journal of Cancer, 43, 2, 220-225 |
1989 |
有 |
英語 |
|
公開 |
| M. Toi; T. Nakamura; T. Wada; A. Yamamoto; T. Toge; M. Niimoto; T. Hattori |
M. Toi; T. Nakamura; T. Wada; A. Yamamoto; T. Toge; M. Niimoto; T. Hattori |
M. Toi; T. Nakamura; T. Wada; A. Yamamoto; T. Toge; M. Niimoto; T. Hattori |
The acceptable delay between biopsy and radical mastectomy in breast cancer patients |
The acceptable delay between biopsy and radical mastectomy in breast cancer patients |
The acceptable delay between biopsy and radical mastectomy in breast cancer patients |
The Japanese Journal of Surgery, 19, 6, 679-683 |
The Japanese Journal of Surgery, 19, 6, 679-683 |
The Japanese Journal of Surgery, 19, 6, 679-683 |
1989 |
有 |
英語 |
|
公開 |
| M. Toi; T. Nakamura; T. Wada; A. Yamamoto; T. Toge; M. Niimoto; T. Hattori |
M. Toi; T. Nakamura; T. Wada; A. Yamamoto; T. Toge; M. Niimoto; T. Hattori |
M. Toi; T. Nakamura; T. Wada; A. Yamamoto; T. Toge; M. Niimoto; T. Hattori |
The discrepancy between immunocytochemical and biochemical assay of estrogen receptor in breast cancer patients treated by endocrine therapy |
The discrepancy between immunocytochemical and biochemical assay of estrogen receptor in breast cancer patients treated by endocrine therapy |
The discrepancy between immunocytochemical and biochemical assay of estrogen receptor in breast cancer patients treated by endocrine therapy |
The Japanese Journal of Surgery, 19, 6, 768-772 |
The Japanese Journal of Surgery, 19, 6, 768-772 |
The Japanese Journal of Surgery, 19, 6, 768-772 |
1989 |
有 |
英語 |
|
公開 |
| T. Saeki; K. Jinushi; R. Kim; M. Toi; K. Saeki; K. Yoshinaka; E. Yanagawa; M. Niimoto; T. Hattori |
T. Saeki; K. Jinushi; R. Kim; M. Toi; K. Saeki; K. Yoshinaka; E. Yanagawa; M. Niimoto; T. Hattori |
T. Saeki; K. Jinushi; R. Kim; M. Toi; K. Saeki; K. Yoshinaka; E. Yanagawa; M. Niimoto; T. Hattori |
Combination chemotherapy of CPM-MTX-5-FU for non-resectable and recurrent cancer patients |
Combination chemotherapy of CPM-MTX-5-FU for non-resectable and recurrent cancer patients |
Combination chemotherapy of CPM-MTX-5-FU for non-resectable and recurrent cancer patients |
Japanese Journal of Cancer and Chemotherapy, 16, 4 I, 827-831 |
Japanese Journal of Cancer and Chemotherapy, 16, 4 I, 827-831 |
Japanese Journal of Cancer and Chemotherapy, 16, 4 I, 827-831 |
1989 |
有 |
英語 |
|
公開 |
| S. Suehiro; K. Inai; S. Tokuoka; Y. Hamada; M. Toi; M. Niimoto; T. Hattori |
S. Suehiro; K. Inai; S. Tokuoka; Y. Hamada; M. Toi; M. Niimoto; T. Hattori |
S. Suehiro; K. Inai; S. Tokuoka; Y. Hamada; M. Toi; M. Niimoto; T. Hattori |
Involvement of the nipple in early carcinoma of the breast |
Involvement of the nipple in early carcinoma of the breast |
Involvement of the nipple in early carcinoma of the breast |
Surgery Gynecology and Obstetrics, 168, 3, 244-248 |
Surgery Gynecology and Obstetrics, 168, 3, 244-248 |
Surgery Gynecology and Obstetrics, 168, 3, 244-248 |
1989 |
有 |
英語 |
|
公開 |
| M. Toi; Y. Hamada; Y. Seto; M. Tanimoto; T. Nakamura; T. Toge; M. Niimoto; T. Hattori |
M. Toi; Y. Hamada; Y. Seto; M. Tanimoto; T. Nakamura; T. Toge; M. Niimoto; T. Hattori |
M. Toi; Y. Hamada; Y. Seto; M. Tanimoto; T. Nakamura; T. Toge; M. Niimoto; T. Hattori |
Immunocytochemical study on the variation in estrogen receptors of primary and nodal metastases of breast cancer |
Immunocytochemical study on the variation in estrogen receptors of primary and nodal metastases of breast cancer |
Immunocytochemical study on the variation in estrogen receptors of primary and nodal metastases of breast cancer |
The Japanese Journal of Surgery, 18, 2, 228-231 |
The Japanese Journal of Surgery, 18, 2, 228-231 |
The Japanese Journal of Surgery, 18, 2, 228-231 |
1988 |
有 |
英語 |
|
公開 |
| Y. Nomura; H. Tashiro; K. Hisamatsu; M. Toi |
Y. Nomura; H. Tashiro; K. Hisamatsu; M. Toi |
Y. Nomura; H. Tashiro; K. Hisamatsu; M. Toi |
Effects of high-dose medroxyprogesterone acetate for advanced breast cancer with special reference to prior endocrine therapy and hormone receptors |
Effects of high-dose medroxyprogesterone acetate for advanced breast cancer with special reference to prior endocrine therapy and hormone receptors |
Effects of high-dose medroxyprogesterone acetate for advanced breast cancer with special reference to prior endocrine therapy and hormone receptors |
Japanese Journal of Cancer and Chemotherapy, 15, 3, 513-518 |
Japanese Journal of Cancer and Chemotherapy, 15, 3, 513-518 |
Japanese Journal of Cancer and Chemotherapy, 15, 3, 513-518 |
1988 |
有 |
英語 |
|
公開 |
| M. Toi |
M. Toi |
M. Toi |
Comparative study on estrogen receptor, epidermal growth factor and epidermal growth factor receptor using immunocytochemical and biochemical assays in breast cancer |
Comparative study on estrogen receptor, epidermal growth factor and epidermal growth factor receptor using immunocytochemical and biochemical assays in breast cancer |
Comparative study on estrogen receptor, epidermal growth factor and epidermal growth factor receptor using immunocytochemical and biochemical assays in breast cancer |
Nippon Geka Gakkai zasshi, 89, 5, 725-736 |
Nippon Geka Gakkai zasshi, 89, 5, 725-736 |
Nippon Geka Gakkai zasshi, 89, 5, 725-736 |
1988 |
有 |
英語 |
|
公開 |
| M. Toi; Y. Hamada; Y. Seto; K. Hisamatsu; S. Suehiro; T. Toge; M. Niimoto; T. Hattori |
M. Toi; Y. Hamada; Y. Seto; K. Hisamatsu; S. Suehiro; T. Toge; M. Niimoto; T. Hattori |
M. Toi; Y. Hamada; Y. Seto; K. Hisamatsu; S. Suehiro; T. Toge; M. Niimoto; T. Hattori |
Comparative study of estrogen receptor assays between immunocytochemical assay using monoclonal antibody and the dextran- coated charcoal method |
Comparative study of estrogen receptor assays between immunocytochemical assay using monoclonal antibody and the dextran- coated charcoal method |
Comparative study of estrogen receptor assays between immunocytochemical assay using monoclonal antibody and the dextran- coated charcoal method |
Gan to kagaku ryoho. Cancer & chemotherapy, 13, 10, 3056-3062 |
Gan to kagaku ryoho. Cancer & chemotherapy, 13, 10, 3056-3062 |
Gan to kagaku ryoho. Cancer & chemotherapy, 13, 10, 3056-3062 |
1986 |
有 |
英語 |
|
公開 |
| K. Hisamatsu; T. Toge; E. Yanagawa; Y. Hamada; Y. Seto; H. Yamada; M. Toi; T. Hattori |
K. Hisamatsu; T. Toge; E. Yanagawa; Y. Hamada; Y. Seto; H. Yamada; M. Toi; T. Hattori |
K. Hisamatsu; T. Toge; E. Yanagawa; Y. Hamada; Y. Seto; H. Yamada; M. Toi; T. Hattori |
Immune reactivities of lymphocytes from peripheral blood, regional lymph nodes and tumor-infiltrating lymphocytes in breast cancer patients |
Immune reactivities of lymphocytes from peripheral blood, regional lymph nodes and tumor-infiltrating lymphocytes in breast cancer patients |
Immune reactivities of lymphocytes from peripheral blood, regional lymph nodes and tumor-infiltrating lymphocytes in breast cancer patients |
Japanese Journal of Cancer and Chemotherapy, 13, 8, 2555-2561 |
Japanese Journal of Cancer and Chemotherapy, 13, 8, 2555-2561 |
Japanese Journal of Cancer and Chemotherapy, 13, 8, 2555-2561 |
1986 |
有 |
英語 |
|
公開 |
| M. Toi; T. Shiramizu; T. Yonemura; T. Ezaki; N. Oka; T. Yoshida; H. Tsurumaru |
M. Toi; T. Shiramizu; T. Yonemura; T. Ezaki; N. Oka; T. Yoshida; H. Tsurumaru |
M. Toi; T. Shiramizu; T. Yonemura; T. Ezaki; N. Oka; T. Yoshida; H. Tsurumaru |
Intraperitoneal cisplatin in peritoneal carcinomatosis patients |
Intraperitoneal cisplatin in peritoneal carcinomatosis patients |
Intraperitoneal cisplatin in peritoneal carcinomatosis patients |
Gan no rinsho. Japan journal of cancer clinics, 31, 5, 522-526 |
Gan no rinsho. Japan journal of cancer clinics, 31, 5, 522-526 |
Gan no rinsho. Japan journal of cancer clinics, 31, 5, 522-526 |
1985 |
有 |
英語 |
|
公開 |
| M. Toi; K. Matsuki; K. Nakagami; M. Hirono; M. Niimoto; T. Hattori |
M. Toi; K. Matsuki; K. Nakagami; M. Hirono; M. Niimoto; T. Hattori |
M. Toi; K. Matsuki; K. Nakagami; M. Hirono; M. Niimoto; T. Hattori |
A case of minute carcinoma associated with an atypical epithelial lesion of the stomach and histopathological analysis |
A case of minute carcinoma associated with an atypical epithelial lesion of the stomach and histopathological analysis |
A case of minute carcinoma associated with an atypical epithelial lesion of the stomach and histopathological analysis |
Gan no rinsho. Japan journal of cancer clinics, 30, 5, 519-523 |
Gan no rinsho. Japan journal of cancer clinics, 30, 5, 519-523 |
Gan no rinsho. Japan journal of cancer clinics, 30, 5, 519-523 |
1984 |
有 |
英語 |
|
公開 |
| 戸井 雅和 |
戸井 雅和 |
TOI Masakazu |
5-Chloro-2,4-dihydroxypyridine, CDHP, prevents lung metastasis of basal-like breast cancer cells by reducing nascent adhesion formation. |
5-Chloro-2,4-dihydroxypyridine, CDHP, prevents lung metastasis of basal-like breast cancer cells by reducing nascent adhesion formation. |
5-Chloro-2,4-dihydroxypyridine, CDHP, prevents lung metastasis of basal-like breast cancer cells by reducing nascent adhesion formation. |
Cancer Med, 7(2), 463-470 |
Cancer Med, 7(2), 463-470 |
Cancer Med, 7(2), 463-470 |
|
有 |
|
|
公開 |
| Tsuda M, Ishiguro H, Yano I, Toi M |
Tsuda M, Ishiguro H, Yano I, Toi M |
Tsuda M, Ishiguro H, Yano I, Toi M |
Re: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment |
Re: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment |
Re: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment |
J Natl Cancer Inst, 106, 7 |
J Natl Cancer Inst, 106, 7 |
J Natl Cancer Inst, 106, 7 |
|
有 |
|
|
公開 |
| 戸井 雅和 |
戸井 雅和 |
TOI Masakazu |
SALL4 - KHDRBS3 network enhances stemness by modulating CD44 splicing in basal-like breast cancer. |
SALL4 - KHDRBS3 network enhances stemness by modulating CD44 splicing in basal-like breast cancer. |
SALL4 - KHDRBS3 network enhances stemness by modulating CD44 splicing in basal-like breast cancer. |
Cancer Med, Feb;7(2), 454-462 |
Cancer Med, Feb;7(2), 454-462 |
Cancer Med, Feb;7(2), 454-462 |
|
有 |
|
|
公開 |
| 戸井 雅和 |
戸井 雅和 |
Matsumoto Y, Asao Y, Yoshikawa A, Sekiguchi H, Takada M, Furu M, Saito S, Kataoka M, Abe H, Yagi T, Togashi K, Toi M. |
Label-free photoacoustic imaging of human palmar vessels: a structural morphological analysis. |
Label-free photoacoustic imaging of human palmar vessels: a structural morphological analysis. |
Label-free photoacoustic imaging of human palmar vessels: a structural morphological analysis. |
Sci Rep, 15;8(1), 786 |
Sci Rep, 15;8(1), 786 |
Sci Rep, 15;8(1), 786 |
|
有 |
|
|
公開 |
| 戸井 雅和 |
戸井 雅和 |
Ueno T, Saji S, Sugimoto M, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Imoto S, Sasano H, Toi M. |
Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy. |
Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy. |
Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy. |
BMC Cancer, 16;16, 230-doi: 10 |
BMC Cancer, 16;16, 230-doi: 10 |
BMC Cancer, 16;16, 230-doi: 10 |
|
有 |
|
|
公開 |
| Ishiguro H, Takashima S, Yoshimura K, Yano I, Yamamoto T, Niimi M, Yamashiro H, Ueno T, Takeuchi M, Sugie T, Yanagihara K, Toi M, Fukushima M. Degree |
Ishiguro H, Takashima S, Yoshimura K, Yano I, Yamamoto T, Niimi M, Yamashiro H, Ueno T, Takeuchi M, Sugie T, Yanagihara K, Toi M, Fukushima M. Degree |
Ishiguro H, Takashima S, Yoshimura K, Yano I, Yamamoto T, Niimi M, Yamashiro H, Ueno T, Takeuchi M, Sugie T, Yanagihara K, Toi M, Fukushima M. Degree |
Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patients |
Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patients |
Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patients |
Support Care Cancer. 2011 Nov 1 |
Support Care Cancer. 2011 Nov 1 |
Support Care Cancer. 2011 Nov 1 |
|
有 |
英語 |
|
公開 |
| Eswaran J, Gupta S, Dutt A, Toi M, Pillai MR, Costa L, Knapp S, Badwe RA, Kumar R |
Eswaran J, Gupta S, Dutt A, Toi M, Pillai MR, Costa L, Knapp S, Badwe RA, Kumar R |
Eswaran J, Gupta S, Dutt A, Toi M, Pillai MR, Costa L, Knapp S, Badwe RA, Kumar R |
The Global Cancer Genomics Consortium: Interfacing Genomics and Cancer Medicine |
The Global Cancer Genomics Consortium: Interfacing Genomics and Cancer Medicine |
The Global Cancer Genomics Consortium: Interfacing Genomics and Cancer Medicine |
Cancer Res. 2012 May 24. [Epub ahead of print] |
Cancer Res. 2012 May 24. [Epub ahead of print] |
Cancer Res. 2012 May 24. [Epub ahead of print] |
|
有 |
英語 |
|
公開 |
| Takeuchi M, Sugie T, Abdelazeem K, Kato H, Shinkura N, Takada M, Yamashiro H, Ueno T, Toi M. |
Takeuchi M, Sugie T, Abdelazeem K, Kato H, Shinkura N, Takada M, Yamashiro H, Ueno T, Toi M. |
Takeuchi M, Sugie T, Abdelazeem K, Kato H, Shinkura N, Takada M, Yamashiro H, Ueno T, Toi M. |
Lymphatic Mapping With Fluorescence Navigation Using Indocyanine Green and Axillary Surgery in Patients With Primary Breast Cancer |
Lymphatic Mapping With Fluorescence Navigation Using Indocyanine Green and Axillary Surgery in Patients With Primary Breast Cancer |
Lymphatic Mapping With Fluorescence Navigation Using Indocyanine Green and Axillary Surgery in Patients With Primary Breast Cancer |
Breast J. 2012 Sep 26. |
Breast J. 2012 Sep 26. |
Breast J. 2012 Sep 26. |
|
有 |
英語 |
|
公開 |
| Imami K, Sugiyama N, Imamura H, Wakabayashi M, Tomita M, Taniguchi M, Ueno T, Toi M, Ishihama Y. |
Imami K, Sugiyama N, Imamura H, Wakabayashi M, Tomita M, Taniguchi M, Ueno T, Toi M, Ishihama Y. |
Imami K, Sugiyama N, Imamura H, Wakabayashi M, Tomita M, Taniguchi M, Ueno T, Toi M, Ishihama Y. |
Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. |
Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. |
Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. |
Mol Cell Proteomics. 2012 Sep 10. |
Mol Cell Proteomics. 2012 Sep 10. |
Mol Cell Proteomics. 2012 Sep 10. |
|
有 |
英語 |
|
公開 |
| Sugimoto M, Takada M, Toi M. |
Sugimoto M, Takada M, Toi M. |
Sugimoto M, Takada M, Toi M. |
Comparison of robustness against missing values of alternative decision tree and multiple logistic regression for predicting clinical data in primary breast cancer. |
Comparison of robustness against missing values of alternative decision tree and multiple logistic regression for predicting clinical data in primary breast cancer. |
Comparison of robustness against missing values of alternative decision tree and multiple logistic regression for predicting clinical data in primary breast cancer. |
Conf Proc IEEE Eng Med Biol Soc. 2013 |
Conf Proc IEEE Eng Med Biol Soc. 2013 |
Conf Proc IEEE Eng Med Biol Soc. 2013 |
|
有 |
英語 |
|
公開 |
| Ohno S, Chow LW, Sato N, Masuda N, Sasano H, Takahashi F, Bando H, Iwata H, Morimoto T, Kamigaki S, Nakayama T, Nakamura S, Kuroi K, Aogi K, Kashiwaba M, Yamashita H, Hisamatsu K, Ito Y, Yamamoto Y, Ueno T, Fakhrejahani E, Yoshida N, Toi M |
Ohno S, Chow LW, Sato N, Masuda N, Sasano H, Takahashi F, Bando H, Iwata H, Morimoto T, Kamigaki S, Nakayama T, Nakamura S, Kuroi K, Aogi K, Kashiwaba M, Yamashita H, Hisamatsu K, Ito Y, Yamamoto Y, Ueno T, Fakhrejahani E, Yoshida N, Toi M |
Ohno S, Chow LW, Sato N, Masuda N, Sasano H, Takahashi F, Bando H, Iwata H, Morimoto T, Kamigaki S, Nakayama T, Nakamura S, Kuroi K, Aogi K, Kashiwaba M, Yamashita H, Hisamatsu K, Ito Y, Yamamoto Y, Ueno T, Fakhrejahani E, Yoshida N, Toi M |
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuva |
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuva |
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuva |
Breast Cancer Res Treat. 2013 Oct 12 |
Breast Cancer Res Treat. 2013 Oct 12 |
Breast Cancer Res Treat. 2013 Oct 12 |
|
有 |
英語 |
|
公開 |
| Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili-Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R. |
Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili-Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R. |
Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili-Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R. |
Adjuvant bevacizumab- containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial |
Adjuvant bevacizumab- containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial |
Adjuvant bevacizumab- containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial |
Lancet Oncol. 2013 |
Lancet Oncol. 2013 |
Lancet Oncol. 2013 |
|
有 |
英語 |
|
公開 |
| 戸井 雅和 |
戸井 雅和 |
TOI Masakazu |
Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1. |
Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1. |
Toi M, Shao Z, Hurvitz S, Tseng LM, Zhang Q, Shen K, Liu D, Feng J, Xu B, Wang X, Lee KS, Ng TY, Ridolfi A, Noel-Baron F, Ringeisen F, Jiang Z. |
Breast Cancer Res, 19(1), 2017 Apr 11;19(1):47. doi: 10. |
Breast Cancer Res, 19(1), 2017 Apr 11;19(1):47. doi: 10. |
Breast Cancer Res, 19(1), 2017 Apr 11;19(1):47. doi: 10. |
|
有 |
|
|
公開 |
| Suzuki R, Saji S, Toi M |
Suzuki R, Saji S, Toi M |
Suzuki R, Saji S, Toi M |
Impact of body mass index on breast cancer in accordance with the life-stage of women. |
Impact of body mass index on breast cancer in accordance with the life-stage of women. |
Impact of body mass index on breast cancer in accordance with the life-stage of women. |
Front Oncol. 2012;2:123 |
Front Oncol. 2012;2:123 |
Front Oncol. 2012;2:123 |
|
有 |
英語 |
|
公開 |
| Horvath A, Pakala SB, Mudvari P, Reddy SD, Ohshiro K, Casimiro S, Pires R, Fuqua SA, Toi M, Costa L, Nair SS, Sukumar S, Kumar R |
Horvath A, Pakala SB, Mudvari P, Reddy SD, Ohshiro K, Casimiro S, Pires R, Fuqua SA, Toi M, Costa L, Nair SS, Sukumar S, Kumar R |
Horvath A, Pakala SB, Mudvari P, Reddy SD, Ohshiro K, Casimiro S, Pires R, Fuqua SA, Toi M, Costa L, Nair SS, Sukumar S, Kumar R |
Novel Insights into Breast Cancer Genetic Variance through RNA Sequencing |
Novel Insights into Breast Cancer Genetic Variance through RNA Sequencing |
Novel Insights into Breast Cancer Genetic Variance through RNA Sequencing |
Sci Rep. 2013 Jul 25;3:2256. doi: 10.1038/srep02256. |
Sci Rep. 2013 Jul 25;3:2256. doi: 10.1038/srep02256. |
Sci Rep. 2013 Jul 25;3:2256. doi: 10.1038/srep02256. |
|
有 |
英語 |
|
公開 |
| 戸井 雅和 |
戸井 雅和 |
Miyake KK, Nakamoto Y, Saji S, Sugie T, Kurihara K, Kanao S, Ikeda DM, Toi M, Togashi K |
Impact of physiological hormonal fluctuations on 18F-fluorodeoxyglucose uptake in breast cancer. |
Impact of physiological hormonal fluctuations on 18F-fluorodeoxyglucose uptake in breast cancer. |
Impact of physiological hormonal fluctuations on 18F-fluorodeoxyglucose uptake in breast cancer. |
Breast Cancer Res Treat, 169(3), 437-446 |
Breast Cancer Res Treat, 169(3), 437-446 |
, 169(3), 437-446 |
|
有 |
|
|
公開 |
| 戸井 雅和 |
戸井 雅和 |
Asao Y, Hashizume Y, Suita T, Nagae KI, Fukutani K, Sudo Y, Matsushita T, Kobayashi S, Tokiwa M, Yamaga I, Fakhrejahani E, Torii M, Kawashima M, Takada M, Kanao S, Kataoka M, Shiina T, Toi M. |
Photoacoustic mammography capable of simultaneously acquiring photoacoustic and ultrasound images. |
Photoacoustic mammography capable of simultaneously acquiring photoacoustic and ultrasound images. |
Photoacoustic mammography capable of simultaneously acquiring photoacoustic and ultrasound images. |
J Biomed Opt, 1;21, 11, :116009. |
J Biomed Opt, 1;21, 11, :116009. |
J Biomed Opt, 1;21, 11, :116009. |
|
有 |
|
|
公開 |
| 戸井 雅和 |
戸井 雅和 |
André F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, O'Regan R, Isaacs C, Toi M, Burris H, He W, Robinson D, Riester M, Taran T, Chen D, Slamon D. |
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. |
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. |
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. |
J Clin Oncol, 20;34, 18, 2115-2124 |
J Clin Oncol, 20;34, 18, 2115-2124 |
J Clin Oncol, 20;34, 18, 2115-2124 |
|
有 |
|
|
公開 |
HOME
教育研究活動データベースについて
利用方法について
